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ABSTRACT
Amyloidosis is a degenerative protein misfolding disorder that leads to the
extracellular accumulation of amyloid deposits containing protein fibrils, heparan sulfate
proteoglycans, glycoproteins and apolipoproteins. To date, at least 27 proteins have
been identified as components of pathologic amyloid fibrils. In systemic forms of the
disease, amyloid deposits can evade the immune system and expand throughout various
tissues.

As the deposits grow, tissue architecture is disrupted, leading to organ

dysfunction and death.
In the US, there are ~3500 newly diagnosed patients with amyloidosis annually.
The deposition of light chains as amyloid (AL amyloidosis) is the most common form of
visceral disease.

The prognoses for patients varies (median survival for AL 12-40

months), but those with cardiac involvement have a considerably less favorable prognosis
(~9 months median survival).

Many researchers and physicians believe that early

detection of amyloidosis could improve patient survival. The current gold standard for
diagnosis involves histological examination of biopsy-derived tissue specimens. This
method is invasive, subject to sampling error, and can be quite challenging. In an attempt
to facilitate diagnosis, molecular imaging techniques using amyloid-reactive tracers have
been developed such that a whole body, non-invasive “picture” of amyloid burden in
patients may be established. There are several imaging agents used clinically worldwide, but each of these has limitations regarding its adoption in the US (i.e. 123[123]I-SAP
is not FDA-approved and cannot image cardiac amyloid deposits,

124[124]I-11-1F4

only

images ~60% of patients, and 99m[99m]Tc-labeled bone-seeking agents cannot image the
most common forms of amyloid disease in patients). Given these limitations, there is an
vi

unmet clinical need for a facile method of quantitatively detecting whole body amyloid
burden in patients.
To this end, we have developed synthetic, pan-amyloid-reactive peptides for use
as radiotracers by using SPECT/CT or PET/CT molecular imaging to non-invasively
detect whole body amyloid load in patients. Through numerous preclinical experiments
using ex vivo and transgenic murine models of amyloidosis, the structurally related
peptides were found to have unique in vivo characteristics. Our findings suggest that, if
further optimized, certain peptides could have clinical merit for the early detection of
multiple types of amyloidosis.
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Chapter 1
Literature Review

1. Amyloidosis
1.1 Overview
Amyloidosis is a protein misfolding disorder which leads to the extracellular
deposition of a complex clinical pathology known as amyloid. To date, 27 different
native proteins have been identified that, after undergoing a conformational, structural
change, have been found associated with the disease in man [1]. Certain types of
amyloidosis are localized and affect only the organ in which the precursor protein is
produced. These include type II diabetes in which the amyloidotic islet amyloid
polypeptide (AIAPP) aggregates and deposits within the pancreas and Alzheimer’s
disease where amyloid beta (Aβ) peptides deposit in the brain. In contrast, the systemic
amyloidoses show no limitation to the organs that can be involved. Partial lists of the
systemic and localized amyloid diseases, including the associated precursor proteins
and the most typically affected organs, are shown in Table 1.1 [1, 2]. Additionally, there
are amyloid diseases which have been shown to affect animals.

Many of these

disorders are systemic in pathology and affect multiple organs much like the systemic
diseases seen in humans; others induce localized amyloid aggregates in the brain
which can lead to Alzheimer’s disease [3]. Animals and humans can also be affected
by prion diseases which result in proteinacious aggregates localized to the brain leading
to neurological deficits [4].
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Table 1.1: Partial list of human amyloidoses

Amyloid disease
(abbreviation)

Precursor protein

Affected tissue(s)

Systemic
Light chain amyloidosis (AL) Immunoglobulin light chain

Heart, kidney, liver

Heavy chain amyloidosis (AH)

Immunoglobulin heavy
chain

Kidney, liver

Senile systemic amyloidosis
(SSA) # now known as wild
type transthyretin (wt-TTR)

Transthyretin

Heart, vessels, soft
tissues

Familial amyloidotic
polyneuropathy (FAP; also
known as ATTR)

Transthyretin

Heart, kidney, central
nervous system

Serum amyloid A protein

Kidney, liver, spleen

β2-microglobulin

Joints, heart,
gastrointestinal tract, lung

Lysozyme amyloidosis (Alys)

Lysozyme

Kidney, liver, spleen

Apo AI amyloidosis (AApoAI)

Fragments of
apolipoprotein AI

Kidney, heart, liver

Secondary (reactive)
amyloidosis (AA)
Dialysis-related amyloidosis
(Aβ2 M)

Apo AII amyloidosis (AApoAII)
Fibrinogen amyloidosis (Afib)

Fragments of
apolipoprotein AII
Fibrinogen α chain
mutants

Kidney
Kidney

Finnish hereditary amyloidosis
(AGel)

Fragments of gesolin
mutants

Cornea, facial and
peripheral nerves, skin

Cystatin amyloidosis (ACys)

Cystatin C

Cerebral blood vessels
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Table 1.1. Continued

Amyloid disease
(abbreviation)

Precursor protein

Affected tissue(s)

Alzheimer's disease (Aβ)

β-amyloid precursor
protein

Brain

Diabetes mellitus type II
(AIAPP)

Islet amyloid polypeptide

Islets of Langerhans
(pancreas)

Spongiform
encephalopathies (APrP)

Prion protein

Brain

Pituitary prolactinoma (APro)

Prolactin

Pituitary

Senile aortic, medin
amyloidosis (AMed)

Lactadherin

Heart

Familial corneal amyloidosis
(ALac)

Lactoferrin

Eyes

Localized

#

The amyloidosis nomenclature committee made this announcement at the
International Symposium on Amyloidosis 2014.
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The underlying biochemical and biophysical causes of amyloidosis are likely myriad and
vary widely, but they include hereditary conditions which lead to the production of
proteins with mutations (e.g. ATTR), acquired diseases due to altered physiological
conditions resulting in an increase in the production of improperly folded proteins (e.g.
AL, AA, AIAPP) and acquired diseases associated with aging (e.g. AMed, wild type
TTR).
While there are numerous structurally and functionally different precursor
proteins associated with amyloidosis, the amyloid deposits themselves share certain
remarkably similar characteristics. The following sections will discuss many of these
characteristics, a possible mechanism of pathogenesis and a description of the most
prevalent components of the pathological amyloid deposit.

1.2. Amyloid Structure
The term “amyloid” was derived from the Greek word amylon which means
starch; however, the term was initially a descriptor for plant composition. Amyloid was
introduced into the field of medicine in the mid-1800’s when Virchow and others used it
to describe lardaceous tissue deposits that stained positively, specified by a bluish
color, with iodine solution, indicating the presence of a starch-like substance [5, 6].
Amyloid has since been used as a designation for the extracellular, proteinaceous
deposits which primarily consist of protein fibrils.

However, these deposits also

ubiquitously include other associated secondary components, whose role in the
pathogenesis of the disease remains enigmatic, such as proteoglycans, namely
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heparan sulfate proteoglycan (HSGP), serum amyloid P component (SAP), and
apolipoproteins. (See Figure 1.1) [5, 7-9].
1.2.1. Fibrils and fibrillogenesis
The initial stage of amyloid fibril formation involves the transition of normally
soluble, amyloidogenic precursor proteins, which are natively folded, into insoluble,
linear fibrils.

Researchers have slightly different perspectives on this process; one

possible mechanism of fibrillogenesis that is commonly seen and has been referred to
as “widely accepted” [10] will be presented later. The structure of amyloid fibrils has
also been a topic of intense discussion amongst amyloid researchers for years, but
three traits common to all types of amyloid fibril have been identified (see Figure 1.2).
Firstly, analysis of data generated from electron microscopy studies suggests that fibrils
are “self-assembling”, unbranching filaments that are approximately ~10 µm in length,
~10 nanometers wide and display crossovers at regular distances (seen as white
arrowheads in Figure 1.2A) [11, 12]. In addition to these features, a second defining
characteristic of amyloid fibrils is the presence of a cross-β-sheet secondary structural
motif as evidenced in X-ray diffraction studies [13-15]. Characteristic deflections in the
X-ray diffraction pattern are ever-present in amyloid fibrils, regardless of the precursor
protein from which the fibrils are formed [16].

These deflections are indicative of

interstrand and intersheet distances at 4.7 and 10-13 Å, respectively (Figure 1.2B) [17,
18]. In addition, these data suggest that the β-sheet motifs are arranged perpendicular
to the long axis of the fibril (see Figure 1.2C). The third common feature associated with
all amyloid fibrils is the ability to give rise to green-birefringence upon staining with
Congo red (CR) dye and viewing the sample microscopically with cross-polarized
5

Figure 1.1: Schematic of amyloid composition on the cell membrane. This model
demonstrates the complexity of amyloid where HSPG is heparan sulfate proteoglycan
and SAP is serum amyloid P component. The various components that are depicted
have all been found associated ubiquitously with amyloid deposits [5, 7-9, 19].

6

Figure 1.2: Structural characteristics of amyloid. (A) Electron micrograph of amyloid
fibrils. The image demonstrates the unbranched structure of amyloid fibrils; arrowheads
pinpoint to the regularly-spaced crossover positions throughout the length of the fibril.
(Image taken from [11]). (B) X-ray diffraction pattern of cross-beta sheet associated
with fibrils (Image adapted from [17]). (C) Demonstration of cross-beta sheet
positioning along fibril axis. The beta sheets are indicated as yellow or green broad
arrows. As shown, they point in opposing directions which creates the cross-beta
pattern. This image additionally reveals that the beta sheets align in a perpendicular
fashion along the length of the fibril axis (Image taken from [20]).
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illumination [11, 21]. An example of CR-stained heart tissue and the localized green
birefringence indicating amyloid deposition is shown in Figure 1.3A. The molecular
rationale underlying the birefringent properties of fibrils is suggested to be due to the
intercalation of several CR molecules amidst the cross-β sheet secondary structure of
the amyloid fibril (Figure 1.3B).
While these three characteristics are associated with all types of amyloid fibril,
they do not give insight into the mechanism by which fibrils form. Researchers agree
that there must be a protein conformational change prior to fibrillogenesis – a shift in the
structure of the native state of the precursor protein that renders it in a pro-amyloid state
[10, 22-24].

Once misfolded, (and perhaps following the dissociation of multimeric

complexes, as in the case of TTR) monomeric precursor proteins self-assemble forming
dimeric and oligomeric “nuclei” which then leads to fibril formation. This process has
been called ‘nucleation-dependent’ fibrillogenesis because it requires the association of
monomers to “seed” the transition, analogous to the formation of salt crystals by the
addition of a pre-formed “seed” or nucleating crystal. As Kumar and Walter’s proposed
mechanism illustrates (see Figure 1.4), the misfolding of the native protein and the
formation of intermediary species are reversible processes and not thermodynamically
favorable; thus, the progression to fibrils is not favored, and this phase of fibrillogenesis
is termed the lag phase or nucleation phase [10, 22-24]. Once a sufficient population
of oligomeric species have been established, likely within affected tissues, they
progress toward protofibrils, assemblies of protofilaments intertwined to form a prefibrillar state, and mature fibrils proceeds much more rapidly—this step is considered to
be auto-catalytic (associated with exponential kinetics) and is known as the ‘elongation
8

Figure 1.3: Congo red binding to amyloid. (A) Congo red (CR) birefringence in
amyloid laden tissue. When viewed with cross-polarized light, the golden regions,
indicated by white arrows, reveal amyloid deposits in cardiac tissue from a murine
model of amyloidosis. (B) Proposed incorporation of CR onto amyloid fibrils. The crosslinking of CR on amyloid fibrils yields birefringent properties which are used for amyloid
detection (Image adapted from [17]).
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Figure 1.4: Nucleation-dependent mechanism of fibrillogenesis.
Misfolded
monomeric proteins self-assemble as dimeric and oligomeric species which “nucleate”
fibrillogenesis (nucleation phase). This phase is thermodynamically unfavorable, but
once a nucleus is formed, the progression to protofibrils and mature fibrils proceeds
rapidly (elongation phase). (Image taken from [10]).
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phase (Figure 1.4).

The sigmoidal curve (green) indicates the different kinetic

properties of each of these phases. Furthermore, the schematic shows what happens
following the addition of pre-formed nuclei to the lag phase of the reaction. As noted
above, this is analogous to seeding a crystallization reaction, and in the case of amyloid
fibrils has been shown to induce the formation of prefibrillar assemblies and increase
the rate of fibril formation, thus shortening (or even completely eliminating) the lag
phase (Figure 1.4 red curve). Many researchers take advantage of this phenomenon in
preclinical animal studies of amyloidogensis by administering, intravenously, a tissue
homogenate containing preformed oligomeric species and amyloid fibrils, known as
amyloid enhancing factor (AEF), to expedite amyloid deposition in vivo [25-27]. This
process shortens the time necessary for amyloid formation in animal models of the
disease, and may be the underlying phenomenon governing the transmissibility of
amyloid-associated diseases such as the spongiform encephalopathies and prion
diseases [17, 28-30].
Fibrillogenesis and the pathogenesis at each phase of the transformation is not
fully understood, however.

Some researchers hypothesize that it is the oligomeric

species that form during the lag phase that may be cytotoxic and result in the death of
neurons in patients with Alzheimer’s disease (Aβ) or pancreatic β-cells in patients with
type 2 diabetes (AIAPP) — not the fibril, itself [31-35]. In Alzheimer’s disease, the
monomeric and fibrillar Aβ peptides are biologically inert, but the oligomeric Aβ species
have been shown to be cytotoxic and show the best correlation with synapse loss and
dementia in neuro-psychiatric analyses [36-40]. However, the systemic amyloidoses
that involve multiple, if not all, visceral organs will be the focus of this thesis, and it is
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widely accepted that in these patients, the deposition of fibrils and amyloid in the organs
is responsible for the pathologic affects.
1.2.2. Heparan Sulfate Proteoglycan
In addition to the protein fibrils within amyloid, glycosaminoglycans (GAGs),
namely heparan sulfate, are major secondary (non-fibrillar) components of the deposit.
GAGs are unbranched heteropolysaccharides that are composed of repeating
disaccharide units [5, 41, 42].

There are five types of GAGs which include

heparin/heparan sulfate, chondroitin sulfate, dermatan sulfate, hyaluronan and keratan
sulfate (See Figure 1.5; Keratan sulfate is not pictured because, unlike the others, it is
not made with uronate). Of these, heparan sulfate GAG, which is structurally similar to
heparin, is ubiquitously associated with amyloid deposits in the form of the perlecan
proteoglycan. The role of heparan sulfate (HS) in amyloidogenesis has been widely
investigated. In the case of AA amyloidosis, serum amyloid A protein, the precursor
protein to the disease, has a HS binding-domain within its sequence which allows for
direct interaction with GAGs on cell surfaces.

In addition, as the deposition of AA

amyloid increases the quantity of HS increases in parallel in a mouse model of the
disease [5].
Circular dichroism analysis of amyloid precursor proteins, Aβ and SAA, in the
presence of HS revealed an increase in the β-sheet content within these proteins,
indicating that the interaction with HS rendered them more likely to become fibrillogenic
[5, 43-46]. This enhanced β-sheet content was only induced by HS; no other GAG that
was examined possessed this property [5]. Studies conducted in transgenic mice that
overexpress human heparanase further suggested the importance of HS in the
12

Figure 1.5: Structures of common glycosaminoglycans (Image adapted from [5]).
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development of AA amyloid [47]. In this chimeric mouse, organs known to produce high
quantities of HS, such as the liver and the kidneys, generated drastically shortened HS
chains. Due to the improper HS production, these organs failed to develop AA amyloid
following induction of the disease. Organs that were capable of producing full chain HS,
e.g. the spleen, remained susceptible to AA amyloid as evidenced by extensive CR
birefringence. These studies unequivocally demonstrated the critical importance of HS
in amyloid formation [47].
It

is

noteworthy

that

Lindahl

and

Lindahl

demonstrated,

by

using

chromatographic techniques, that the HS found associated with perlecan proteoglycan
[48] in amyloid-laden liver, spleen and kidney was structurally similar, but this type of
HS differed from that found in amyloid-free tissues [7]. This observation suggested that
amyloid-associated HS is structurally different from the HS found in healthy tissues.
This finding was confirmed by Smits et al. in which a phage display-derived small chain
variable fragment (scFv), designated NS4F5, was used to show the HS heterogeneity
between healthy and diseased tissues [49]. The anti-HS scFv specifically bound to a
region of highly sulfated disaccharides that is commonly found in heparin but is rarely
seen in HS [49, 50].

When NS4F5 was introduced into a murine model of AA

amyloidosis [27], the antibody bound to the HS affiliated with amyloid-deposits and did
not bind to the normally distributed HS throughout healthy tissue as indicated by
microautoradiography and histological examination of the co-localization of radiolabeled
NS4F5 in regions observed to be rich in Congo red birefringence [49]. Thus, the major
difference between amyloid-associated HS and normal HS may be the enhanced
sulfation pattern found in the amyloid-associated HS; the greater abundance of negative
14

charges generated by the excessive sulfation may enable amyloid-associated HS to
recruit additional molecules and proteins [49], thereby contributing to amyloidogenesis.
GAGs are usually found linked to a protein backbone, and this GAG:protein
complex yields a proteoglycan (PG). As major components of all mammalian tissues,
PG play a vital role in mammalian physiology by acting as local regulators of tissue
function and homeostasis as well as structural elements [51, 52]. They are expressed
ubiquitously on all cell surfaces and are present within extracellular matrices. It has
been widely accepted that GAG and PG are involved in the recruitment of a range of
proteins which typically aid in tissue remodeling during inflammatory and diseaseinduced

immune

responses

[51,

53];

additionally,

GAGs

bind

to

matrix

metalloproteinases and their inhibitors which, together, can be sequestered by PG to
promote enzymatic regulation following tissue injury [51, 53]. Given these properties of
tissue PGs, the GAG associated with amyloid deposits may recruit proteins and other
components to the amyloid which contributes to its complexity. Immunohistochemical
techniques have established that HS, likely linked to perlecan core protein, is the PG
most commonly associated with amyloid deposits in man and animals [5, 26, 54].
Heparan sulfate proteoglycans are found in all amyloid deposits and, as mentioned
above, are structurally and electrochemically different from the HSPG contributing to
healthy tissue physiology. It has been suggested that these non-protein components
undoubtedly contribute to the pathological process of fibril formation; additionally,GAGs
should be considered a part of amyloid—not just “associated” materials [5, 55].
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1.2.3. Serum amyloid P component
Another biological constituent of amyloid is the pentameric glycoprotein, serum
amyloid P component (SAP) which is a normally, soluble, circulating plasma protein that
is known to bind to all types of amyloid fibrils in a calcium-dependent manner (Figure
1.6) [16, 56, 57]. The biological function of SAP is not fully understood, but it has been
shown to avidly bind to the DNA in chromatin that has been released into extracellular
spaces in apoptotic or necrotic conditions [58, 59]. Once bound, the SAP is able to
stabilize and protect the DNA from degradation [59].

Additionally, reproducible

experimental observations suggest that SAP may contribute to a host’s innate immunity
against certain bacterial and parasitic infections [57, 59]. When mice with targeted
deletion of the SAP gene, SAP knockout (KO) mice, were injected with lethal doses of
smooth E. coli strain O111:B4, they were significantly more susceptible to infection than
mice with inherent SAP. The role of SAP in amyloidogenesis is not entirely understood,
but studies suggest that it may be able to prevent proteolytic digestion of amyloid fibrils,
thus, contributing to their stability in vivo [8, 16, 59, 60]. Tennet et al. studies showed
that SAP can prevent fibril digestion in an ex vivo assay but only if SAP is bound to
them; the addition of SAP in the presence of its specific ligands, a cyclic pyruvate
acetal, inhibited its binding to fibrils and rendered it incapable of protecting fibrils from
proteolysis [60]. Additionally, in vivo studies have been conducted which reveal that
SAP KO mice have delayed and reduced AA amyloid deposition when compared to
SAP “sufficient” mice that underwent amyloid induction [8, 61, 62].

These studies

suggested that SAP may indeed play a role in amyloidogenesis; however, Botto et al.
also concluded that SAP is not a requirement for amyloid formation because, when
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Figure 1.6: Crystal structure of serum amyloid P component. (Image taken from
[16]).
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given a sufficient stimulus, AA amyloid readily formed in SAP-deficient mice in the
system as well [8, 62]. Therefore, SAP is associated with, and may provide stability to,
all amyloid deposits.
Certain countries, mainly in Europe, utilize the amyloid fibril-binding property of SAP
as a method of non-invasively detecting and monitoring visceral amyloid deposits in
patients [56, 57, 63-66]. The use of SAP as a non-invasive amyloid imaging agent will
be discussed further in a later section.
Recently, anti-SAP antibodies have been developed for use as a novel
immunotherapy for systemic amyloidosis [67]. Bodin et al. reported the therapeutic
efficacy of anti-SAP antibodies in a transgenic mouse model of AA amyloidosis which
produces human SAP instead of mouse SAP (Notably, mouse SAP does not bind
amyloid as well as human SAP) [67-69]. Prior to antibody administration, the mice were
injected

with

(R)-1-[6-[(R)-2-carboxypyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-

carboxylic acid (CPHPC), which has a high affinity for human SAP and can, thus, clear
the majority (~ 90%) of SAP from the circulation [67, 69, 70]. Some residual SAP
remains within the amyloid deposits, and this was the material targeted by the
opsonizing antibody [68, 70]. Since amyloid is typically an acellular deposit with no
surrounding indication of inflammation, the observance of cell infiltration at 24 hours
post injection (pi) of anti-SAP antibody was noteworthy [67].

These cells stained

strongly with antibodies to F4/80 indicating they were likely macrophages; this was not
observed in amyloid deposits from mice that did not receive the antibody [67]. The antiSAP antibody treatment initiated a cellular response which resulted in nearly complete
amyloid clearance by day 16 pi; at this point, there was evidence of restored tissue
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architecture [67]. Given these findings, this therapeutic approach was deemed to be
clinically relevant and has been implemented into an ongoing clinical trial
(NCT01777243).
Based on the foregoing discussion, biological reagents that bind specifically the
components of amyloid, such as the small chain variable fragment NS4F5 [71-73] and
SAP [67] can be expected to yield novel diagnostic and potentially therapeutic agents
for patients with amyloidosis The research presented in this thesis will further explore
and exploit this potential by studying a novel class of amyloid-reactive peptides.

2. Clinical Manifestations

2.1. Overview
The clinical impact of the amyloid diseases depends on the type of amyloid and
the location of the pathological deposits.

2.2. Light chain amyloidosis – AL
Of the human amyloidoses, light chain amyloidosis (AL), presenting as either a
systemic or localized disease, is the most common form with an incidence of
approximately 1 case in 100,000 per year in Western countries [17, 74, 75].

AL

amyloidosis is a form of plasma cell dyscrasia that results in an overproduction of
monoclonal immunoglobulin light chains (IgLCs), the precursor proteins that initiate the
amyloid cascade for this disease. Not all secreted monoclonal IgLCs form amyloid. In

19

patients with multiple myeloma, a related plasma-cell dyscrasia, only 12-15% of patients
develop amyloidosis regardless of elevated levels of free IgLCs [17]. Additionally, it has
been stated that the presence of monoclonal free IgLC in the serum or urine of
individuals over the age of 50 is not uncommon; however, only a minor fraction of these
individuals will progress to develop AL amyloidosis [1, 75, 76]. Of the 2 IgLC isotypes (λ
and κ), the λ isotype, in particular, has been shown to have greater amyloidogenic
propensity [1, 19]. For example, two germline genes that encode for the variable region
of lambda light chains (Vλ), the 6a and 3r germlines, contribute to 42% of cases of
lambda IgLC-related amyloidosis, approximately ⅓ of all patients with AL [17, 75, 77,
78]. In fact, (with singular exception, protein Jto), products of the λ6a germline gene
have been found exclusively in AL patients and are rarely seen in the normal light chain
repertoire [1, 19, 77, 79]. One Vλ6a amyloid-related IgLC protein, isolated from patient
Wil, has 11 somatic mutations and was shown, by using heat and chemical denaturation
experiments, to be less thermodynamically stable and have a faster kinetic rate of
fibrillogenesis in vitro relative to the non-AL associated Jto protein and other λ6 proteins
[1, 80, 81]. These studies were among the first to demonstrate an inverse correlation
between the thermodynamic stability of a native state folding domain and the propensity
for, and rate of, fibril formation in vitro [81]. A similar correlation using a series of Vκ4
IgLC proteins has also been shown [82]. The fibrillogenic characteristics of Vλ6 Wil
have been exploited in numerous in vitro studies to further elucidate the biochemical
and biophysical factors that render IgLCs prone to fibrillogenesis [1, 77, 80]. In cases of
AL amyloidosis, secreted free IgLCs circulate in the blood, and under certain conditions,
i.e. when their local concentration increases, following proteolytic digestion, or after
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other modifications of unfolding of the variable domain, they self-associate into amyloid
fibrils. A summary of the mechanism of AL amyloidosis, as illustrated by Blancas-Mejía
and Ramirez-Alvarado, is shown in Figure 1.7.
The clinical implications of AL amyloidosis depend on the organ involvement.
Merlini estimated that approximately 25% of AL patients present with only single organ
involvement; this particular organ would determine the prognoses for these individuals
[17].

However, the vast majority of AL patients (~ 75%) have multiple organ

involvement or, albeit less common, deposition of amyloid localized at a single anatomic
site, including the brain, as a tumor-like amyloidoma [1, 83, 84].
The site of AL deposition likely depends on numerous different environmental
factors, e.g., localized high IgLC concentration and low pH, both of which favor the
formation of fibrils [1, 17, 85-87]. The tissues most typically affected by AL amyloidosis
are the kidneys, heart, spleen, gastrointestinal tract, peripheral nerves and liver [1, 17,
88]. Gross clinical manifestations in several organs are shown in Figure 1.8. The
lardaceous, white material present within the kidneys is amyloid deposition (Figure
1.8A). The gastrointestinal tract may be affected, and if so, it can lead to internal
bleeding (Figure 1.8B). The liver and heart, both of which are enlarged, have been
stained with Lugol’s iodine solution; the evidence of bluish discoloration after the
application of dilute sulfuric acid indicates regions that are rich in starchy components—
in these cases, amyloid (Figure 1.8C and 1.8D) [17, 89].
Cardiac deposition of AL is usually observed within the myocardium as
evidenced by thickening of the interventricular septum, and the distribution in the liver is
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Figure 1.7: Basic mechanism of AL amyloidosis (Taken from [1]).
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Figure 1.8: Clinical manifestations of AL amyloid in various tissues. (A) Kidney, (B)
Gastrointestinal tract, (C) Heart, (D) Liver and (E) Spleen (All images adapted from [17]
except the spleen which came from [89]).
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generally localized to the space of Disse between the hepatocytes and sinusoids [17,
89].

Amyloid deposition in the spleen often appears similar to the kidney with the

formation of dense, white material (Figure 1.8E); typically, the area around the follicles
is the primary region of splenic deposition, but the amyloid can infiltrate further into the
red pulp as well. Patients with renal or cardiac AL amyloidosis have the poorest
prognoses with a median survival of one year, or less [90-93]. This is likely due to
dysfunction caused by the disruption of sensitive tissue architecture in these organs in
response to small amounts of amyloid, leading to progressive organ failure, comorbidities and ultimately death. Therapeutic approaches for AL amyloidosis typically
involve targeting the amyloidogenic plasma cell clones with chemotherapy which
reduces the production of free IgLCs; this treatment, in rare cases, has been shown to
improve cardiac and renal function even without the resolution of amyloid deposition,
but the approach is not curative [17, 94-96].

2.3. Transthyretin amyloidosis – ATTR
Certain potentially amyloidogenic proteins contain heritable (familial) mutations
which cause the protein to be either kinetically or thermodynamically less stable than
the native, non-mutated variant.

This is the case in patients with familial amyloid

polyneuropathy (FAP) which is associated with the deposition of mutant transthyretin
(TTR)—a homotetrameric protein that binds and transports thyroxine and retinol in the
circulation [97-100]. The crystal structure of human transthyretin has been determined,
and it includes 4 units comprising primarily beta sheets with one helix per unit (Figure
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1.9). Unlike AL amyloidosis, the amyloid precursor protein, TTR, is not secreted by
plasma cells; instead, TTR is produced exclusively by the liver. It is worth noting that, in
addition to the familial form of ATTR, certain patients (normally > 60 years of age)
present with a non-heritable form of the disease associated with the aggregation of
“wild-type” protein [101]. This disease, formerly known as senile systemic amyloidosis
(SSA), has recently been given the name wild-type TTR (wt-TTR) by the amyloidosis
nomenclature committee which was announced at the XIVth International Symposium on
Amyloidosis.
More than 100 point mutations have been characterized in TTR and most result
in destabilization of the natively folded protein and/or cause dissociation of the TTR
tetramer [102]—the critical event that leads to formation of the unstable structural
conformation and precedes fibril formation [99, 103-106].

ATTR is a progressive,

eventually fatal, disease that is typically characterized by sensory, motor, and
autonomic neuropathy in addition to cardiomyopathy; thus, with its phenotypic
variability, the disease may be difficult for physicians to recognize and properly manage
[107-110]. In fact, under-diagnosis and misdiagnosis is quite common in these patients,
which results in years of inappropriate treatment and increased likelihood of irreversible
damage to the affected tissues [111]. The genetic inheritance of TTR-FAP is autosomal
dominant; the variant TTR protein circulates from fetal life into adulthood, but no
amyloid forms until later in life which suggests the importance of host factors, such as
immune surveillance, in disease progression [111-113]. The clinical manifestations of
ATTR-FAP paint a grim picture of diverse complications including peripheral neuropathy
which initially affects the lower limbs. With time, numbness and discomfort make
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Figure 1.9: Crystal structure of homotetrameric transthyretin. The structure shown
includes all 4 units of TTR which is almost entirely made of beta sheets (PDB accession
number: 1DVQ).
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walking more difficult. Some amyloid may accumulate locally which can cause carpal
tunnel-like symptoms. The autonomic nervous system can also be affected which leads
to gastrointestinal complications.

Additionally, amyloid can infiltrate cardiovascular

structures including atrial and ventricular myocardium; this causes thickening of the left
and right ventricular walls. In some cases, heart failure progresses due to amyloidassociated restrictive cardiomyopathy [111, 114, 115].
TTR amyloidosis is the most common form of familial amyloidosis.

Some

germline mutations that are commonly observed clinically include Val122Ile, Ile68Leu,
Thr60Ala and Leu111Met which generally result in cardiomyopathy as the predominant
feature, and Val30Met, the most common TTR mutation, is primarily associated with
peripheral neuropathy [111, 116].

Due to its heritability and late onset, there are

populations around the world associated with higher prevalence of the disease [117119]. For instance, in Portugal, Sweden, Japan and Brazil, the Val30Met mutation is
predominant making this mutation the most frequently seen world-wide [120-122]. A
region in northern Portugal is estimated to have an incidence of 1 in 538 individuals with
the Val30Met mutation [123].

In the US African American population, the most

commonly seen mutation is Val122Ile which has an incidence of approximately 4
percent in this population [124, 125].
Of the approximately 120 TTR mutations that have been characterized, only 13
have been deemed as non-amyloidogenic [111, 114, 126]; this, as one might expect,
results in remarkable variability in the disease presentation in these patients. Given the
high incidence of cases in various regions around the world, there are likely many cases
of ATTR that are not recognized or misdiagnosed [111, 127, 128]. Knowledge of the
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disease and detection strategies to diagnose TTR amyloidosis sooner would benefit
patients worldwide.

2.4. Reactive amyloidosis – AA
Amyloid that results secondary to a chronic inflammatory stimulus or infection is
known as secondary, reactive (AA) amyloidosis [9]. As described in a seminal review
by Röcken and Shakespeare, diseases that can cause AA amyloidosis include:
rheumatic diseases (arthritis); idiopathic disease (sarcoidosis, Crohn’s disease and
ulcerative colitis); inherited diseases (familial Mediterranean fever); infectious diseases
(tuberculosis) and some malignant tumors (mesothelioma and Hodgkin’s disease) [9,
129, 130].
AA amyloidosis is initiated by the production of serum amyloid protein A (SAA),
which is the precursor of amyloidogenic protein, AA; SAA is produced principally by
hepatocytes in the liver under the influence of certain pro-inflammatory cytokines such
as IL-6 and TNF-α [131-133]. There are two types of SAA acute phase proteins, SAA1
and SAA2 in humans [9]. Both types are synthesized by the liver in response to an
acute phase inflammatory response. During this response, the serum concentrations of
these two proteins can reach 1-2 mg/mL which is 1000-fold higher than normal
[9, 132, 133]. Once synthesized, 80% of SAA1 and SAA2 proteins bind to lipoproteins
with approximately 90% complexing with high-density lipoprotein (HDL). The SAA
bound to HDL is trafficked through the blood prior to uptake by certain tissues—
predominantly the spleen, liver or kidneys—where there are macrophages known to
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express receptors for SAA-HDL [9, 134-136].

The cellular compartment for the

displacement of SAA from HDL following receptor-mediated endocytosis is unknown,
but data suggests that it may occur in the late endosome as was demonstrated with
SAA conjugated with a fluorophore and monitored with scanning confocal microscopy
[135].

In response to the acidic environment, SAA leaves the HDL particle and

undergoes proteolysis to form AA fragments which are typically N-terminal fragments
spanning the first 66 – 76 amino acid residues of the 122 amino acid protein [137]. The
pathogenetic pathway of AA amyloidosis was summarized by Röcken and Shakespeare
(Figure 1.10) [9].
In the acute inflammatory state, SAA (and perhaps any AA amyloid that forms) is
degraded, but in individuals with chronic inflammatory disorders, fragments of SAA
persist, undergo fibrillogenesis and lead to amyloid deposition in a wide variety of
tissues [138]. Interestingly, the proteolytic digestion of SAA in vivo resulted in products
of varied amino acid length depending on which protease was used [139-141]. It has
been postulated that certain cleavage sites are protective and, once cleaved, render the
products incapable of forming amyloid fibrils [141, 142].

More specifically stated,

cleavage at the N-terminal of SAA has been shown to prevent amyloid formation while
C-terminal cleavage can yield potentially amyloidogenic protein fragments [9, 143].
Figure 1.11 illustrates various possible outcomes of SAA proteolysis.
The deposition of AA amyloid in man is thought to initially occur in the spleen
(mediated by the perifollicular macrophages), followed by the liver and the kidneys
before involving the vasculature and other visceral organs [9]. The most prominent
clinical feature of the disease is renal involvement (> 90% of patients), which results in
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Figure 1.10: Mechanism of AA amyloidogenesis. This diagram illustrates the
biological processes involved in the development of reactive amyloidosis beginning with
the necessary inflammatory stimulus and ending with fibrillogenesis (Taken from [9]).
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Figure 1.11: Possible outcomes of SAA proteolysis leading to fibril formation. (A)
Site of SAA cleavage dictates amyloidogenic potential. The pathogenic SAA fragments
that have been identified contain intact N-termini which suggests that cleavage in this
region may be protective against fibril formation [143]. (B) Cleavage of SAA post
fibrillogenesis. This outcome demonstrates that cleavage at this point in the pathogenic
mechanism of fibrillogenesis may rid deposits of redundant peptides [144-146]. (C)
Cleavage of SAA during the formation of fibrils. It is thought that cleavage during fibril
assembly may assist in the process because it facilitates the removal of protein regions
that might be hindering fibril formation [9]. (D) Cleavage after fibril formation. After
fibrils have assembled, cleavage may have no effect, or it could result in complete
degradation of the protein into amino acids [9] (Image taken from [9]).
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proteinuria [147]. Cardiac AA amyloidosis, albeit rare in humans (~ 2% of patients), can
disrupt tissue architecture and lead to restrictive cardiomyopathy and organ failure
[148]. Gastrointestinal involvement, which presents as diarrhea and malabsorption, is
also observed in ~ 20% of patients [149]. AA amyloidosis, unlike the other types of
amyloidosis previously discussed, can be reversed if the serum concentration of SAA is
substantially decreased, i.e. to < 10 µg/mL. Thus, if the underlying inflammatory cause
of increased SAA levels is treated, the progression of AA amyloidosis can be delayed,
halted, or even reversed [9, 150, 151]. While the incidence in man is typically low,
experimental animal models of AA amyloidosis are one of the primary models used for
researching amyloid diseases.

2.5. Other types of amyloidosis
In addition to the major forms of visceral amyloidosis mentioned above, there are
other diseases associated with amyloid formation (see Table 1.1). For patients that
must undergo long-term kidney dialysis, usually for 10 years or longer, an accumulation
of β2-microglobulin (β2m) leads to dialysis-related amyloidosis (DRA) [1, 152]. Under
normal physiological conditions, β2m is synthesized by all nucleated cells and
associates with major histocompatibility complex class I (MHC I) which assists in the
binding and presentation of short peptide sequences to appropriate CD8 + Tlymphocytes as part of an immune response [152-154]. The average life-time of MHC
class I molecules varies from seconds to days [155, 156], but at the time of their
degradation, the β2m component is released into circulation [157]. Nearly all of the β2m
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is filtered through the kidney glomeruli and then reabsorbed by the proximal tubular
cells where endocytosed β2m is degraded [152, 158, 159]. Consequently, less than
0.1% of the filtered β2m appears in the urine [160]. In patients that must undergo long
term dialysis, the glomerular filtration rate is hindered due to renal dysfunction, and as a
result, the serum concentration of β2m remains elevated.

The dialysis membrane

molecular weight cut off is near or below the molecular weight of β2m; thus, the protein
accumulates in vivo despite the renal filtration assistance of dialysis [152].

This

sustained elevated concentration of β2m (60-fold higher than healthy individuals)
ultimately leads to DRA which tends to target cartilage associated with osteoarticular
tissues leading to bone destruction (See Figure 1.12) [161-163].
Another amyloid-associated disease is type II diabetes (T2D) in which there is an
accumulation of the amyloidotic islet amyloid polypeptide (AIAPP; also known as
amylin) [164].

The deposition of AIAPP solely in the Islets of Langerhans in the

pancreas is a pathological characteristic of T2D [31]. Human IAPP (hIAPP) is stored in
the β-cell secretory granules, in association with insulin [165] and is released in
response to events that lead to insulin secretion [166, 167]. While hIAPP it is a highly
fibrillogenic protein, in non-diabetic individuals, it is normally soluble and unfolded in its
native state [164]. Given its propensity to form fibrils, hIAPP must be protected in nondiabetic individuals in order to circumvent inevitable aggregation [164]. Association with
insulin is thought to be the primary factor in the inhibition of hIAPP fibril formation as
evidenced by several studies demonstrating the inhibitory effect of insulin on
fibrillogenesis [164, 168-172]. Thus, the insulin dependency of individuals with T2D
may predispose them to conditions in which IAPP is not fully protected from
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Figure 1.12:
Mechanism of β2m pathogenicity leading to dialysis-related
amyloidosis. This illustration demonstrates how individuals on dialysis can develop an
over-accumulation of β2m which aggregates and forms amyloid deposits. The amyloid
leads to the destruction of joints and osteoarticular tissues (ITaken from [161]).
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aggregation. It has been determined that AIAPP in the islets is not the cause of T2D,
but it is widely accepted that amyloid formation leads to pancreatic β-cell dysfunction
and cell death—a manifestation that leads to the loss of islet β-cell mass and insulin
deficiency [31, 33, 173-175]. The normal physiological roles of IAPP have not been fully
elucidated, but they may include controlling gastric emptying, maintaining glucose
homeostasis, suppressing glucagon release and controlling satiety [31, 164, 176, 177].
Studies to determine whether or not the deposition of amyloid leads to islet β-cell death
have been conducted. The data indicate that it is the oligomeric intermediate species
that form prior to fibril elongation that are more cytotoxic in vitro [174, 178].

The

addition of fully formed AIAPP fibrils to islet cells in culture did not induce apoptosis, but
there was evidence of amyloid on the viable cells; in contrast, addition of an aqueous
solution of hIAPP to islet cells resulted in apoptosis, and electron microscopy revealed
the presence of nonfibrillar IAPP oligomeric species that had disrupted the cell
membranes and permeated the cells [33, 174]. These data suggest that oligomers,
formed prior to, but on the pathway to, fibril formation are more cytotoxic than the fibrils
themselves; this is analogous to the pathology seen in Alzheimer’s patients [10, 37,
179].

Several hypotheses have been offered to explain why islet amyloid forms in

individuals with T2D, the simplest of which is that there is an increased production of
IAPP as a result of increased secretory demand on the β-cell due to insulin resistance
[177, 180].

This overproduction may lead to intracellular IAPP aggregation and

extracellular amyloidogenesis [181, 182] as is the case with elevated SAA yielding AA
amyloid deposition (see Figure 1.10). Additionally, Montane posits that there may be
defects in the β-cell handling of IAPP due to impaired β-cell function associated with
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T2D [177, 183]. More specifically, the granules within β-cells—where IAPP is produced
and harbored until secretion—may not possess mature functionality under secretory
stress.

Indeed, the pH of β-cell granules under secretory stress is elevated which

favors aggregation [177, 184]. While the mechanisms of AIAPP fibrillogenesis are not
fully understood, two recent hypotheses have been outlined in the literature (Figure
1.13A and 1.13B); in addition to these, a compilation of “proposed mechanisms of IAPPinduced toxicity during amyloid formation” is also presented (Figure 1.13C) [31, 185192]. Regardless of the pathway, AIAPP is associated with β-cell loss in individuals
with T2D.

Early detection of amyloid deposition could benefit T2D patients by

implementing therapies sooner and sparing excessive loss of β-cells; thus, it may be of
clinical import to develop non-invasive imaging strategies to detect and monitor AIAPP
in patients.
Perhaps the most well recognized amyloid-associated disorder is Alzheimer’s
disease (AD). The amyloid pathology with AD is localized to the brain and cerebral
vasculature and arises from the misfolding of the Aβ peptide—arising from the
proteolytic cleavage of the amyloid precursor protein (APP) [32, 179]. Under normal
conditions, Aβ peptide cleaved by certain secretase enzymes remains soluble, is
released into the cytosol and plays a role in nuclear signaling and induction of
transcription and gene expression [193, 194]; however, in patients with AD, the peptide
fragments [e.g. Aβ(1-40) or Aβ(1-42); [195, 196]] adopt conformations that are rich in βsheets (Figure 1.14A) rendering them more prone to aggregate and form extracellular
amyloid plaques in the brain and vasculature [32, 197-199]. An example of amyloid
plaques in brain tissue can be seen in Figure 1.14B; these plaques have been stained
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Figure 1.13: Proposed methods of AIAPP toxicity leading to β-cell death and
amyloid formation associated with type 2 diabetes. (A) Intracellular amyloid leads
to apoptosis forming an amyloid seed propagating extracellular deposition [adapted
from [164]]. (B) Metabolic stress leads to β-cell dysfunction causing amyloid deposition
[adapted from [177]]. (C) List of other possible mechanisms leading to AIAPP-induced
cellular toxicity (compiled from [31]).
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Figure 1.14: Crystal structure of Aβ(1-42) peptide fragment and demonstration of
the fragment within amyloid plaques of a sample of AD brain tissue. (A) Crystal
structure of the β-sheet rich, fibrillogenic Aβ(1-42) peptide (PDB accession number
2BEG). (B) Immunohistochemistry of AD brain tissue with anti-Aβ(1-42) antibody. The
tissue specimen demonstrates the presence of Aβ(1-42) peptide within amyloid plaques
(arrows) (Image adapted from [200]).
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with an anti-Aβ(1-42) antibody indicating the presence of this fibrillogenic peptide within
the AD amyloid deposits. There are two types of AD; one is a rare hereditary condition
(< 3% of cases), in which APP is mutated leading to altered metabolism of the protein
and an increase in Aβ peptide concentration. The other form of AD is more commonly
seen; it likely involves the sporadic overproduction of aggregation-prone Aβ peptides
and/or the reduced degradation and clearance of these species [32, 34]. According to
the amyloid cascade hypothesis of AD, which suggests that AD is a result of Aβ amyloid
accumulation in the brain, the formation of β sheet-rich Aβ peptide and fibrillogenesis
are the first events that start the pathological changes which lead to dementia [201,
202]. Much focus has been directed toward understanding the pathogenesis of AD due
to its devastating clinical and socio-economic impact. It was estimated that “in 2012,
more than 15 million family members and other unpaid caregivers provided an
estimated 17.5 billion hours of care to people with AD and other dementias—a
contribution valued at more than $216 billion” [203]. Investigation of the disease has
now led many researchers to believe that it is the oligomeric species, which result from
the association of multiple improperly folded Aβ peptides, that are more toxic to
microglial cells than amyloid plaques [38] and are the underlying causative agent of the
disease [36, 39, 40].

Given this, many therapeutic approaches involving the

development of monoclonal antibodies targeted towards the Aβ peptide monomer in
addition to a variety of Aβ dimers and oligomers produced prior to amyloid deposition
have been investigated [38, 204]; however, treatment of the disease still remains a
challenge [38].
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Prion diseases, also known as transmissible spongiform encephalopathies
(TSE), are fatal neurodegenerative disorders of the central nervous system (CNS) and
are either inherited, arise sporadically or are acquired from an infection [205-207].
Several prion diseases are known to affect humans while others are typically seen in
other mammals.

The most common human TSE are Creutzfeldt-Jakob disease,

Gerstmann-Sträussler-Scheinker syndrome and fatal familial insomnia disease [208]. A
less common TSE, one of the few acquired human diseases that make up 5 percent of
all TSE cases, is called Kuru which was found associated with villages in Papua New
Guinea [209].

The clinical features of TSE include widespread neuronal loss,

astrocytosis, spongiform changes within the gray matter and amyloid plaque deposition
in the blood vessels of the central nervous system which, in humans, presents with loss
of motor coordination, neurophysiological deficits and dementia due to synaptic
dysfunction [207, 210-213].

The pathogenicity of these diseases initiates with the

misfolding of the inherently circular prion protein (PrPc)—a glycosylphosphatidylinositol
(GPI)-anchored cell surface glycoprotein with no certain function that is abundantly
expressed by neurons in the CNS [214-216].

The pathogenic form of this protein

(PrPSc) is rich in β-sheet which increases its likelihood to associate with other misfolded
prion proteins resulting in the deposition of fibrillar protein aggregates - amyloid [217].
Numerous mutations in the PrPc gene account for the inheritable forms of these
diseases, and it is thought that the transformation of the protein into the PrP Sc isoform
occurs spontaneously under the influence of the mutation [217, 218]. As with other
neurological forms of protein-misfolding diseases, the intermediate species that develop
as the protein progresses to amyloid plaque deposition may be the cytotoxic agents that
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result in synaptic dysfunction and neuronal loss [217, 219, 220]. Perhaps the most
remarkable feature of TSE was the identification that it was a “transmissible” condition –
indeed, it was originally thought that the pathologic aggregates that could induce
pathology in another human carried some sort of biological information akin to DNA.
However, this phenomenon has since been explained by the ability of amyloid fibrils to
seed and induce amyloid formation due to the presence of a preformed template (the
seed or nucleus). It is now widely accepted that seeding with preformed PrPSc fibrils is
the underlying mechanism for transmissibility. This observation has led to the finding
that other forms of amyloidosis are also transmissible both naturally and experimentally
– AA in goats [28] and in mice [221, 222], ApoA2c in mice [30] and Aβ in mice [223].

2.6. Non-human amyloid-associated diseases
Protein-misfolding diseases are not restricted to humans; they can affect other
mammals as well [206, 207].

As previously stated, certain TSE are pathogenic in

animals; Scrapie which affects goats and sheep, bovine spongiform encephalopathy
(BSE) which is also known as “mad cow” disease [224] and chronic wasting disease
(CWD) which affects both deer and elk are the most common [225].
In addition to TSE, animals can also develop AA amyloidosis which likely
progresses, as it is seen in many cases in humans, coincident with chronic
inflammation. Tissue samples from several different animals including, but not limited
to, dogs, cats, ducks, guinea pigs, cheetahs, tigers, gazelles, rabbits, bats, chickens
and hamsters have demonstrated presence of the disease [9, 226-228].
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The

mechanism by which the amyloid forms in these animals is thought to follow the same
progression as that seen in Figure 1.10—the proposed mechanism for human AA
amyloidosis.
The islet amyloid polypeptide that is associated with T2D is present in many
animals, but it is not always an amyloidogenic protein [229]. In addition to humans, cats
and monkeys contain versions of IAPP with mutations in the central region of the protein
that make them more likely to misfold leading to amyloid deposition and T2D [164, 229];
the appearance of a proline residue in the sequence of rat and pig IAPP renders these
proteins non-amyloidogenic [229] unless, in the case of rats, they are genetically altered
to express human IAPP [230-232]. Studies have been conducted comparing the IAPP
homology between cats and humans which reveal that cat IAPP is not as amyloidogenic
as human IAPP [233], but both can misfold and lead to AIAPP amyloidosis.
Given that there are naturally occurring animal models of protein misfolding
disorders including TSE’s, AA amyloidosis and T2D, the use of these disease models
provides a tractable in vivo system in which amyloid-seeking agents can be evaluated
for efficacy. These disease model systems are invaluable to investigators who are
developing diagnostic and therapeutic agents for the treatment of amyloidosis. They
provide important test beds prior to seeking FDA approval of new drugs before
translation into human clinical studies.
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3. Diagnosis

3.1. Pathobiology
Amyloidosis is considered an orphan disease (not including AD or T2D), which
accounts for approximately one per thousand deaths in developed countries [8];
however, since it is not a clinical condition that physicians commonly see and typically
involves multiple tissues in the disease presentation, missed or delayed diagnoses often
occur [8]. While there is a considerable challenge in making an accurate diagnosis of
any type of amyloidosis, it is important to strive for the development of tools, such as
imaging agents, to foster earlier and more complete diagnoses; appropriate treatment
plans being implemented sooner could provide better prognoses for affected individuals.
The realm of diagnostic tools for amyloidosis has somewhat expanded over the
last decade, but the most widely used method for recognition of the pathology relies
heavily on the oldest technique, i.e. histological examination of biopsied tissues [1, 8,
17].

Unlike other protein aggregates, the fibril composition of amyloid enables its

binding to Congo red (CR)—a histological dye that, according to recent work, utilizes
both hydrophobic and electrostatic interactions to bind parallel to fibrils that contain βstrands along the edge or in the middle of a β-sheet [21, 234]. A proposed localization
of Congo red within amyloid fibrils was shown in Figure 1.3B.

When viewed

microscopically with cross-polarized light, the fibrils show green birefringence which is
indicative of amyloid deposition within the tissue (see Figure 1.3A). Examination of CRstained tissues has been the gold standard for amyloid detection for more than 50
years, but this technique has its challenges and limitations; it requires proper application
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of the stain along with other chemicals and skilled interpretation for accurate results [1].
Additionally, the test requires adequate amounts of amyloid and sufficiently thick tissue
sections—without these, the sensitivity of the test falters [8]. According to Pepys, the
British National Health Service National Amyloidosis Center sees more than 1100
patients with known or suspected amyloidosis annually; thus, they have reviewed
thousands of CR biopsies. He states that they continue to see both false positive and
false negative CR diagnoses from many hospitals around the world which further
elucidates the challenges that physicians face when diagnosing the disease [8].
Experiments have shown that CR can bind many “native proteins including cellular prion
protein [235], elastin [236], RNA polymerase [237] and human prostatic phosphatase
[238]” [234]. In addition, CR lacks secondary structure specificity which may suggest an
explanation for the false-positive results that are commonly obtained [234].

While

observing positive CR-stained tissues may provide a diagnosis of amyloid, the type of
amyloid cannot be determined without further testing.
Once it has been detected, classification of the amyloid is a necessity for each
individual patient so that the origin and possible pathogenesis of the amyloid disease
can be recognized and appropriate therapeutic regimens implemented [239-243].
There are different approaches to amyloid typing including the macro- and microextraction of the amyloid protein from tissues and immunohistochemical analysis of
formalin-fixed paraffin-embedded tissue samples [241]. The former has been performed
on autopsy-derived amyloid-laden tissues by multiple centrifugations as described by
Pras et al. [244]. This macroextraction method of separation and purification yielded
approximately 1100 mg of amyloid protein within the resultant supernatants from 20 g of
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amyloid-laden tissue which differed from the normal tissue controls in which no
detectable protein was recovered by adhering to the same protocol [244]. The
microextraction of amyloid proteins has also been performed on biopsy-derived tissue
specimens [245-247] and formalin-fixed tissues [248]; once extracted, the derived
proteins can be identified by amino acid sequencing or mass spectrometry [249, 250].
In addition to protein extraction and sequencing, amyloid classification can be
determined with immunohistochemical techniques in which amyloid-specific antibodies
to some of the most common amyloid proteins (e.g. AA, ALκ, ALλ, ATTR) are applied to
fixed tissues [251-256].

This approach is relatively inexpensive [241], but it has

limitations including the lack of appropriate antisera to conduct the studies [254].
Murphy et al. explains that “commercially available reagents are prepared against the
native form of the amyloidogenic precursor” and may, therefore, not be suitable for
amyloid binding [254]. As was previously demonstrated in the proposed mechanism of
nucleation-dependent fibrillogenesis

(see

Figure

1.4), the

process introduces

conformational changes to the precursor protein. Due to the lack of standardization of
the reagents used for amyloid typing and the lack of regularization of the processing of
the tissue sample, results from immunohistochemistical analysis may be inconclusive;
however, if the appropriate antibody is available and stains amyloid within the sample
strongly and uniformly, it is likely diagnostic [241].
Given that these methods of amyloid characterization may render inconclusive
results, Murphy et al. explored the use of mass spectrometry to identify amyloid type
within biopsy samples and fat aspirates [254].

The application of tandem mass

spectrometry (MS/MS) to various samples of amyloid-containing biopsies or fat
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aspirates that had previously been characterized (e.g. ALλ, ALκ, AA, ATTR) yielded
fragmentation indicative of each of the amyloid types studied; a limitation to this
procedure is the amount of material needed for MS/MS analysis—additional biopsy
samples were often necessary [254].
Whether it be due to: the untrained observer’s inability to detect scant amyloid
birefringence; the difficulty associated with discerning between amyloid-associated
congophilic material and native tissue components with cross-polarized birefringence
when attempting amyloid detection; the lack of appropriate sample preparation or
amyloid stains for amyloid characterization; or the limited availability of material
necessary for MS/MS amyloid typing, there is an extreme challenge associated with
detecting and characterizing amyloid deposition by these methods. Therefore, other
techniques need to be developed and validated.

3.2. Imaging
In most instances, patients with amyloidosis begin their clinical path by seeing
physicians who do not specialize in the treatment of the disease (most often
oncologists, cardiologists and nephrologists).

Consequently, accurate diagnosis of

amyloidosis can take more than 18 months and usually requires consultation at one of
the amyloid treatment centers such as the Mayo Clinic, Rochester. Therefore, more
effective approaches need to be implemented for routine detection and diagnosis of
amyloid in the general clinical arena. To this end, dedicated efforts have been made in
the realm of medical imaging for the facile detection of amyloid diseases. Advances in
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molecular imaging can help provide these patients with a non-invasive alternative for
disease detection—prior to advances in the field of imaging, biopsy-derived histological
test results were the only means of detecting the disease. Some of the imaging
modalities that have been utilized for the detection of amyloid include magnetic
resonance imaging (MRI), ultrasound (US), optical imaging (OI), computed tomography
(CT), positron emission tomography (PET) and single photon emission computed
tomography (SPECT).
3.2.1. Modalities
CT and MRI—anatomical imaging modalities
While anatomical imaging such as CT, MRI and US should not be used alone as
diagnostic tools for amyloidosis, they can provide valuable information about the
anatomic consequences of amyloid deposition. For instance, abnormalities present in
CT/MRI/US can offer guidance as to where biopsies should be taken if amyloid disease
is suspected [257-259]. Additionally, the presence of abnormalities can help discern the
type of amyloid disease. If, upon CT examination, pulmonary deposits are detected,
there is greater likelihood that the amyloid disease in question is AL and not ATTR or
AA because, unlike AL, these amyloidoses rarely affect the lungs [260].
CT is an imaging modality capable of visualizing the anatomical characteristics of
an individual (spatial resolution of clinical scanners is 0.5 – 1.0 mm) without having to
collapse a 3D structure into two dimensional images like conventional radiography [261,
262]. The principles behind this imaging system rely on the ability of X-ray beams to
physically traverse the cross-section of an object, be attenuated by the object and then
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be detected [263]. Multiple projections are necessary to reconstruct a representative
3D image. As the X-rays travel through diverse types of material, they become variably
attenuated; for instance, water, bone, muscle and air attenuate X-rays differently. Each
attenuation is assigned a linear attenuation coefficient (μ) which is a measurement
reflecting the degree to which the X-ray intensity was reduced by a certain material.
These values are used in the formula below to determine the CT number, known as the
Hounsfield unit (HU), associated with the materials detected in the CT acquisition [264]:
𝐶𝑇 𝑛𝑢𝑚𝑏𝑒𝑟 = (𝜇 − 𝜇𝑤𝑎𝑡𝑒𝑟) ∕ 𝜇𝑤𝑎𝑡𝑒𝑟
The assigned CT numbers represent a range of gray values which are used to
generate an image (i.e. the HU of water is 0 and air is -1000). The materials of lowest
density appear darker; air will look black in the image. More dense materials will appear
lighter with bone looking white in the image (Figure 1.15). In some clinical cases, only
certain regions of patients are of interest, and to efficiently visualize those regions, the
HU window can be set to only display a particular range of values—alteration of the
window width. This is an advantage of CT imaging and image analysis, as compared to
MRI or 2D X-ray, because it can improve lesion detection and diagnostic accuracy [265267].

Additionally, CT imaging is often much faster than MRI imaging which is

beneficial for the patients and their level of comfort. While CT provides much more
information than X-ray radiography, this imaging modality exposes individuals to more
radiation [268]. To address this concern, faster multidetector CT scanners with the
automatic exposure control have been implemented into many systems [268, 269].
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Figure 1.15: CT image demonstrating visualization of air and bone in a patient.
Air within the lungs of this individual is black which is assigned the HU value of -1000
(red arrow); bone, a more dense material, appears white which has the HU value of
1000 (green arrow). This is an unpublished image generated in Dr. Wall’s lab at the
University of Tennessee Medical Center, Knoxville, TN.
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MRI is a non-invasive method for examining the tissue architecture that does not
rely on an internal or external source of radiation.

This imaging modality takes

advantage of the magnetic properties within the body’s composition, especially those
associated with the nuclei of hydrogen atoms. With the Earth’s magnetic field, atoms
align, but once the body is subjected to the presence of another magnetic field, like that
within an MRI system, the atoms move to align with the new magnet—this can be
manipulated and measured to form an image. MRI can provide exquisite soft tissue
imaging and is advantageous in that it does not require much energy absorbance. MRI
has been used to image patients with amyloidosis, but most often, the anatomical
imaging reveals tissue abnormalities that may have resulted due to amyloid deposition,
not the presence of amyloid itself. The observed abnormalities, however, can guide the
biopsy which will confirm, after histological examination, if amyloid is present in the
tissue abnormality. Typical amyloid-associated MRI findings include myocardial and
interventricular thickening associated with cardiac amyloidosis in patients with AL or
ATTR [270, 271]. Additionally, patients with ATTR occasionally undergo MRI analysis
to visualize neuronal amyloid deposits around the leptomeninges and brain stem [272].
In rare cases, patients with localized amyloidosis develop focal deposits known as
amyloidomas; this pathology can be well visualized with MRI [273, 274].

When

investigating cardiac abnormalities that are possibly attributed to amyloid deposition,
post-contrast MRI has been shown to display “global, subendocardial late gadolinium
enhancement” which is characteristic of cardiac amyloid, but this abnormality can be
challenging to detect when amyloid has infiltrated the interstitium or when arrhythmias
degrade the quality of the image [275-278].
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Ultimately, MRI can assist in the

visualization of pathological sequelae arising from amyloid deposition, can assist in the
detection of rare, focal amyloidomas and can display contrast-enhanced abnormalities
indicative of cardiac amyloidosis. However, it cannot provide information about the
whole body distribution of amyloid itself.
PET Imaging
In recent years, much effort has been directed toward the implementation of
molecular imaging technologies for the quantitative detection of amyloid in patients.
The goal of these protocols is to create images that capture the in vivo whole body
distribution of the amyloid, to assess the molecular-based characteristics of diseases
and to monitor therapeutic responses in both humans and animals [261]. PET imaging
involves the detection of positron-emitting radionuclides; positrons are particles that
have the same mass as electrons but the opposite charge and are emitted by protonrich nuclei such as Fluorine-18 (18F), Carbon-11 (11C) and Iodine-124 (124I) [261, 279].
These radionuclides are conjugated to tracers that are injected into or inhaled by the
patient, and it is the distribution of the radiotracer that is imaged with PET. The signal
that is detected with PET imaging is generated by the annihilation of a positron/electron
pair which usually emits a 511 keV coincident gamma photon pair in opposite directions
at 180° [261].

The line that could be drawn to connect the two detected gamma

photons is called the line of response (LOR). Numerous photon pairs are detected by
the 511 keV-sensitive crystal scintillation detectors which are typically positioned
cylindrically around the imaged subject. The scintillation material is able to emit visible
light when it absorbs energy from charged gamma rays [280-282]. The positron and
electron do not always annihilate and create a 180° coincident event, also known as a
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true event; some annihilations result in skewed emissions called scatter events or
random events (Figure 1.16). Scatter events arise when the emitted photons, either
both or just one, undergo Compton scattering—a photon encounters an electron
causing the electron’s energy to be released and the photon’s direction to be changed
[283]—prior to their detection. Thus, the lack of 180° opposing deflections does not
generate a LOR that accurately pinpoints the origin of emission (Figure 1.16A).
Random events occur when photons from distinct nuclei are generated and detected
simultaneously, but the LOR between the two detections is not indicative of the origin
from which either photon was emitted (Figure 1.16B). For an image to be processed,
the detected photon energy which has been transformed into light energy by scintillators
must be converted into electronic signals; this is accomplished with photomultiplier
tubes (PMT) [280].

The sensitivity of PET imaging, which is greater than that of

SPECT, is reliant upon both geometric and intrinsic detection efficiencies; the former
pertains to the placement of detectors as close to the subject as possible to lessen the
likelihood that any photons are emitted and not captured. The latter pertains to the
material used within the detectors—thicker, denser materials will be more likely to stop
511 keV gamma rays, allowing for their detection. The use of PET imaging provides a
unique capability for in vivo monitoring of the biodistribution of radiolabeled materials in
real time—an acquisition known as dynamic PET imaging. Analysis of dynamic data
can generate time activity curves (TAC) which can elucidate the biokinetic properties of
radiotracers in the subject. The high sensitivity of PET imaging makes it a desirable
modality for disease detection in both preclinical and clinical studies, but it has
limitations. The noncolinearity of annihilation photons and the range of positron
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Figure 1.16: Types of coincidence events associated with PET photons (Image
taken from [261]).
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emissions hinder the system’s ability to distinguish and detect subtle differences in
molecular signals from miniscule structures (generally < 4 mm), known as the spatial
resolution, of PET [261, 284].

Recent advances in Alzheimer’s disease molecular

imaging utilize PET to image the radiotracer, Amyvid™, in amyloid-laden regions of the
brain that may be indicative of the disease (which will be discussed in a later section)
[285].
SPECT Imaging
In addition to PET molecular imaging, SPECT imaging is also used to noninvasively detect diseases and clinical manifestations. SPECT is the most common
molecular imaging modality in the clinic and requires the use of an injectable tracer
which has been radiolabeled with isotopes that emit gamma ray photons. Some of the
most commonly used gamma ray-emitting SPECT radionuclides are iodine-125 (125I),
iodine-123 (123I) and technetium-99m (99mTc). Unlike PET imaging, where detection of
the radionuclide is dependent upon the formation of a LOR generated from two high
energy positrons through electric collimation, with SPECT, the one photon emission
associated with each event must be detected through what is termed physical or
geometric collimation [261, 284]. The collimators within a SPECT imaging system are
usually made of a dense material such as tungsten or lead.

They contain a

configuration of pinholes through which photons that will contribute to the image enter;
those that do not go through the pinholes will not be detected [261]. The pinholes, in
combination with a position-sensitive detector, determine the LOR affiliated with photon
emissions in SPECT systems. Much like that seen with PET systems, not all events
that are recorded by the camera are true events that should contribute to the image;
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events are considered true if the LOR that is drawn between the point of interaction with
the detector and the photon emission location passes through a collimator pinhole [286].
Scatter events occur when photons enter the pinholes from skewed directions thus
creating false events.

With both PET and SPECT imaging modalities, scattered

photons generate what is referred to as “background noise” within the image—this
“statistical uncertainty” creates a haze and reduces the image’s contrast resolution [261,
287, 288]. The data from SPECT systems are acquired much like that seen in PET
systems, but, instead of the detector elements being placed in a ring around the imaged
subject, the detectors are on plates (one plate is required, but two plates increase the
sensitivity of the system) which rotate around the individuals to generate 3D images.
Pre-clinical and clinical SPECT imaging systems offer different advantageous properties
as compared to PET. These include a range of radionuclides with longer physical halflives than those routinely used in PET protocols, which may better estimate the
biokinetics of radiotracers, and the ability to perform multiple energy studies
simultaneously [280]. The latter refers to studies in which more than one radiotracer
can be introduced into the imaged subject; the tracers are individually labeled with
different radionuclides (i.e. 123I with 99mTc or 125I), and since the energies associated with
these radionuclides do not overlap (99mTc has an energy of 140 keV and

125I

has an

energy of 20-35 keV), the two tracers can be discerned within the individual
simultaneously [289].

This capability provides a means of comparing two imaging

agents, perhaps the gold standard agent and a novel agent, under the same
physiological conditions within the same individual; it also allows visualization of two
different physical processes, such as the measurement of blood flow, metabolic rates or
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protein binding, amidst the detection of other characteristics simultaneously [289-294].
The ability to detect and acquire multiple measurements within an individual subject with
SPECT imaging circumvents the questionable reproducibility of in vivo conditions that
arise with sequential imaging acquisitions when concurrent dual energy studies are not
feasible. For example, an individual, amyloid-laden mouse which was simultaneously
administered the gold standard amyloid imaging agent, SAP, radiolabeled with
an amyloidophilic, synthetic peptide, p5, radiolabeled with

99mTc,

125I,

and

can be seen in Figure

1.17 [293]. This study illustrated a direct comparison of two radiotracers—insight into
the relative efficacy of either (i.e. comparative effectiveness) can be ascertained with
SPECT dual energy imaging in a single subject.
Dual Modality Imaging
In many instances, CT imaging is informative as a singular modality; however,
recently, CT is used in conjunction with PET and SPECT to provide enhanced
capabilities.

This approach yields images that provide anatomical reference to the

radioactivity introduced by the PET or SPECT imaging agent. A review by Schöder et
al. on the subject refers to this system as “an imaging technology that combines highquality PET and CT in a single device and provides simultaneous structural and
biochemical information under nearly identical conditions” [262]. Without an anatomic
frame of reference, the precise location of radiotracers in vivo is not evident, and thus,
the image may be misinterpreted. Studies have been conducted to assess the value of
the dual modality system in which individual modalities and combined PET/CT
modalities were used to detect pathology; results in each study show that the use of
PET/CT enhanced detection of disease [262, 295, 296]. In addition to the benefit of
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Figure 1.17: Dual energy SPECT imaging with 125I-SAP and 99mTc-p5 in an
amyloid-laden mouse. The use of two radiotracers allowed for simultaneous imaging
of both SAP and peptide p5 in a single mouse. (A) In vivo distribution of 125I-SAP. The
radioactivity has localized to amyloid in the liver and spleen of this AA mouse with slight
accumulation of free iodide in the thyroid. (B) In vivo distribution of 99mTc-p5 in the
same mouse. The image demonstrates accumulation of radiotracer in the liver, spleen,
kidneys, pancreas and intestine. Direct comparison of SAP and p5 suggests that p5
targets more of the amyloid load in this mouse. (Adapted from [293]).

57

anatomical reference, CT can be used to provide attenuation correction to the PET
image data which results in better image quality and a reduction in whole body scan
time by at least 40% [279] . Without attenuation, the uncorrected PET image can form
“a rim of apparently increased activity along the periphery of the body and relatively
lower tracer uptake in organs in the center of the body” [262].

Thus, attenuation

correction is necessary in order to provide more accurate image display and
interpretation.
Nowadays, all clinical and preclinical PET imaging is performed by using dual
modality PET/CT systems.

SPECT/CT systems have also been implemented to

address many of the same concerns that single modality PET imaging faces. As stated
by Mariani et al., “the main advantages of SPECT/CT are represented by better
attenuation correction, increased specificity and accurate depiction of the localization of
disease” [297].

Additionally, dual SPECT/CT imaging improves visualization of

functional and metabolic information that is provided with nuclear medicine tests which
monitor molecular changes that may not be observed with anatomical tests such as CT
or MRI alone [297-299]. To demonstrate the advantage of anatomic localization using
SPECT/CT, the same data presented in Figure 1.17 is displayed in Figure 1.18 as a
SPECT/CT dual modality image.
3.2.2 Tracers
Molecular imaging in the form of PET or SPECT relies on the use of radiotracers
which have been developed to target disease and metabolic functions. I will focus
exclusively on those that relate to amyloid imaging. These agents can be categorized
into one of the following types: small molecules, antibodies and proteins or amyloid58

Figure 1.18: Dual modality SPECT/CT images. Co-registration of the CT data with
the SPECT data (B and C) provides anatomical reference for the distribution of
radiotracers. Thus, the labeled tissue accumulation shown (A and C) are more readily
interpreted (Image taken from [293]).
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associated materials. The tracers have been radiolabeled with positron emitters such
as

18F, 124I, 11C

or gamma emitters such as

123I

or

99mTc

for PET or SPECT detection,

respectively.
3.2.2.1. Small molecules
Due to its immense socio-economic impact, much clinical focus has been
devoted to the molecular imaging of amyloid associated with Alzheimer’s disease (AD)
which has been determined to be one of the “defining neuropathologic findings” of the
disease [300]. The greatest risk factor for AD is advanced age, and with enhanced
medical discoveries leading to longer life-spans, there is greater likelihood that more
individuals will become afflicted with the disease [179, 301, 302]. According to the AD
organization’s annual review, it is estimated that 5.2 million Americans have AD; this
estimate can be broken down into approximately 5 million that are over the age of 65
and 200,000 individuals under age 65 that have developed the disease with earlier
onset [303, 304]. The report also indicates that “one in nine people age 65 and older
(11 percent) has the disease”; this estimation is based on the U.S. population records
projected by the 2013 U.S. Census Bureau [304].
The pathological, extracellular deposition of amyloid in the brain parenchyma and
cerebral vasculature of AD patients and patients with mild cognitive impairment (MCI)
results from the accumulation of misfolded beta-amyloid peptide fragments as amyloid
[32]. The discovery of extensive and site-specific amyloid in AD patients warranted the
development of an amyloid-seeking agent which could aid in detection of the disease.
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The first amyloid imaging agent to be approved by the FDA for clinical
assessment of the amyloid load in patients suspected of AD is Amyvid™ (formerly
known as Florbetapir or AV-45; Avid Radiopharmaceuticals/Eli Lilly, Indianapolis, IN).
Several multicenter trials have been conducted in which Amyvid™ was administered to
patients with AD and patients with MCI along with a group of healthy controls (HC) [305307]. PET/CT imaging was performed after ~ 50 – 70 minutes post injection of the
radiotracer. The results from these studies indicated that the accumulation, determined
visually and quantitatively using standard uptake values (SUV), in cortical regions was
higher in AD and MCI patients than that seen in HC.

While these findings were

encouraging for both physicians and patients affected by AD, there are limitations to its
clinical use. The quantitative information collected from each of these scans must be
interpreted by a skilled and trained reader in order to get credible results; it has been
reported that the discernment between AD/MCI patient data and HC data could be
simplified if efforts are made to improve the spatial resolution of the images and if
appropriate training is offered for nuclear medicine physicians [305]. News reports have
indicated an additional limitation on the clinical use of Amyvid™ because of the
decision, one that took many months to reach, by the Centers for Medicare and
Medicaid Services (CMS) to not cover the drug’s use for β-amyloid PET imaging for the
diagnosis and treatment of neurodegenerative disorders [308, 309]. According to the
detailed memo provided by the CMS, there was a lack of sufficient evidence to support
the use of PET imaging with AmyvidTM; however, there was a realization that the drug
may be beneficial in specific cases in which the goal would be to exclude AD as a
diagnosis (e.g., in patients with fronto-temporal dementia) [310]. They also believed
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Amyvid™ could facilitate clinical studies seeking better treatment and prevention
strategies (i.e., used as an endpoint in clinical trials). While there are positive results for
Amyvid™’s ability to detect amyloid plaques within the brain, there is a lack of evidence
that the radiopharmaceutical could be used for the whole body detection of systemic,
visceral amyloid. A recent study using AmyvidTM to detect systemic amyloid deposition
revealed that distribution of the radiotracer provided target-to-background ratios
indicative of amyloid pathology in only the heart of amyloid patients [311]. Given that it
was a pilot study, they were unable to calculate the specificity, sensitivity or diagnostic
accuracy of the imaging agent, and they were unable to discern the whether the amyloid
was AL or ATTR in those patients with positive images. Additional, multicenter studies
are being performed to further assess Amyvid’sTM utility as a visceral amyloid imaging
agent [311].
Another small molecule used for β-amyloid detection is known as Pittsburgh
compound B (2-[4´-(methylamino)phenyl]-6-hydrobenzothiazole; PiB).

The molecule

also binds to Aβ amyloid in the brain parenchyma and blood vessel walls of AD patients
[312-317]. Initial studies with the PiB used carbon-11 as the radionuclide. While

11C-

PiB has been shown to detect β-amyloid, the positron emitter hinders the effectiveness
of

11C-PiB

due to its very short half-life (20.4 min)—essentially, in order to use the

molecule, the in vivo image acquisition must be performed in an institution with a
cyclotron for radioisotope preparation and immediate use [317, 318]. To circumvent the
inconvenience of the short half-life of carbon-11, PiB has been radiolabeled with
fluorine-18 (T1/2 = 109.8 min); this molecule, recently approved by the FDA, is known as
18F-Flutemetamol

(or clinically Vizamyl™: GE Healthcare, Arlington Heights, IL).
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Studies in clinical trials have shown that the fluorinated molecule performs similarly to
the parent

11C-molecule

and additionally provides wider accessibility for both clinical

and research purposes [317].
However, it suffers from the same regulatory limitations imposed on Amyvid TM.
Recent data indicate that 11C-PiB, because of its retention by amyloid, can also be used
to image cardiac amyloid deposits associated with both ATTR and AL amyloidosis
[319]. This group concluded that the molecule could image cardiac amyloidosis within
the myocardium of affected patients, but there was reversibility in the binding which
would suggest early time point imaging in future studies [319]. Notably, the amyloid in
other visceral organs was not imaged using this tracer. Studies using

18F-Flutemetamol

for imaging cardiac amyloidosis have yet to be published.
Many other small molecules have been utilized as amyloid-imaging agents also.
These include
DPD) and

99mTc-labeled

99mTc-labeled

3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-

hydroxymethylene diphosphonate (99mTc-HDP). These

99mTc-

labeled phosphate derivatives were developed decades ago as bone seeking agents to
be used in nuclear medicine planar, gamma scintigraphy as a means of detecting bone
abnormalities such as skeletal metastases and benign bone disease [320-322].
Calcifications that present in some amyloid deposits—especially those seen in the heart
of patients with ATTR and those with SSA (wild type ATTR)—may explain the uptake of
these tracers in cardiac amyloid [323]. Myocardial involvement associated with TTR
amyloidosis, both mutant and wild type TTR amyloid, has been imaged with

99mTc-DPD;

positive image data correlated with high amounts of amyloid fibrils [323-325]. The same
tracer used in AL patients with cardiac amyloid deposition gave negative image data
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[323, 324]. Thus, this imaging agent may be used to discern between ATTR and AL
cardiac amyloid. A recent study using

99mTc-HDP

concluded that scintigraphic analysis

with this tracer may be able to detect cardiac amyloidosis in ATTR patients, and like
DPD, the amount of uptake correlated with the severity of amyloid deposition [326].
These small molecules have been shown effective in certain types of amyloid
diseases, but they are not suitable for whole-body detection of amyloid in the case of
systemic disease. Thus, the small molecules available for amyloid detection do not
address all clinical needs.
3.2.2.2. Antibodies and proteins
In addition to small molecules, certain antibodies and proteins have been
developed as amyloid-targeting agents. Two antibodies that have been explored as
therapeutic and/or diagnostic (“theranostic”) agents for amyloidosis are 11-1F4 [327329] and 2A4 [330, 331].

Initially developed as therapies for the disease, these

antibodies have since undergone PET and SPECT imaging studies to assess their
efficacy for amyloid detection in vivo. In addition, the most commonly used protein that
has been evaluated as an amyloid-imaging agent is aprotinin [332]. It was shown to be
efficacious as an amyloid imaging agent, but, as with other tracers, there are limitations
associated with its use.
The monoclonal antibody (mAb) 11-1F4 was generated using human light chain
amyloid-related aggregates and recognizes an epitope common to fibrils associated
with ALκ and ALλ [327, 328, 333]. Initial studies conducted with 11-1F4 revealed its
ability to expedite resolution of subcutaneous (sc) human AL in “amyloidoma”-bearing
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mice; these studies involved formation of a palpable sc AL amyloidoma by injection of
~100 mg of amyloid extract derived from autopsy tissue specimens [327].

After iv

injection of a total of 600 μg mAb 11-1F4 (administered over a 12 day period), the
amyloidomas in treated mice, by day 15, were reduced in size as compared to control
mice which received equivalent amounts of an isotype matched control antibody or were
left untreated altogether [150]. Furthermore, iv administration of radioiodinated 11-1F4
into mice with an AL amyloidoma and PET/CT imaging showed co-localization of

124I-

11-1F4 radiotracer in the amyloid xenograft [328, 329] as shown in Figure 1.19. Given
the potential therapeutic and diagnostic potential of the mAb, an FDA-approved Phase 1
exploratory investigational new drug (eIND) trial to study the efficacy of

124I-11-1F4

as a

systemic amyloid targeting agent was initiated. The results of this study indicated that 9
of the initial 18 enrolled patients with known amyloid deposition demonstrated uptake of
124I-11-1F4

in the liver, lymph nodes, intestines, bone marrow and spleen as shown in

PET/CT images [329]. A representative patient from this study can be seen in Figure
1.20 where the image revealed uptake of the mAb in the amyloid-laden liver. For all
imaged patients, the renal and cardiac deposits were not visualized, however. The lack
of uptake in these affected organs was thought to be due to the absence or
inaccessibility of the mAb’s epitope. The conclusion from this study was that imaging
with

124I-11-1F4

could be a good predictor of patients that may benefit from a passive

immunotherapeutic approach with this mAb (i.e., as a preliminary patient stratification
tool before recruitment into an 11-1F4 therapy protocol).
The other mAb that has been generated to possibly assist in the detection and/or
therapeutic removal of amyloid deposits is known as 2A4 [330, 331]. This mAb was
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Figure 1.19: Co-localization of mAb 124I-11-1F4 with a sc AL amyloid xenograft as
evidenced by PET/CT. The image shows uptake of the radiotracer within the AL
amyloidoma which is located between the scapulae of the mouse. This finding led to
further development of the radiotracer as a potential imaging agent in patients with AL
amyloidosis. (Adapted from [328]).
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Figure 1.20: The mAb 124I-11-1F4 can image amyloid-laden liver in an AL patient.
The mAb was administered 5 days prior to imaging.
As shown, 124I-11-1F4
accumulated in the hepatic amyloid of this patient. (Taken from [329]).
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developed to bind the carboxy-terminal epitope (amino acid sequence His-Glu-Asp-Thr;
HEDT) which was created following proteolysis of serum amyloid A protein (SAA), the
precursor protein for AA amyloidosis. The antibody does not recognize native SAA
which contains 103 amino acids; it was shown to bind the -HEDT epitope of the cleaved
SAA fragment (~ 75 residues) associated with AA amyloid fibrils [142, 330, 334, 335].
When radiolabeled with iodine-125 and injected into AA amyloid-laden mice,

125I-2A4

co-localized with the amyloid deposits as evidenced by SPECT imaging (Figure 1.21A)
and microautoradiography [330].

Surprisingly, further preclinical studies with this

antibody indicated that it is also capable of in vitro binding to amyloid fibrils composed of
immunoglobulin light chains associated with AL amyloidosis [331].
Furthermore, in vivo analysis revealed that administration of

125I-2A4

to mice

bearing sc human AL amyloidomas resulted in preferential SPECT imaging of the
amyloid mass (Figure 1.21B), and treatment of these mice with the mAb expedited
resolution of the amyloidomas when compared to control mice which received an
isotype-matched antibody.

Thus, preclinical studies provided evidence that 2A4,

because of its ability to selectively bind amyloid in vivo, could be a valid agent for
imaging and immunotherapy in patients with AL amyloidosis in addition to its diagnostic
utility for AA amyloidosis [330, 331]. A humanized GMP version of the murine mAb 2A4
was generated, known as NEOD001 (Prothena; Dublin, Ireland), is currently in a Phase
1 clinical trial investigating the maximum tolerated iv dose in AL amyloidosis patients
[336] (NCT01707264).
The protein that has been investigated most thoroughly as a potential amyloid
imaging agent is 99mTc-labeled bovine aprotinin (Trasylol), a protease inhibitor. Since
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Figure 1.21: SPECT/CT imaging and ARG of both AA and AL amyloid with mAb
125I-2A4.
(A) Distribution of 125I-2A4 in an AA amyloid-laden mouse. SPECT/CT
imaging showed uptake of the mAb in the liver and spleen of an AA mouse. The black
silver grains in the ARG of both liver and spleen tissues coincide with the birefringent
regions in consecutive tissue slices stained with CR indicating co-localization of mAb
with AA amyloid. (B) Uptake of 125I-2A4 in a sc human AL amyloidoma. The
SPECT/CT indicates radiotracer in the AL amyloidoma (arrow), and ARG/CR
comparison confirmed co-localization of mAb with AL amyloid (Images adapted from
[330, 331]).
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amyloid deposits are known to contain antiproteinases such as α 1-antichymotrypsin
[332, 337, 338], it was hypothesized by Aprile et al. that aprotinin may react with this
component of amyloid deposits [332]. There is evidence that this protein accumulated
in the renal cortices as part of natural catabolism; thus, initial investigations with the
imaging agent focused on the detection of extra-abdominal AL amyloid deposition by
planar scintigraphy [332, 339-342]. Cardiac amyloid involvement in the 24 AL patients
participating in this study was imaged in all patients with known myocardial deposition;
additional amyloid deposits were also imaged in the lung, thyroid, salivary glands and
tongue leading to the conclusion that

99mTc-aprotinin

could be a cost-effective approach

to imaging extra-abdominal amyloid involvement in AL patients [332]. A more recent
study conducted in 2003 showed similar results in 23 patients with known or suspected
AL amyloidosis; uptake of

99mTc-aprotinin

was, again, visualized in the heart and other

organs previously mentioned. Of note, this study included a patient which showed
positive myocardial uptake of the radiotracer but had no clinical signs of cardiac
involvement; thus,

99mTc-aprotinin

was able to detect “clinically silent” amyloid pathology

in an individual [343]. Conclusions from this study revealed that

99mTc-aprotinin

may be

useful for detection of extra-abdominal amyloid lesions, but, due to renal excretion, “it is
not suited for detection of amyloid deposits in kidneys or bladder” [343].

Other

limitations include the inability of the radiotracer to reveal amyloid within the central or
peripheral nervous system and nonspecific binding in the liver. While aprotinin has
been used by several institutions world-wide, it has been suspended from clinical use in
the United States due to adverse effects seen in studies utilizing the drug to reduce
bleeding during heart surgeries [344].
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Thus, 11-1F4 and aprotinin have been developed for imaging amyloid deposition
in patients, but there are limitations to each of their use—namely, the antibody has not
shown efficacy in detecting cardiac or renal amyloid, and aprotinin, which has shown
merit in cardiac amyloid detection, can no longer be used in the United States.
3.2.2.3. Visceral amyloid-related agents
Given the need for amyloid imaging agents, some investigators have explored
the use of radiolabeled amyloid components as a strategy to detect the deposits. There
are two amyloid-associated agents that have been utilized: serum amyloid P component
(SAP), which is found ubiquitously in amyloid deposits and β-2-microglobulin (β2M),
which is found in amyloid fibrils related to dialysis-associated amyloidosis.
Of all the imaging agents developed for amyloidosis, SAP has been most widely
investigated and utilized clinically, albeit exclusively in Europe (UK, Italy and the
Netherlands). As previously stated in section 1.2.3, SAP is a 250 kDa glycoprotein that
is associated with all types of amyloid deposits with the exception of Aβ plaques in the
brain. In an individual with no amyloid, SAP circulates in the plasma at ~ 20 mg/L; the
concentration of SAP is increased in the amyloid, and there can be 20,000 mg of SAP
within the deposits as well as free SAP in circulation [8]. SAP binds to the fibrillar
component of amyloid deposits in a calcium dependent manner [8]. Given this, the
abundance of SAP associated with amyloidosis patients has been exploited as a means
of amyloid detection. It was first introduced as a potential imaging agent by Hawkins et
al. when they discovered that

123I-SAP

targeted amyloid after iv injection in a murine

model of AA amyloidosis as evidenced by planar scintigraphy [65]. The imaging agent
was introduced into patients with amyloidosis in a study conducted by Hawkins,
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Lavender and Pepys in which 50 biopsy-proven patients were enrolled (25 AL and 25
AA patients) [345]. The protocol for this study included iv administration of

123I-SAP

into

patients and control individuals which was then followed by whole body scintigraphic
imaging 24 hours post injection. This landmark study revealed that

123I-SAP

imaged

amyloidotic organs in all confirmed patients, and uptake was also seen in 6 individuals
whom had negative biopsies prior to the study.

These patients either underwent

subsequent biopsies or tissue was analyzed at autopsy, and amyloid disease was later
confirmed in all 6 patients [64]. The control individuals showed no uptake of the tracer.
A representative image of a patient with AL amyloidosis alongside an image of a healthy
control can be seen in Figure 1.22. The image shows uptake of the tracer in the liver,
spleen and bone marrow of the AL patient while the healthy control reveals evidence of
radiotracer in the blood pool and tissues involved with hepatobiliary clearance. The
specificity of

123I-SAP

patients [64].

localization to amyloid deposits was confirmed at autopsy in 6

Additionally, the investigators found that the “density of amyloid

deposition demonstrated histologically in the various tissues corresponded exactly to
the quantity of tracer present in the in vivo images” [345]. This study indicated that,
although the tracer cannot provide convincing images of cardiac amyloid,

123I-SAP

can

be used as a diagnostic tool for amyloidosis and as a method to ascertain disease
progression or regression for AL and AA patients [346]. With the success of this tracer,
scintigraphic imaging with

123I-SAP

has been incorporated into the clinical management

of many patients at multiple institutions in Europe [56, 64, 345, 347-350]; the tracer,
however, is not FDA approved and cannot be used as a means of determining amyloid
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Figure 1.22: 123I-SAP planar scintigraphy acquired 24 h pi in an AL patient and a
healthy control. The image on the left shows uptake of the radiotracer in AL amyloidladen tissues such as the liver, spleen and bone marrow of a patient. (Image taken from
[351]). The distribution of 123I-SAP (and free 123I-iodide) in a healthy individual is shown
on the right to account for non-specific accumulation of the radiotracer at 24 h pi.
(Image taken from [352].

73

distribution for patients in the US. An alternative whole-body imaging agent is needed
for patients that cannot undergo an SAP imaging acquisition.
The final amyloid component that has been developed as an imaging agent for
amyloidosis detection is

111In-

or

131I-

β2M.

Patients that have undergone chronic

dialysis for longer than 10 years are at risk of developing dialysis related amyloidosis
(DRA) which involves an over-abundance of circulating β2-microglobulin rendering it
amyloidogenic (Aβ2M) [161, 353]. The amyloid is typically deposited in soft tissues
surrounding joints but can also affect the gastrointestinal tract, lungs and heart [1]. It
has been reported that the relatively safe methods of amyloidosis diagnosis—Congo
red histological analysis of a fat aspirate or rectal biopsy—fail in the cases of DRA [354359]; additionally, the method that can, indeed, detect Aβ2M involves examination of
amyloid within synovial fluid invasively extracted from joints such as the knee, ankle,
wrist or shoulder [354, 358, 360]. As an alternative to these invasive strategies, imaging
agents for Aβ2M detection have been investigated. While

123I-SAP

can detect some

amyloid deposits in long-term hemodialysis patients, accumulation in other sites such as
joints in the hips and shoulders were not accomplished with this tracer [361]. Studies
conducted by Floege et al. demonstrate that scintigraphy with radiolabeled β2M could
adequately visualize Aβ2M amyloid deposition in patients with confirmed DRA; patients
that underwent hemodialysis but had no evidence of amyloid deposition were also
131I-

β2M

111In-

β2M

administered the tracer, and no uptake was detected [361]. They used either
or

111In-

β2M to assess amyloid deposition, and they determined that the

provided improved image contrast and sensitivity along with reduced radiation
exposure. This imaging agent could offer a non-invasive approach to diagnosing DRA
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in patients with end-stage renal failure [360], but it is not applicable to other forms of
systemic amyloidosis.

4. Preclinical evaluation of amyloidosis

4.1. Model systems
Based on the previous description of amyloid-specific radiotracers, there is a
clear need to develop alternatives, particularly for whole body imaging in the US. To
discover and optimize new amyloid-targeting imaging agents, preclinical models of the
disease have been developed. Proper assessment of novel techniques and reagents
must be performed prior to their introduction into a clinical setting; this section discusses
many of the model amyloid systems, both in vitro and in vivo, that are utilized by
investigators and employed in this thesis for studying new potential imaging agents for
amyloidosis.
4.1.1. Synthetic fibrils
Given that all types of amyloid deposits contain proteinaceous fibrils, one of the
earliest model systems that has been developed for in vitro studies of amyloidosis is
synthetic fibrils. The use of synthetic fibrils gives insight into the structural, biochemical
and biophysical properties of protein polymerization, or fibrillogenesis, and has been
employed to study numerous types of protein fibrils [81, 182, 362, 363]. This model
system

can elucidate

protein-protein

interactions in

a

simple,

non-biological

environment—an advantage and limitation of this method. A certain dye, known as
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thioflavin T (ThT), is a fluorescent marker that binds to all amyloid fibrils; upon binding,
the emission intensity of ThT at 490 nm, as measured with a fluorimeter, increases by
orders of magnitude which indicates the presence of fibrils or the process of fibril
formation if measurements are taken over time [364, 365]. This type of assay can also
be used to evaluate potential inhibitors of synthetic fibril formation [366]. Additionally,
the in vitro formation of amyloid-like fibrils facilitates high resolution structural studies of
the fibrils and the intermediates that exist on the pathway of fibrillogenesis. Techniques
such as X-ray diffraction [367], solid state nuclear magnetic resonance [368, 369] and
cryo-electron microscopy [370] have been performed on various amyloid-like synthetic
fibrils—processes that would not be amenable using tissue amyloid extracts due to the
heterogeneity and complexity associated with such samples. Synthetic fibrils composed
of the variable domain of λ6 light chains, e.g. Vλ6Wil, are generated [81] and used
routinely in our laboratory.
4.1.2. Tissue extracts
Since there are more components to amyloid deposits than solely the fibrils,
amyloid extracts derived from tissues provide a more complex model system of the
disease.

Tissue extracts derived from autopsy materials (livers and spleens), of

patients with AL amyloidosis have been used in characterization studies of potential
amyloid-binding agents [363, 371]. Patient amyloid extracts are often prepared using
techniques which removed extraneous materials leaving amyloid fibrils, proteoglycans
and minimal SAP components within the samples [244]. In contrast, tissue amyloid
extracted from patient material or from mouse organs (e.g., with AA or ApoA2c
amyloidosis) yields homogenate samples which contain all the essential amyloid
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components mentioned above, but they might be complicated by the presence of other
polymers such as intracellular materials. When compared to synthetic fibrils, the use of
tissue extracts provides an ex vivo environment that more closely resembles the
composition of amyloid material in vivo.

This model system is amenable to

characterization studies which assess the binding affinity of certain amyloid-targeting
probes—namely those to be utilized in vivo as amyloid imaging agents (as is presented
in this thesis).

Specificity of such agents can be established using this amyloid

substrate by various techniques such as sodium chloride (NaCl) titrations (to assess the
strength of electrostatic interactions) and heparinase treatments (see later sections).
Heparinase treatment has been applied to AL patient extracts to remove the HSPG
component and determine if amyloid-binding agents can interact with amyloid in the
absence of this prevalent component [363]. These studies were used to elucidate the
heterogeneity of patient AL extracts as indicated by the vastly differing binding abilities
of a single agent on diverse ALλ and ALκ preparations. These component-specific
studies would not be possible without access to “complete” amyloid present in extracts;
synthetic fibrils alone would not be as informative for analyzing amyloid-peptide
interactions. The amyloid extract model system can help characterize amyloid-targeting
agents, but the possible hindrances that exist in vivo, such as tissue vascularity and
competing “sinks” for the agent, are absent in this system; thus, positive findings ex vivo
may not fully translate to the in vivo system—something I explore in this thesis.
4.1.3. Mice
Experimental in vivo models of amyloidosis are the most informative system for
evaluating amyloid-targeting agents and/or potential therapeutics. Given that there are
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several amyloidoses which are known to affect various tissues, many mouse models
have been developed to facilitate the investigation of these diseases; however, the
repertoire is incomplete.

Although there are several mouse models of Alzheimer’s

disease which deposit localized Aβ amyloid, they are beyond the scope of this thesis.
The following section discusses mouse models of visceral amyloidosis (e.g., AA,
ApoA2c, ATTR, Aβ2M and AL).
The most historically used model is that of AA amyloidosis which relies on the
induction of amyloid deposition by the injection of compounds including casein [372],
silver nitrate [373] and lipopolysaccharide [374]—all of which stimulate the production of
pro-inflammatory cytokines, such as IL-1 and IL-6, and the subsequent secretion of SAA
[27]. The repeated induction of an inflammatory stimulus causes an overproduction of
SAA ultimately leading to AA amyloidosis. This model has been used extensively to
study the disease and is believed to mimic amyloid distribution seen in patients with AA
amyloidosis [375], but in the absence of the stimulus, amyloid deposition can resolve
spontaneously with time [27, 376]; thus, there are limitations to the types of studies
which can be conducted.
An alternative model for AA amyloidosis is a transgenic mouse which
constitutively expresses human IL-6 leading to the overproduction of SAA.

The

transgenic mouse strain, B6(C)-Tg(H2-Ld_IL-6)Kish(H2/huIL-6), was developed at the
National Institutes of Health as a model for studying myelomas and plasmacytomas
[377, 378]. The C57BL/6 mouse germ line was modified by the introduction of human
IL-6 cDNA with transcriptional control mediated by the murine major histocompatibility
complex class I (H-2Ld) promoter. These mice (H2/IL-6) were crossed with mice of
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BALB/c genetic background [379], and after more than 20 generations had been
performed, spontaneous AA amyloidosis was detected in the spleen, liver, tongue,
heart, intestines and kidneys by 8 to 9 months of age [378].
The amyloid deposition associated with both mouse models of AA could be
induced by injection of AEF [380, 381], but the transgenic model circumvents the need
for repeated inductions of inflammatory stimuli, and it provides a system to study earlyonset, spontaneous, chronic AA disease which has proven suitable for both amyloidtargeting and therapeutic studies.
As an experimental model for mouse senile amyloidosis,—a disease which
demonstrates progression in an age-associated manner—transgenic mice were
developed that overexpress apolipoprotein A-2c (ApoA2c) under the cytomegalovirus
immediate early gene enhancer/chicken beta promoter on the apoA-II gene [382]. The
ApoA2c protein self-associates to form amyloid fibrils (AApoA2c) in these mice as they
age. Other allelic variants of this gene, namely ApoA2a and ApoA2b, are unable to
form amyloid fibrils in transgenic mice [383]. An abundance of ApoA2c in combination
with administration of pre-formed AApoA2c fibrils (8 to 10 μg) generated severe
amyloidosis which can be observed in the testes, liver, kidneys, heart, lungs, spleen,
tongue, stomach and intestine [382]. While the human form of AApoA2c amyloidosis is
extremely rare (< 10 cases described in the literature), this model of the disease offers
another in vivo system in which potential amyloid-targeting agents can be evaluated,
particularly in the heart where significant amyloid is observed.
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Mouse models of human ATTR amyloidosis have been produced, but “they have
not been as successful as investigators would wish” [384]. These models involve the
expression, as transgenes, of both mutant and wild-type human TTR genes, and while
deposition does occur in some tissues, the model does not consistently generate
amyloid deposits; additionally, the deposition does not recapitulate the neuropathology
seen in patients [384]. Some studies involve the introduction of TTR genes into C57Bl/6
x DBA/2 F1 mice in which the inserted human genomic DNA contained all elements
known to regulate tissue specific expression; this technique, however, led to deposition
in organs that are not known to synthesize the protein [385]. Later studies found that
approximately 80 % of transgenic mice modified with wild type human TTR older than
18 months of age developed non-fibrillar deposits; the remaining 20% of these mice
developed lesions consistent with the human condition [386]. A model utilizing insertion
of human genomic DNA from a patient with FAP confirmed these same findings in that
mice most commonly generated what was considered to be “non-fibrillar, amorphous
aggregates” as indicated by the presence of human TTR with immunohistochemical
analysis and a lack of Congo red staining in histological examination [384]. In mice
where amyloid is deposited, the hepatic and cardiac deposits are similar to those seen
in patients; additionally, the late onset of the disease is analogous with the ageassociated manner of disease progression that affects patients [387-390].

Overall,

these studies suggest that since there is inconsistent amyloid deposition in mice, this
system may be most useful for only evaluating TTR aggregates which may form prior to
amyloid deposition.
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As previously stated, patients that undergo long-term hemodialysis are at a risk
of developing DRA by the deposition of amyloidotic β2M [391, 392]. Studies indicate
that murine β2M is not amyloidogenic; thus, a transgenic model generated to
overexpress human β2M (hβ2M) in mice with β2M knockout background has been
developed [393, 394]. The concentration of hβ2M in mouse plasma measures 100
times greater than that seen in normal human plasma, and it is more than 4 times that
measured in long-term dialysis patients [394]. In regard to these plasma levels, the
mice are similar to patients seen clinically. The amyloid deposition that is associated
with patients, however, was not observed in the transgenic mice; even by 2 years of
age, there was no birefringent material detected in the mice when tissues were
examined with Congo red stain [394].

The model may provide information on the

diseased state of animals with elevated hβ2M levels, but the lack of amyloid deposition
makes it unlike the human condition. These data also imply that certain pro-amyloid
host factors may be present in man but lacking in mice.
Given that AL is the most common form of amyloidosis in humans, a mouse
model of the disease for experimental studies of potential amyloid-targeting agents for
detection or therapy would be of great value.

Investigators have used different

approaches to reproduce the disease in mice, but a model that closely resembles the
pathology seen clinically is still lacking. One model involved the intraperitoneal injection
of various amounts of Vλ6 Bence Jones protein (BJP; extracted from AL patient urine)
into C3H/HEJ mice [395]. These mice received multiple injections over several weeks.
It was found that a single injection of 300 mg BJP was unsuccessful at producing
amyloid deposits in mice euthanized 48 hours post injection; similarly, repeated
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injections of 100 mg over 2 to 5 weeks, which was the equivalent of 900 to 2200 mg of
protein, resulted in no amyloid deposition [395]. Slight renal deposition was detected
only after mice had received ~ 5300 mg BJP over a 12 week period. Since this requires
large amounts of patient material, they employed a strategy that had been previously
used to accelerate the induction of renal casts in mice receiving BJP—dehydration of
the mice (48 hour without water prior to BJP injection) increased the extent of deposition
[395, 396]. Amyloid deposition occurred in mice that were dehydrated for 24 hours prior
to each of ten 200 mg injections of BJP over an 8 week period (2 g BJP total)—
renovascular deposits within vessel walls and the interstitium were Congo red positive.
This model proved to be useful for the investigation of amyloidogenicity of certain BJP,
but as previously stated, there is a need for large amounts of patient materials which is
not ideal for an experimental animal model since a limited amount of patient-derived
BJP may hinder experimental protocols. Additionally, the repeated injection of BJP in
immunocompetent mice could result in a mouse-anti-human immunological response
[397]. The administration of AL patient-derived BJP into mice was used in another
model in which the light chains were injected (1 mg per day) through the mouse penile
vein; renal tissues were examined for amyloid deposition at various time frames, up to
14 days, post-injection [398]. This model was generated as a means to investigate
mesangial glomerular amyloid deposition that contributes to the renal failure seen in AL
patients. By 12 h pi of patient light chains, mice had extracellular deposition of amyloid
fibrils; at 7 d pi, amyloid deposition was clearly evident, but by 14 d pi, amyloid
formation was abundant as evidenced by transmission electron microscopy and
polarized Congo red stain. As stated by Teng et al., this model system “is potentially a
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significant scientific advance toward future development of new therapeutic avenues to
ameliorate the progressive renal failure which represents the typical clinical course of
patients with AL amyloidosis with renal involvement” [398]. Since the aforementioned
AL mouse models involve the introduction of potentially limited patient-derived
materials, and there is potential for a mouse immune response to injected materials, the
use of this model for long-term, in vivo AL studies may be challenging. To circumvent
these obstacles, a transgenic mouse model was generated by insertion of cDNA from a
λ6 AL patient who had amyloid involvement in the heart, liver, kidney, spleen and
adrenals [397]. While the transgenic mouse was able to produce human light chains,
Congophilic amyloid material was only found in the lumen of gastric glands of the
stomach. The amyloid was of light chain origin, but the clinical manifestation of AL
amyloid is not typically localized to the stomach nor presents with this type of
distribution. This transgenic mouse model is useful for AL amyloid detection which is
amenable to potential oral therapeutics [397], but it is not representative of the disease
state which affects humans.
4.1.4. Naturally occurring disease models
For certain amyloid diseases, there are naturally occurring animal models. As
previously mentioned, AL is the most common amyloid disease to affect humans. In
other mammals, however, AA amyloidosis is the most common form of the disease.
Two of the most widely recognized naturally occurring models are in Chinese Shar pei
dogs and Abyssinian cats. AA amyloidosis in the former, which presents much like an
inherited disorder known as familial Mediterranean fever (FMF) in humans, causes renal
disease; however, the gene responsible for FMF differs from that seen in dogs [399,
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400].

Studies suggest that Chinese Shar pei dogs with renal amyloidosis in

combination with recurrent fever of unknown origin may be useful as a naturally
occurring model of human disease due to the common organ distribution [400]. In
Abyssinian cats, renal medullary and glomerular amyloidosis along with papillary
necrosis has been observed as a result of familial predisposition; studies suggest that
this amyloid is AA and that these animals may be a naturally occurring model of familial
secondary amyloidosis or FMF leading to papillary necrosis [399-402].
In addition to naturally occurring cases of AA amyloidosis, feline diabetes mellitus
is another common naturally occurring model of amyloidosis in that there is deposition
of IAPP detected in the pancreatic tissue, most commonly within the islets of
Langerhans, of cats [403-405]. It has been postulated for years that AIAPP could play a
significant role in the impairment of islet cells in individuals with Type 2 diabetes
mellitus; islet amyloid deposition occurs in more than 90% of humans with the disease
and more than 65% of adult diabetic cats [166]. Given that diabetic cats generally
exhibit the same amyloid distribution detected in human pancreatic tissue, this naturally
occurring animal model may prove valuable for investigating IAPP amyloid-targeting
agents and can be used to evaluate in vivo efficacy and toxicology.

4.2. Preclinical amyloid-targeting agent: Peptide p5
Since the clinically available amyloid-targeting agents discussed above (Section
3.2.2) have limitations to their use, much focus has been directed toward the preclinical
development and translation of novel agents. For example, the camelid antibody, B10,
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has been shown to target a particular epitope on Aβ and AL fibril fragments through an
electrostatic interaction by using in vitro binding studies [362, 406, 407]. In addition, we
have shown that the small chain variable fragment (scFv), NS4F5, which interacts with
a unique hypersulfated form of HS, also preferentially binds amyloid deposits as
evidenced by SPECT/CT imaging [49, 71-73, 408].

These preclinical agents have

demonstrated the utility of electrostatic interactions for targeting amyloid deposits. They
also have limitations to their use. For example, B10 has not been shown effective as a
pan-amyloid binding agent [362], and the amyloid-NS4F5 interaction was transient, and
this probe was incapable of detecting amyloid at 4 h pi [73]. These limitations led to our
further investigation of synthetic peptides as an alternative amyloid-targeting agent.
Since the HSPG in amyloid appears to have sulfation patterns more like heparin
[7] and is distinct from the HS in all other tissues and organs, recent studies have
focused on the idea of amyloid-targeting through GAG involvement and have explored
the use of heparin-binding peptides for amyloid detection [409]. The attention shifted
from scFv to peptide development because “peptides can be chemically synthesized,
are rapidly cleared from the circulation when not bound to target, are relatively small,
can penetrate blood vessel walls and are generally nonimmunogenic” [409-413]. Seven
heparin-binding peptides were radiolabeled with

125I

and investigated by small animal

SPECT imaging, biodistribution measurements and micro-autoradiography in H2/IL-6
AA mice (previously described in section 4.1.3). These peptides, referred to as p1
through p7 in the comparative study, all exhibited a polybasic amino acid motif but
revealed variable affinities for AA amyloid in vivo, as evidenced by SPECT/CT,
biodistribution measurements and microautoradiography studies [409].
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The lead

candidate peptide after image analysis at both 1 hour post injection and 4 hours post
injection was peptide p5—a 31 amino acid peptide whose parent structure, referred to in
the literature as K8, was initially synthesized for heparin neutralization [414].

The

polybasic sequence of p5 includes a heptad repeat Lys-X-X-Lys-X-X-X (where X is Ala
or Gln) which provides a +8 net positive charge and was predicted to adopt an α-helical
conformation. Interestingly, the secondary structure prediction illustrated that the basic
lysine residues aligned to one face of the helix as seen in Figure 1.23. Previous circular
dichroism studies with K8 indicated that the peptide is, indeed, α-helical in the presence
of heparin [414]. These experimental data, together with the predicted structure of the
peptide, led to the hypothesis that the binding of p5 with HSPG in amyloid deposits may
be the result of an electrostatic interaction between the polybasic surface of the αhelical peptide and the enhanced sulfation pattern uniquely seen in amyloid-associated
HSPG. Microautoradiography of tissue samples obtained after the comparative peptide
SPECT imaging study revealed that p5 preferentially bound amyloid as evidenced by
the co-localization with amyloid in multiple organs (Figure 1.24). This specificity has
been further demonstrated by staining amyloid with biotinylated p5 in formalin-fixed
tissue sections from patients with e.g., ALκ, ALλ, ATTR and Aβ [409].
Given the amyloid-targeting specificity of peptide p5 in the aforementioned
SPECT imaging study of AA mice, a dual energy SPECT/CT comparative effectiveness
imaging analysis was performed by comparing p5 and the clinically available agent,
SAP.

This study allowed for the direct comparison of p5 distribution with SAP

distribution in the same H2/IL-6 AA mouse [293]. SAP was radiolabeled with

125I

and

injected into the lateral tail vein of mice; at 22 h pi, 99mTc-p5 was injected into the same
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Figure 1.23: Predicted structure of peptide p5. Structure was generated by I-Tasser
[415], and images were adapted from [416].

Figure 1.24: Microautoradiography (ARG) of 125I-p5 distribution in various AA
mouse tissues and Congo red (CR) histological confirmation of peptide colocalization with amyloid. (Image taken from [409]).
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mice. They were euthanized and imaged at 24 h pi of
protocol) and 2 h pi of

99mTc-p5

125I-SAP

(adhering to clinical

[293]. The resulting images reveal that both SAP and

p5 were able to localize to hepatic and splenic amyloid, but p5 bound to pancreatic and
intestinal amyloid more effectively than SAP (Figure 1.25).

Conclusions from this

comparison suggest that p5 was a valid alternative to SAP and could fill a clinical need
for patients in the United States.
Additional studies with p5 have been conducted to show that the amount of

125I-

p5 that localizes to amyloid-laden mouse tissues after injection correlated with the
amount of amyloid within the tissue [417]. This study compared amyloid load assessed
by quantification of Congophilic, birefringent material in tissue sections with

125I-p5

uptake, i.e. biodistribution measurement (percent injected dose of peptide/gram of
tissue), of the same tissue. The amount of peptide p5 uptake and birefringent material
correlated linearly with a correlation coefficient of > 0.7 and a p value less than 0.00001
[417], which indicated that p5 could not only detect amyloid deposition but that it could
do so in a quantifiable manner.
While the initial hypothesis implied that peptide p5 binds to amyloid-associated
HSPG, recent work has demonstrated that heparinase-treated, human AL amyloid
extracts could still exhibit an interaction with p5. This study compared p5 binding to
various AL patient amyloid extracts before and after heparinase treatment utilizing an ex
vivo binding assay [363]. The data indicated that binding of p5 to many of the extracts
was decreased, but not completely abolished, after the removal of the HSPG sulfate
groups, suggesting that p5 may have another target in amyloid deposits. This was
confirmed when the peptide was shown to bind synthetic AL amyloid fibrils composed
88

Figure 1.25: Dual energy SPECT/CT images illustrating 99mTc-p5 and 125I-SAP
distribution in an individual AA mouse. (A, B and E) Distribution of 99mTc-p5. There
was uptake in the liver (L), spleen (Sp) pancreas (P) and intestines (I). The stomach
(St) and thyroid (T) were devoid of radiotracer. (C, D and F) Distribution of 125I-SAP.
The image revealed uptake in the liver and spleen. The stomach showed no uptake of
radiotracer, but the thyroid sequestered free 125I-iodide as a result of radiotracer
dehalogenation. These images depict that radiolabeled p5 provided more information to
the whole body amyloid burden than radiolabeled SAP. (Image taken from [293]).
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exclusively of rVλ6Wil [363]. Furthermore, Scatchard analyses supported the “multiple
target” hypothesis of p5 revealing that the peptide, in the presence of tissue amyloid
homogenate, has 2 binding sites which are, hypothesized to be HSPG and fibrils [371].
Although the peptide has proven efficacious at targeting amyloid in multiple
systems and in various studies, certain biological parameters of p5, specifically the
kinetics of the radiotracer in vivo and the stability of peptide-amyloid interaction, were
undeterminable using the methods mentioned in previous studies. To gain insight into
the biodistribution and pharmacokinetics of p5 in diseased and healthy animals,
dynamic PET imaging acquisitions were performed, and the time activity curves
generated from the data illustrated that the peptide is rapidly cleared from the blood
pool in both WT and AA mice. The accumulation of

124I-p5

in amyloid-laden liver and

spleen began abruptly after blood pool clearance and remained stable throughout the 2
h duration of the acquisition; in healthy mice, at ~ 7 min pi, the radiotracer uptake
peaked in the kidneys then washed out leaving no accumulation of intact

124I-p5

in any

tissues—only free isotope was detected in the stomach and thyroid due to
dehalogenation in the kidneys. The kinetic profiles of diseased and healthy mice were
drastically different which could facilitate diagnosis of amyloidosis (Figure 1.26).
Additionally, this study revealed that the dehalogenation of p5 in the absence of amyloid
target was important and could be beneficial for imaging renal amyloid. The stability of
p5 binding was also assessed, and there was evidence of

125I-p5

bound to amyloid in

SPECT/CT images acquired at 72 h pi (Figure 1.27). With such stability comes the
advantage of waiting “extended periods of time post injection without the loss of positive
signal” [416]. This allows for clearance of background noise and enhances the
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Figure 1.26: 124I-p5 PET dynamic time activity curves. The radiotracer distribution
throughout a 2 h acquisition in AA mice (blue) and WT mice (red) is shown. Notice the
rapid blood pool clearance (heart) in both diseased and healthy mice. Additionally,
there was evidence of radiotracer clearance through the kidney in WT mice which led to
stomach and thyroid accumulation. The liver and spleen of diseased mice showed
rapid 124I-p5 accumulation. These distinct kinetic profiles could identify diseased mice.
(Image adapted from [416]).

Figure 1.27: SPECT/CT images revealing the stability of 125I-p5 binding to
amyloid. AA mice were administered 125I-p5 and imaged multiple times pi. The images
indicate radiotracer stability in amyloid-laden tissues for at least 72 h. (Image taken from
[416]).
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likelihood of the critical detection of small deposits that form in early stages of the
disease—a valuable property of an imaging agent for any disease but especially
valuable for the under-diagnosed, yet deadly, amyloidosis.
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Chapter 2
Project Rationale and Summary

The systemic amyloidoses are particularly devastating diseases which are
thought to be clinically underdiagnosed due to their heterogenous nature and the, often
times, inconclusive presentation of clinical symptoms. With the most common forms of
systemic amyloidosis, namely light chain amyloidosis and hereditary or wild type
transthyretin amyloidosis, renal and cardiac pathological involvement contribute to the
most ominous prognoses for patients. Since these organs are typically affected in the
later stages of the disease, it is of the opinion of many researchers and clinicians that
early diagnosis could lead to the implementation of appropriate treatments and, thus,
better prognoses for patients. Currently, the accepted method of amyloidosis detection
and diagnosis involves histological (Congo red) evaluation of biopsy-derived tissue
samples – an invasive procedure prone to clinical complications. The use of Congo red
for amyloid detection in tissue samples has been employed for decades, but for
untrained observers, the samples can be difficult to interpret. Additionally, this method
is subject to sampling error and cannot offer insight into the whole body distribution or
the extent of amyloid deposition in an individual. Therefore, a more facile, non-invasive
method of amyloid detection would be valuable to both physicians and patients.
While histological examination of tissue specimens remains the gold standard for
disease diagnosis, efforts directed toward the development of amyloid-targeted imaging
agents have been made. The following imaging agents are clinically available or are in
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human clinical trials for systemic amyloidosis:
DPD/HDP,

11C-PiB, 18F-PIB, 18F-florbetapir,

and

123I-SAP,

124I-11-1F4.

99mTc-aprotinin,

99mTc-

These agents, however,

all have limitations which include the lack of availability in the United States, the inability
to detect cardiac amyloid deposits, isotope half-life constraints and inconsistent findings,
i.e. the inability to detect all known amyloid-laden organs in a patient. Given these
restrictions, the development of novel amyloid-imaging agents is of clinical import.
Since the composition of amyloid deposits contains a unique, hyper-sulfated form
of heparan sulfate proteoglycan which “looks” biochemically and electrochemically
similar to heparin, we have investigated a series of heparin-binding peptides as
potential amyloid-targeting and imaging agents.

These studies elucidated positive

binding characteristics of one peptide in particular, known as p5. This peptide has been
shown in vivo to preferentially co-localize to amyloid deposits found in the murine H2IL6 model of AA amyloidosis, and comparative studies of p5 and SAP in this mouse
model indicate that the peptide may be a valid imaging agent for AA amyloidosis.
Histological examination of the peptide on tissue samples of various other visceral
amyloid diseases—ALκ, ALλ and ATTR—demonstrated co-localization of the peptide
with these forms of amyloid also.

Since there are no well-defined experimental or

naturally-occurring animal models of AL or ATTR in which to further validate the
peptide, another murine animal model of amyloidosis, an ApoA2c transgenic model,
was used for additional ex vivo and in vivo testing of p5.
Although the peptide p5 has been shown to interact with multiple types of
amyloid including human AL, AA and ATTR as well as murine AA, p5 was not detected
in ApoA2c tissue homogenates in an ex vivo peptide-binding assay.
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This lack of

interaction was also seen in vivo where radiolabeled p5 peptide was incapable of
binding and imaging amyloid in ApoA2c mice. This conundrum led us to develop other
synthetic peptides as prospective imaging agents, based on the structure of the parent
p5 peptide.
In order to optimize peptides as agents for enhanced ApoA2c amyloid-targeting,
multiple p5 variants were synthesized that focused on biochemical characteristics that
govern amyloid detection. Initially, the modification consisted of substituting all lysine
residues with arginine residues to potentially increase the α-helicity of the peptide and,
in turn, the strength of amyloid binding. Next, extended peptides with four additional
basic amino acid residues were created with the hypothesis that an increased net
positive charge would enhance the peptide-amyloid interaction, which is principally
electrostatic in nature.

A peptide with an N-terminal polyethyleneglycol (PEG)

modification was synthesized to investigate the supposition that extended half-life via an
increase in size would improve amyloid binding and coverage. Finally, peptides with the
incorporation of non-natural D-amino acids at the N-terminal were also developed and
tested to hypothetically extend the half-life without altering the size of these amyloidtargeting agents and, thereby, permit greater amyloid uptake.
The work described in this thesis investigates these peptide variants for their
ability to bind amyloid in both the AA and ApoA2c mouse models. Surprising findings
seen using the p5 peptide and peptides evaluated herein indicate that amyloid is a
complex pathology and that it may be unreasonable to speculate that one peptide could
detect all amyloid types. Nonetheless, peptides optimized for the detection of certain
amyloid diseases could be of clinical import for diagnosing the diseases and monitoring
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responses to appropriate therapies. An optimized peptide would be invaluable and
permit earlier detection of amyloidosis.
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Chapter 3
Materials and Methods

3.1 Peptides and proteins

The peptides used in the following studies were synthesized by Keck
Laboratories (New Haven, CT) and RS Synthesis (Lexington, KY).

A table of the

peptides along with their sequences, molecular weights and net charges is included
(Table 3.1). Synthetic recombinant Vλ6Wil fibrils were produced as described [81] by
expression in E. coli. The pelB leader resulted in accumulation of the protein in the
periplasmic space from where it was isolated by osmotic shock and purified by reverse
phase HPLC using a C8 solid phase matrix with a gradient of acidified acetonitrile as
the mobile phase.

3.2 Reagents

Ascorbic acid ................................................................ Sigma Aldrich (St. Louis, MO)
Blue dextran ................................................................. Sigma Aldrich (St. Louis, MO)
Chloramine T ................................................................ Sigma Aldrich (St. Louis, MO)
Heparinase I ................................................................. Sigma Aldrich (St. Louis, MO)
Iodogen ........................................................................ Pierce (Rockford, IL)
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Table 3.1: Physical properties of synthetic peptides

Peptide

Amino Acid Sequence

Molecular
Weight
(Da)

Net
Charge
(+)

p5

GGGYS KAQKA QAKQA KQAQK AQKAQ AKQAK Q

3257.7

8

p5R

GGGYS RAQRA QARQA RQAQR AQRAQ ARQAR Q

3481.8

8

5102.6

12

4766.4

12

~ 25,000.0

12

p5R+14
p5+14
PEG-p5R+14*

GGGYS RAQRA QARQA RQAQR AQRAQ ARQAR QAQRA
QRAQA RQARQ
GGGYS KAQKA QAKQA KQAQK AQKAQ AKQAK QAQKA
QKAQA KQAKQ
PEG-GGGYS RAQRA QARQA RQAQR AQRAQ ARQAR
QAQRA QRAQA RQARQ

p43**

AQAYS KAQKA QAKQA KQAQK AQKAQ AKQAK Q

3356.8

8

p50

AQAYS KAQKA QAKQA KQAQK AQKAQ AKQAK Q

3356.8

8

*The polyethyleneglycol modification is 20 kDa.
**Those in red are D-type amino acids.
The molecular weights and net charges were calculated using ProtParam [418].
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Isoflurane ..................................................................... Abbott Laboratories (Chicago, IL)
Leupeptin ..................................................................... Thermo Scientific (Rockford, IL)
Lyophilized gelatin ........................................................ Bio-Rad Labs (Hercules, CA)
NaCl ............................................................................. Fisher Scientific (Fair Lawn, NJ)
NaN3............................................................................. Sigma Aldrich (St. Louis, MO)
NuPAGE™ LDS sample buffer 4X ............................... Novex (Carlsbad, CA)
NuPAGE™ sample reducing buffer 10X ...................... Invitrogen (Carlsbad, CA)
Phenylmethylsulfonyl fluoride ....................................... Sigma Aldrich (St. Louis, MO)
Phosphate buffered saline ............................................ Sigma Aldrich (St. Louis, MO)
Sodium metabisulfite .................................................... JT Baker (Phillipsburg, NJ)
Tween-20 ..................................................................... Fisher Scientific (Fair Lawn, NJ)

3.3 Mice

Transgenic mouse models of AA and ApoA2c amyloidosis were used in the
following studies.
The H2-IL6 mouse model of AA amyloidosis was generated by the incorporation
of human interleuken 6 (IL-6) cDNA into the C57BL/6 germ line with transcriptional
control mediated by the murine major histocompatibility complex class one promoter (H-
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2Ld). These transgenic mice were then mated with BALB/c mice for >20 generations.
The overabundance of constitutively expressed IL-6 in these mice led to spontaneous
AA amyloidosis by 8 to 9 months of age [379]. A breeding pair of H2-IL6 mice on the
BALB/c background were kindly provided by Dr. Michael Potter from the Laboratory of
Genetics at the National Cancer Institute of the National Institute of Health, Bethesda,
MD.
An experimental model of senile ApoA2c amyloidosis was generated by the
overexpression of apolipoprotein A-2c, controlleded by the cytomegalovirus immediate
early gene enhancer/chicken beta constitutive promoter [382].

Production of high

concentrations of the amyloidogenic ApoA2c protein, in combination with an iv injection
of preformed AApoA2c fibrils (amyloid enhancing factor (AEF): 10 – 100 µg), yielded
severe systemic amyloidosis.

The initial breeding pair was kindly provided by Dr.

Keiichi Higuchi from the Department of Aging Angiology at the Shinshu University
School of Medicine, Matsumoto, Japan.
Wild type BALB/c mice from Charles river or non-transgenic H2/IL-6 littermates
were used as controls in these studies.
All animals were housed in microisolator cages and provided food and water ad
libitum.

The University of Tennessee Medical Center vivarium is an IAAALAC-

accredited facility, and all procedures described in this thesis were conducted in
accordance with Institutional Animal Care and Use Committee (IACUC) approved
protocols and in accordance with the Guide for the Care and Use of Laboratory Animals
(8th Edition, National Academic Press, Washington, D.C. 2011).
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3.4 AL amyloid extract preparation

Human AL amyloid was extracted from autopsy-derived tissues, both liver and
spleen were used for this purpose.

The water floatation method used to separate

amyloid proteins from unwanted tissue was previously described [244]. Briefly,
approximately 20 g of tissue and 400 mL of 0.15 M NaCl were homogenized using a
Polytron homogenizer (Binkmann Instruments, Westbury, NY) and then centrifuged at
10,000 rpm (~ 15,000 x g) for 30 minutes. The pellet was then mixed with 400 mL of
0.15 M NaCl, and then homogenized and centrifuged, again, as described above. This
was repeated six or seven times; the supernatant from each centrifugation was
discarded because it contained unwanted soluble proteins and non-amyloid tissue
components.

After serial homogenization in 0.15 M NaCl the final pellet was

resuspended in 300 mL of distilled H2O followed by further homogenization and one
hour centrifugation (25,000 rpm). This step was repeated using 200 mL of distilled H2O
for two more consecutive runs; the final run was performed with 70 mL of distilled H 2O
for 3 hours at 10,000 rpm. The supernatants from the final four centrifugation steps
were pooled and contained the amyloid material. The pooled amyloid suspension was
lyophilized using a VirTis system (Gardiner, NY) and stored at room temperature in
glass vials until used. This material was supplied to me by the Human Immunology and
Cancer Program at the University of Tennessee Graduate School of Medicine.
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3.5 Radiolabeling peptides with Iodine-125 or Iodine-123

Several methods of radioiodination have been reported [419, 420], but the
method used for our in vivo and ex vivo studies with iodine-125 (125I) or iodine-123 (123I)
utilized the oxidative property of chloramine T [328, 421] to incorporate the radioiodide
into the phenol ring of tyrosine residues within the peptide sequence. The radiolabeling
procedure was described previously [328, 363, 409, 416].
modification,

a 5-mL

Sephadex G-25 resin-packed

Briefly, and with slight

column

(GE Healthcare,

Buckinghamshire, UK), with glass wool as a stopper was equilibrated with at least two
bed volumes of carrier protein solution (0.2 µm pore size-filtered 0.1% gelatin in
phosphate buffered saline [PBS], pH 7.2).

Peptides were dissolved in H2O to obtain a

stock solution of ~ 1- 2 mg/mL, and for radiolabeling, ~50 μg of peptide (25 – 50 µL)
was used in each reaction. The peptide was added to 5 μL of NaPO 4 buffer (pH 7.6) in
a 1.5 mL-volume microfuge tube. The

125I

(Perkin Elmer, Waltham, MA) or the

123I

(Nordion, Ottawa, ON, Canada) was then added to the reaction mixture—amounts of
radioiodide varied with the planned experiment.

For example, in vivo imaging

experiments required more radiolabeled peptide and, therefore, more radioactivity than
ex vivo tissue binding assays (described in Section 3.9).
contained ~ 1 mCi of radioactivity per 10 μL of

125I

or

123I.

The purchased isotope

Therefore, between 5 (500

µCi) and 25 μL (2.5 mCi) was used for radiolabeling peptides for ex vivo and in vivo
experiments, respectively. Next, 10 μL of 2 mg/mL chloramine T dissolved in distilled
H2O was added to initiate the labeling reaction. As an oxidative agent, chloramine T
was able to assist in the iodination of peptides by oxidizing iodide (I-) into iodine
monochloride which was highly reactive and bound covalently to the aromatic rings
102

present in tyrosine side chains [422]. The iodination reaction was complete within one
minute of chloramine T addition [328]; however, any residual reaction was quenched by
the addition of 10 μL of 2 mg/mL Na2S2O5 (sodium metabisulfite) dissolved in distilled
water. Thirty microliters of blue dextran exclusion marker (MW ~ 2x10 6) and 50 μL of
carrier protein solution were added to the reaction mixture prior to chromatographic
separation of free radioiodide. The reaction mixture was introduced onto the Sephadex
G-25 column and elution buffer (0.1% gelatin in PBS) added drop-wise to the column.
Once the blue dextran reached the column tip, 10 “30 second fractions” (~ 200 μL) were
collected into plastic tubes to ensure that the radiolabeled peptide was collected. A
constant flow rate was maintained by continuous manual addition of carrier protein
solution to the top of the column.

A small amount (~ 1 μL) of each fraction was

transferred into a glass tube and the radioactivity measured using a gamma scintillation
counter (Packard Cobra II, Perkin Elmer, Waltham, MA) set to detect either
a larger energy detection window,

123I.

125I

or, using

The fractions containing the majority of

radioisotope (generally 3 fractions) were pooled and used for experiments.

The

radiolabeling efficiency (i.e. the yield of radioiodinated peptide relative to the starting
material) was typically > 50%.

3.6 Radiolabeling peptides with Iodine-124
The method used for radiolabeling with iodine-124 (124I: IBA, Richmond, VA)
used the same principles as those mentioned with
possible that stock solutions of

124I

125I/123I

radiolabeling; however, it was

from the manufacturer contained oxidized iodine (I2),
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instead of iodide (I-). Therefore,

124I

reactions were reduced prior to the oxidation step

and reaction with the peptide [416]. The protocol began with the addition of 10 μL of 0.5
M NaPO4 buffer at pH 7.6 to a 1.5 mL microfuge tube. The radioisotope was then
added in an amount appropriate for the planned experiment—these were usually in vivo
studies so the number of mice to be used was an important consideration. The stock
solution was decay-corrected for 1 mCi per 10 μL; therefore, volumes between 10 - 50
μL were generally used. To reduce the

124I

2

to

124I-iodide,

1 μL of 2 mg/mL fresh

ascorbic acid in PBS, pH 7.2, was added. The peptide, 50 μg dissolved in H2O (10-25
μL), was brought up to 100 µL by the addition of PBS and was then added to the
reaction mixture. At this point, oxidation of the radioisotope was achieved by addition of
7 μL of 1 mg/mL Iodogen dissolved in 100 % acetonitrile. Two minutes were allotted for
the reaction. To fully quench the reaction, 50 μL of 2 mg/mL ascorbic acid was then
added. Approximately 20 μL of blue dextran exclusion marker and 50 μL of filtered
0.1% gelatin in PBS were added to the reaction mixture before being introduced to a G25 size exclusion column (Section 3.5).
Fractions were manually collected after the blue dextran marker reached the
column tip. The first fraction was collected for 30 sec and the following three fractions
collected for 1 min each. Another 30 sec fraction was collected and the remaining
volume discarded once it eluted. The radioactivity of the fractions were measured with
a dose calibrator (Capintec, Inc., Ramsey, NJ) set to detect

124I.

The majority of the

radiolabeled product was within the 2nd and 3rd “one-minute” fractions, but the 4th
fraction also often contained a salvageable amount of radiolabeled peptide product. The
radiolabeling efficiency of this protocol was also typically 50%.
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3.7. Radiolabeling peptides with Technetium-99m

To conduct SPECT imaging studies which utilize multiple radiotracers (i.e. dual
energy SPECT imaging),

99mTc-radiolabeling

The technique used to radiolabel with

99mTc

[293] of one of the tracers was necessary.

yielded incorporation into the peptides.

To prepare for this technique, ~ 1 mg of SnCl2 and ~ 1 mg of cysteine were
weighed in separate 1.5 mL microcentrifuge tubes (Fisher Scientific, Pittsburgh, PA). A
5 mL Sephadex G-25 column was poured as described in Section 3.5. In the assigned
reaction mixture tube, 20 μL of 0.15 N NaOH was added prior to the addition of ~ 20 μg
of CGGY-p5 peptide. To the tube containing SnCl2, 1 N HCl was added to yield a 100
mg/mL suspension which was then diluted 100-fold by the addition of ultra-pure water.
A 1:10 dilution of this solution in water yielded a final concentration of 0.1 mg/mL in Sn
in 0.01 N HCl. The cysteine was made up to 1 mg/mL by addition of PBS. The

99mTc

solution was supplied by the Nuclear Medicine department at the University of
Tennessee Medical Center in Knoxville, Tennessee. An appropriate amount of

99mTc

was added to PBS in a separate tube. At this point, there were 4 separate tubes: 1)
SnCl2 solution; 2) Cysteine solution; 3)

99mTc

solution; 4) the reaction mixture containing

the peptide.
Approximately 2 μL of the SnCl2 solution was applied to side of the reaction tube
just above the peptide mixture.

The entire

99mTc

solution was then added to the

reaction tube, and the 2 μL of SnCl2 washed into the reaction mixture. The reaction was
allowed to take place for ~ 1 min at room temperature prior to the addition of 1 μL of the
cysteine solution which quenched the reaction.
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To the mixture, 2 drops of carrier

protein solution (0.1 % filtered gelatin in PBS) and ~ 20 μL of blue dextran solution were
added.

The reaction mixture was then passaged through the Sephadex G-25 size

exclusion column, and 4 fractions were collected once the blue dextran reached the
glass wool at the tip of the column: fraction 1 was collected for 30 seconds and fractions
2 – 4 were collected for 1 minute. The radioactivity in these was measured using the
Capintec (99mTc setting), and those with the majority of radiolabeled peptide were
pooled for further use.

3.8. Radiochemical purity testing

For all radiolabeled peptides, it was necessary to ensure that the product was
radiochemically pure, i.e., that there was little free radioisotope present. To do this, one
μL of a 1:100 dilution of the radiolabeled peptide in PBS or 0.1% gelatin solution was
analyzed using 10 % acrylamide SDS-PAGE gel electrophoresis (Novex, Carlsbad,
CA). To the peptide was added 7.5 μL of NuPAGE™ LDS sample buffer (4X) and 10
μL of distilled H2O, and the solution was then boiled for 10 min. A second sample of
peptide, prepared by addition of 7.5 μL of SDS buffer, 10 μL of distilled H 2O and 2.5 μL
of NuPAGE™ sample reducing buffer (10X), was also boiled for 10 min. Approximately
10 µL of both reduced and non-reduced peptide samples were loaded onto the gel. If
the sample was pure and did not contain aggregates or contaminants, both the reduced
and non-reduced preparations migrated similarly through the gel (if the peptides
contained no cysteine residues).

Electrophoretic separation was achieved with an

FB200 system (Fisher Scientific, Dubuque, IA) set at a constant voltage of 200 V and a

106

current of ~ 1.0 Ǻ for 30 min. To visualize the peptides, the gel was removed, covered
with plastic wrap, and placed on a phosphor imager screen (Cyclone Storage Phosphor
System, Perkin Elmer, Shelton, CT) for up to 1 h depending on how much radioactivity
was in the loaded sample (samples with greater radioactivity required less exposure
time).

In certain cases when very little radioactivity was loaded onto the gel, the

exposure time was extended beyond 1 h with only slight increases in non-specific
background occurring. Image analysis, i.e. measurement of radiochemical purity, was
performed using the OptiQuant software package (Packard, Downers Grove, IL). If
more than one band was observed, there may be aggregates or contaminants in the
preparation. Free radioisotope, when present, was seen at the gel “running” front. In
general, the radiochemical purity of the peptides used in these studies was > 95 %
[328]. This procedure can be used for quality assurance of peptides labeled with many
radioisotopes, i.e.

125I, 123I, 124I

and technetium-99m (99mTc), but the half-life of the

radioisotope should be taken into consideration so that this assay is performed in a
timely manner.

3.9. Tissue homogenate preparation

Preparation of the tissue homogenates used in all ex vivo peptide binding assays
followed a procedure that has been reported [371]. The procedure remains unmodified
for most experiments. To begin, mouse tissues, namely liver, spleen, heart and lung,
from two or three amyloid-laden mice (AA amyloid or ApoA2c amyloid) as well as
control (healthy mice) were harvested at necropsy. A portion of tissue from each mouse
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was combined to yield a “pooled sample” and placed within a pre-weighed 50 mL plastic
conical tube (Fisher Scientific, Pittsburgh, PA). The total combined amount of each
tissue was ~ 200 mg – 1500 mg net weight (depending on the tissue) and a 10-fold
volume of PBS added to the sample. To reduce the risk of tissue proteolysis, serine
protease inhibitors, leupeptin and phenylmethylsulfonyl fluoride (PMSF), were included
at 100 μg/mL each. The solution was then mixed vigorously (speed 6) with 3 x 10 s
bursts using a Polytron homogenizer (Brinkmann Instruments, Westbury, NY) before
being centrifuged at 4,000 x g for 10 min. The supernatant was discarded, and the pellet
was resuspended in another 10-fold volume of PBS with 0.05 % Tween-20 (PBST) to
prevent the homogenized material from sticking to the sides of the tube and 0.05 %
NaN3 to inhibit bacterial growth. This solution was then homogenized a second time (as
described above), before being stored at 4 °C for use in ex vivo peptide binding assays.
This same procedure was used for healthy, amyloid-free (WT) tissues.

3.10. Ex vivo peptide binding assays

For these binding assays, tissue homogenates prepared from: AA, ApoA2c, or
WT mice; human AL amyloid extracts, or; synthetic recombinant λ6 Wil variable domain
(rVλ6Wil) fibrils were used. The general procedure for all materials was the same, but
some parameters were unique. The method for tissue homogenate (specifically AA
liver) binding assays and AL extract/rVλ6Wil fibril binding assays have been described
in the literature [363, 371].
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3.10.1. Tissue homogenates
For an ex vivo peptide binding assay using tissue homogenate as the substrate,
50 μL of the tissue homogenate was centrifuged at 21,000 x g for 3 min in a 1.5 mLvolume microfuge tube. This was done in duplicate (i.e., 2 samples per peptide). The
resultant supernatants were discarded and the pellets resuspended in 400 μL PBST. A
1:100 dilution of radiolabeled peptide in either 0.1 % gelatin/PBS or PBST was added to
the tissue samples. Twenty microliters of peptide (~ 200,000 counts per minute [cpm] of
radioactivity) were added and the samples rotated for 1 h (Tube Rotator, Scientific
Equipment Products, Baltimore, MD) at room temperature.

Samples were then

centrifuged at 10,000 x g for 3 min; the supernatants, which contained unbound peptide,
were carefully aspirated and placed in glass tubes, and the pellets were resuspended
gently by hand in 400 μL PBST and washed by centrifugation, as described above.
Supernatants from the second wash were added to those previously collected,
and pellets were resuspended in 800 μL PBST and transferred into glass tubes. The
radioactivity in both the pooled supernatant samples (free peptide) and the pellet
samples (bound peptide) were measured using a gamma scintillation counter with a 1
min acquisition time and an energy window optimized for detection of

125I.

The

percentage of radiolabeled peptide bound to the pellet was determined using the
following formula:

% 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑏𝑜𝑢𝑛𝑑 = [𝑃𝑒𝑙𝑙𝑒𝑡

𝐶𝑃𝑀
] ∗ 100
𝑃𝑒𝑙𝑙𝑒𝑡 𝐶𝑃𝑀 + 𝑆𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 𝐶𝑃𝑀
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3.10.2. AL extracts and rVλ6Wil fibrils
For ex vivo peptide binding assays using human AL amyloid extracts and
rVλ6Wil fibrils, the protocol was essentially the same as described in Section 3.10.1 with
the following modifications. The amount of amyloid extract or fibril used was 25 μL (~ 25
µg of protein).

Since this procedure used half the reaction volume of the tissue

homogenate protocol, only 10 μL of a 1:100 dilution of radiolabeled peptide (~100,000
cpm) was added to all samples prior to their 1 h rotation at room temperature. The
samples were washed by centrifugation at 15,000 x g for 10 min because the pellets
formed in this assay were not as “tightly packed” as tissue homogenates when using the
standard protocol of 10,000 x g for 3 min. Increasing the speed and time of the
centrifugation for the human AL extracts and rVλ6Wil fibrils yielded a more reliable
(“stable”) pellet for the assay. The reactivity in the supernatant and pellet fractions was
measured as previously described, and the percent of radiolabeled peptide bound to the
extract or fibril was determined (Section 3.10.1).

3.11. Assessment of relative peptide affinity to amyloid using NaCl titration

Since the binding of poly-basic peptides to amyloid is thought to be due to
principally electrostatic interactions of the peptide with the negatively-charged sulfate
moieties presented by the hyper-sulfated heparan sulfate proteoglycans associated with
amyloid, the peptide binding assay was modified slightly to determine a measure of the
relative affinity of peptide for the substrate (e.g., tissue amyloid, AL extract or rVλ6Wil
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fibrils).

This was achieved by performing the binding reaction in increasing

concentrations of NaCl which will perturb the electrostatic binding interactions.
The protocol was altered, from that described above (Section 3.10.2) after the
initial centrifugation; the pellets were resuspended in either 0.25, 0.5, 0.75, 1.0 or 2.0 M
NaCl instead of PBST. The volumes of each NaCl concentration were, as before, 400
μL for tissue homogenates and 200 μL for AL extracts or rVλ6Wil fibrils. The addition of
NaCl at this step was designed to perturb the binding of radiolabeled peptide to the
substrate during the 1 h incubation. All wash and resuspension steps after the rotation
used PBST, and the protocol was performed as described (Sections 3.10.1. and
3.10.2).

3.12. Imaging acquisitions
To assess the in vivo amyloid-targeting peptides, SPECT, dynamic PET and CT
small animal imaging were performed.

All imaging data were acquired using the

Inveon trimodality SPECT/PET/CT platform with the Inveon Acquisition Workplace
software version X (Siemens Preclinical Solutions, Knoxville, TN).
3.12.1. SPECT imaging
SPECT imaging was used for visualization of

125I-

or

99mTc-radiolabeled

tracer

distribution in mice. The imaging protocol for the studies described herein has been
previously reported [371, 416] with only slight modifications tailored to each study. The
basic protocol included injection of the radiotracer (i.e.,
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125I-peptide, 125I-SAP, 99mTc-

peptide) iv in the lateral tail vein of amyloid-laden or WT mice. At the appropriate time
post injection (dependent upon the radiotracer used), mice were euthanized, by
isoflurane overdose, for post mortem imaging or anesthetized in an induction chamber
with 3 % isoflurane in air at 2 L/min for live imaging.

For live imaging, paralube

ophthalmic veterinary ointment (Dechra, Overland Park, KS) was applied to the eyes of
the mice prior to positioning in a heated imaging chamber (M2M, Cleveland, OH) with a
nose cone delivering 2 % isoflurane for the duration of the acquisition. The Inveon
imaging system acquired gamma photons (125I: 25 – 45 keV;

99mTc:

140 keV) at 60

different projections, each acquired for 16 seconds, over 90 mm of scanner bed travel.
To enhance the image resolution, the multi-pinhole (Mouse Whole Body) collimator
[261] was used with a 30 mm radius of rotation. SPECT data were reconstructed using
a 3D ordered subset expectation maximization (OSEM) algorithm with 8 iteration and 6
subsets. The resulting image was displayed onto an 88 x 88 x 312 matrix with isotropic
0.5 mm voxels.
For studies utilizing two radiotracers in a single animal, a dual energy SPECT
acquisition was performed. This protocol has been described previously [293], but there
were minor modifications for these studies. Both radiotracers (e.g., 2 different peptides
labeled with

125I

and

99mTc)

were injected simultaneously with similar amounts of

radioactivity (~100 μCi / isotope). After an appropriate uptake time (e.g., 2 h pi), mice
were euthanized as described above. The comparison of 2 radiolabeled peptides was
achieved by performing 2 consecutive SPECT acquisitions (as described above).
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3.12.2. Dynamic PET imaging

Dynamic PET imaging was used to visualize the biodistribution of radiolabeled
peptides and to obtain their kinetic biodistribution in vivo.
outlined previously [416].

Mice were injected with

The protocol has been

124I-labeled

peptides following

anesthesia and placement in the imaging chamber on the PET scanner bed—anesthetic
delivery and mouse positioning were performed as described in section 3.12.1 for live
SPECT imaging. The data acquisition was initiated ~ 5 sec prior to injection of the
radiotracer—this time delay was used to obtain the full kinetic biodisitrubtion of the
radiolabeled peptide after injection.
AA amyloid-laden or WT mice received ~ 20 μg of
–

400

μCi)

in

~

200

μL

of

sterile

124I-radiolabeled

gelatin/PBS

solution

peptide (200

with

1

mM

ethylenediaminetetraacetic acid (EDTA), which prevented blood coagulation upon
injection. PET data were acquired for either 60 or 120 min, depending on the study.
The data were histogrammed for

124I

with appropriate scatter and attenuation correction

using a low resolution CT dataset (see section 3.12.3). Reconstruction of the images
was completed with the following binning parameters: 10 frames × 1 sec, 10 frames ×
30 sec, 30 frames × 114 sec and 60 frames covered the remainder of the data.
Reconstruction was performed using a 3D OSEM with the Maximum A Posteriori (MAP)
algorithm, and the image matrix was 256 × 256 × 159 with a pixel size of 0.0215 ×
0.0215 × 0.796 mm.
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3.12.3. CT imaging

Low-resolution CT data were acquired in conjunction with both SPECT and
dynamic PET image acquisitions, which provide anatomical reference correct for
attenuation and scatter, respectively.

Images were acquired with an x-ray voltage

biased to 80 kVp with an anode current of 500 μǺ . Two bed positions were acquired to
obtain a CT image of the entire mouse body.

Each acquisition comprised 121

projections with a 225 ms x-ray exposure collected over 220° of continuous rotation
around the imaged subject.

Low resolution (i.e., binning of 4) were used.

Reconstruction of the data was performed with an implementation of the Feldkampfiltered back-projection algorithm onto a 224 × 224 × 635 matrix with isotropic 212.1 μm
voxels.

3.13. Image analyses

Both SPECT and dynamic PET data were analyzed with the 2D Inveon Research
Workplace visualization software (IRW; Siemens Preclinical Solutions). The methods of
analysis for SPECT/CT data and dynamic PET/CT data were described by Martin et
al.[416].
3.13.1. SPECT/CT analysis

The SPECT data were automatically co-registered with CT data using IRW. To
obtain measurements of radioactivity (displayed as voxel intensities in arbitrary units),
regions of interest (ROI) were manually drawn over multiple organs including the liver,
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spleen, heart, lungs, leg muscle, stomach, pancreas, kidneys, intestines and bladder. A
3D ROI drawing tool (spherical or cubical) was used to encompass multiple CT slices of
the organ. This method provided a better representation of the radioactivity within the
ROI. The mean voxel intensity in the SPECT data associated with each ROI was used
as a measure to compare radiotracer accumulation in each tissue and to compare the
accumulation between amyloid-laden (AA or ApoA2c) and WT mice.
3.13.2. Dynamic PET/CT analysis

The 2D IRW software automatically co-registered PET data with CT data. Prior
to drawing ROI in the same manner as described in section 3.13.1, all image frames for
the entire acquisition were summed.

The ROI for kinetic biodistribution analyses

included the vena cava (a measure of blood pool), heart, liver, kidneys, stomach, thyroid
and bladder of each mouse. The software’s kinetic analysis tool generated time activity
curves (TAC) for each ROI drawn. The TAC data were fit to exponential equations
using Prism version 6.0 (GraphPad Software Inc., La Jolla, CA).

3.14. Necropsy

Mice were euthanized by isoflurane overdose in accordance with IACUCapproved animal protocols and amyloid-laden and healthy tissues were harvested for
tissue homogenate preparation, biodistribution measurements, histological examination
and microautoradiography.

The tissues that were harvested for homogenate

preparation (section 3.9) to be used in the ex vivo assay (section 3.10) were the liver,
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spleen, kidneys, heart, lungs, intestines and pancreas. These tissues were taken in full
and stored in -20°C until used.
When performing experiments with radiolabeled peptides, tissues were
harvested

for

biodistribution

microautoradiography (when

125I

measurements
or

124I

and

was used).

histological

examination

or

The tissues taken for these

procedures were leg muscle, liver, pancreas, spleen, kidneys, stomach, ~ 2 inches of
upper intestine (taken from the base of the stomach), ~ 2 inches of lower intestine
(taken near the anus), heart, lung and, in some cases, tongue. The contents of the
stomach and intestinal samples were emptied prior to analyses. A small portion of each
tissue was used for biodistribution measurements, and the remainder of the tissue was
placed in 10 % buffered formalin to be fixed for histology and microautoradiography.
After use, the radioactive carcasses were held in a biohazard/radioactive freezer for
radioisotope decay and disposal.

3.15. Biodistribution measurements
The amount of radioactivity within tissues was measured as described previously
in several articles [378, 381, 409]. Samples of tissue, harvested at necropsy, were
placed into tared plastic vials (Wheaton, Millville, NJ) and weighed. The radioactivity
(125I,

123I, 124I

or

99mTc)

in each sample was measured for 1 minute using a Wizard 3

gamma counter (1480 Wallac Gamma Counter; Perkin Elmer, Boston, MA).
Additionally, 10 μL of a diluted sample of the injected dose of radiotracer was added to
2 separate vials and counted. These were considered “decay-corrected” standards by
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which to determine the number of counts equivalent to the injected dose.

The

biodistribution data were determined with the following formula and the data expressed
as a percent injected dose per gram (%ID/g):
% 𝐼𝐷⁄𝑔 = (𝑐𝑜𝑢𝑛𝑡𝑠 𝑝𝑒𝑟𝑚𝑖𝑛[𝑐𝑝𝑚]⁄𝑡𝑜𝑡𝑎𝑙 𝑐𝑝𝑚) × (100⁄𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡[𝑔])

3.16. Autoradiography and Histology

Confirmation of radiotracer localization to amyloid deposits in tissue sections was
obtained by comparing microautoradiography and Congo red (CR)-stained histological
tissue sections [378, 381, 409]. Tissues harvested at necropsy were fixed in 10%
buffered formalin for at least 24 h prior to being embedded in paraffin blocks. For
autoradiography, sections ~ 4 – 6 μm thick were cut from the blocks and placed onto
Plus™ microscope slides (Fisher Scientific, Pittsburgh, PA).

The slides were then

dipped in NTB2 emulsion (Eastman Kodak, Rochester, NY) and stored in the dark for a
predetermined amount of exposure time depending on the study [423]—tissue
specimens taken from imaging experiments were typically stored for 4 days prior to
development; studies of biodistribution only, that did not require as much radioactivity,
were exposed to the photographic emulsion for 10 days prior to development. The
sections were then counter-stained with hematoxylin and eosin and examined with light
microscopy. Radiotracer accumulation was evidenced by the presence of black silver
grains within the tissue sections.
Consecutive 4 – 6 μm-thick slices of the same paraffin-embedded specimens
were then stained with freshly prepared alkaline CR solution. For the detection of CR
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birefringence, all sections were examined by light microscopy (DM500, Leica,
Bannockburn, IL) using cross-polarized illumination. Microscopic images were taken
using a cooled, charge-coupled device camera (SPOT, Diagnostic Instruments, Sterling
Heights, MI). Some studies involved imaging CR fluorescence using epifluorescent
illumination with a rhodamine (red) filter [416].

3.17. Statistical analyses
Statistical analyses (e.g., unpaired/two-tailed/student t-tests and correlation
analyses) were performed using the Prism software package (GraphPad, LaJolla, CA).
Estimation of statistical significance was based on p < 0.05.
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Chapter 4

Peptide characterization studies

4.1. Overview

The peptides to be studied in this thesis for amyloid binding were characterized
using several in vitro and ex vivo studies. Previously, circular dichroism of the peptide
p5 revealed that it has a propensity to form an α-helix in a solution of more than 30%
trifluoroethanol (TFE)—a chemical known to promote the formation of helical secondary
structure [371, 424]. Additionally, the peptide from which p5 was derived, K8, was
shown to adopt an α-helix in the presence of heparin [414]. These studies suggested
that p5 adopts a secondary structure in the presence of its ligand (or “when bound to
target”); the notion of helical peptide structure was reiterated in the predicted structure
of the peptide [363, 371, 415]. A linear array of positive charges aligned to one face of
the peptide was predicted by I-TASSER modeling; this structural property was thought
to facilitate in p5-GAG interactions [371]. Given these structural properties which likely
make the peptides more amenable to bind all amyloid, we characterized the interaction
of peptides to a battery of amyloid-related substrates. The ex vivo binding assays
described in section 3.10 were used. This chapter surveys the interactions of peptides
p5, p5R and p5R+14 with various amyloid-laden materials including AL patient-derived
amyloid extracts, recombinant Vλ6Wil fibrils, and AA or ApoA2c amyloid-laden mouse
tissue homogenates. Although AL and ATTR are the most common forms of human
visceral amyloidosis, there are no good experimental models of these diseases;
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therefore, we used murine models of AA and ApoA2c amyloidosis which represent the
most widely studied models of visceral amyloidosis.

4.2. AL extract binding studies with 125I-p5
Patient-derived AL amyloid extracts that contain fibrils, HSPG and numerous
accessory molecules were used to study peptide binding. The study outlined below was
recently published in Biochemical and Biophysical Research Communications [363].
Briefly, 9 patient samples derived from either the liver or spleen of confirmed AL amyloid
patients was evaluated; additionally, the collection included both ALκ and ALλ amyloid
types so as to not bias the study to one isotype of AL fibril. Radioiodinated p5 was
incubated with approximately 25 μg of amyloid extract (which contains HSPG and fibrils
but only negligible amounts of SAP and no DNA components) and a peptide binding
assay performed (Section 3.10.2).
Results
As seen in Figure 4.1, results of this study indicated that the reactivity of p5 with
the extracts was quite variable (% peptide bound to the amyloid pellet ranged from 2%
to 74%). Since amyloidosis in patients is such a heterogenous disease in terms of
amyloid load per organ [1, 19], the inconsistent amyloid-binding was not entirely
unexpected; however, as evidenced by Alcian blue measurements, these extracts
contained sulfated GAGs, a major ligand of p5, making the near lack of p5 binding, in
some cases, perplexing.
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Figure 4.1: 125I-p5 binding to AL extracts. The heterogeneity of AL patient-derived
extracts was demonstrated by the variable reactivity of 125I-p5 with the extracts in the
peptide binding assay. There was a wide range of peptide reactivity in the nine samples
tested. (L) liver, (S) spleen.
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Therefore we used the GAG-clearing enzyme, heparinase I, to remove the
heparan sulfate GAGs [363]. We posited that without the hypersulfated GAGs, a known
target of p5, there would be diminished binding in all of the samples. Heparinase I was
added to each AL extract prior to performing the ex vivo peptide binding assay. We
observed a decrease in p5 binding to all samples; however, there was still significant
binding. This finding suggested that there must be another component in the amyloid
extracts to which p5 can bind. In the heparinase-treated samples, a positive linear
correlation was found between p5 binding and ThT fluorescence (a measure of the
fibrils) in the 5 samples which exhibited the highest ThT measurements (Figure 4.2).
These data suggested that, in the absence of HSPG, there was a positive correlation
with p5 binding relative to the fibril content. Thus, we hypothesized that p5 may also be
able to interact directly with AL amyloid fibrils.
It is known that synthetic fibrils display an electronegative surface to which the
primarily positive antigen binding site of camelid antibody, B10, can interact [362, 407].
Furthermore, the polybasic nature of p5 with a predicted linear array of positivelycharged amino acids positioned on one face of the peptide may render the peptide
capable of also binding fibrils. This was tested using synthetic rVλ6Wil fibrils, which
lack GAGs and other amyloid associated proteins, in the peptide binding assay. Our
data showed that p5 interacted with synthetic fibrils with ~ 80% peptide bound (Figure
4.3). Therefore, p5 was shown to interact with both the HSPG and the fibril components
of AL amyloid, and our studies demonstrated that: 1) amyloid is an extremely
heterogenous material; and 2) p5 can recognize two of the primary components in
amyloid deposits.

122

ThT fluorescence (au)

300
250
200
150
100
50
0

10

15

20

25

30

Peptide p5 bound (%)
Figure 4.2: Positive correlation of 125I-p5 binding and ThT fluorescence in
heparinase-treated samples. The five AL extracts with the highest ThT measurement
showed a positive correlation with 125I-p5 binding after heparinase treatment. This
proposed that peptide p5 may bind to amyloid fibrils directly. (Image adapted from
[363]).
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Figure 4.3: 125I-p5 binds to synthetic recombinant Vλ6Wil fibrils. The binding of
125I-p5 to heparinase-treated AL samples and Vλ6Wil fibrils supported the interaction of
this peptide with fibrils directly. (Image taken from [363]).
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4.3. Peptide binding to amyloid-laden tissue homogenates
Mouse tissue homogenates were used to assess peptide binding with a more
“complex” amyloid system which includes HSPG, fibrils, SAP, as well as DNA and other
cellular debris that was not fully separated from the amyloid in the tissue homogenate
preparation. One of the experiments routinely performed when screening new peptides
for amyloid binding was an ex vivo binding assay utilizing liver homogenate from H2-IL6
transgenic mice with confirmed AA amyloidosis. The assay was performed as described
in section 3.10.1.

The peptides tested were: the parent peptide, p5; an arginine

derivative of the peptide, termed p5R; and an extended version of p5R, known as
p5R+14. The arginine variant of p5 was analyzed because literature suggested that
arginine has a higher propensity to form an α-helix which may enhance binding with
amyloid [425]. Thus, it was hypothesized that p5R would exhibit greater binding to AA
amyloid-laden tissue when compared to p5. The extended version of these peptides,
p5R+14, combined both the higher propensity to form an α-helix with an additional 14
amino acids that included four more arginine residues making the resultant net charge
+12 instead of +8 as seen with p5 and p5R. It was postulated that, due to these two
properties (enhanced helicity and increased charge), p5R+14 would bind more
effectively than p5R. The reasoning behind this stemmed from a recent study which
investigated the in vivo binding efficacy of a 24 amino acid p5R variant with a +6
charge. Data suggested that this shortened p5R peptide did not bind to amyloid as well
as the intact peptide [371]. Therefore, we hypothesized that an increase in peptide
charge may enhance amyloid binding. Based on this hypothesis, we expected to see
the following peptide pattern relative to their binding to amyloid-laden tissue
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homogenates: p5 < p5R < p5R+14. For these studies, we used organs from the H2/IL-6
and ApoA2c transgenic mice.
Results
Our studies indicated that all 3 peptides were able to bind to AA amyloid-laden
homogenates from liver, spleen, kidney, pancreas and intestines in a peptide binding
assay (Figure 4.4A). The lung had much less binding with all peptides, but this was
expected because very little, if any, AA amyloid forms in the lungs. The heart revealed
increasing binding from p5, to p5R, to p5R+14, but even with the p5R+14, there was
less interaction than with all other tissues—again, due to the scant deposits in this
tissue. The differential binding of the peptides (p5 < p5R < p5R+14) was also seen in
the kidney and the intestines (Figure 4.4A). Thus, with some tissues, the expected
pattern of peptide binding, based on our conceptual model, was observed, but this was
not the case for all tissues studied. The liver and spleen generally have more amyloid
relative to the other tissues (Congo red scoring of these 2 tissues was typically 3+ to 4+
on a scale of 0 – 4+) which could explain the higher percentages with all peptides in
these tissues (nearly all were > 50%).
The binding of these peptides to WT tissues revealed that, in all tissues, the
p5R+14 peptide had the most non-specific binding (Figure 4.4B). In some tissues,
namely the pancreas and the intestine, p5R also displayed more off-target binding than
that seen with p5. The greater net positive charge associated with p5R+14 may have
enhanced its affinity for other components within the homogenates, possibly the
negatively charged DNA. Regardless, all peptides exhibited much greater binding to
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Figure 4.4: Peptide binding to tissue homogenates. (A) Peptide reactivity with AA
tissues. (B) Non-specific binding of peptides to WT tissues. (C) Peptide reactivity with
ApoA2c tissues. In all graphs: 125I-p5 ,125I-p5R and 125I-p5R+14 .
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the highly AA amyloid-laden homogenates, suggesting that each of these are capable of
specifically interacting with ex vivo AA amyloid deposits.
Given these findings for the 3 peptides, they were further tested in the same
assay to determine their efficacy in binding to ApoA2c amyloid-laden mouse tissues
(Figure 4.4C). The distribution of amyloid in these tissues varies slightly from that seen
in AA mice; the main difference is that there is much more amyloid deposition in the
lung and heart relative to AA tissues. The data indicated that p5 and p5R interacted
much more weakly with ApoA2c amyloid in this system relative to the binding with AA
amyloid.

The spleen, a site known to be largely affected with ApoA2c amyloid,

exhibited minimal binding with the p5 and p5R peptides. In contrast, positive binding
was seen in all ApoA2c tissues with p5R+14 (Figure 4.4C).
These findings suggest that AA and ApoA2c amyloids, although they do contain
HSPG and fibrils, are remarkably physico-chemically different.

Given that the

homogenized mixtures should, theoretically, expose the amyloid for binding with no
hindrances to the interaction (e.g. access to the vasculature), the structural composition
of the deposits themselves must be different—e.g. p5 and p5R do not recognize their
targets within ApoA2c amyloid as compared to AA amyloid.

The ApoA2c tissues

appear to require a peptide with higher net positive charge to achieve the best peptideamyloid interaction. There are numerous reasons why this may be the case: ApoA2c
amyloid may contain a ratio of the 2 known peptide targets, hypersulfated HSPG and
fibrils, which makes certain peptides less effective at binding to this type of amyloid; the
ApoA2c amyloid deposits may consist of more apolipoproteins than AA amyloid
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deposits, hindering peptide reactivity; or ApoA2c fibrils may have a different charge
motif than AA fibrils, thus, decreasing peptide binding.
This study led us to investigate the relative strength of binding between the
peptides and certain AA and ApoA2c tissues.

4.4. Binding studies in the presence of increasing concentrations of sodium
chloride to assess the relative strength of electrostatic binding of peptides with
amyloid
Since there were unexpected inconsistencies in binding between the peptides
and the two amyloid types, sodium chloride (NaCl) titrations were performed to assess
the strength of the electrostatic interaction between p5, p5R and p5R+14 with AA and
ApoA2c amyloid. The tissues used included AA liver and spleen and ApoA2c liver,
spleen, heart and lung—all were known to contain considerable amyloid for their
respective disease.

The pancreas and intestine were not used in these studies

because of the inappropriate nature of the material after incubation with NaCl (i.e. the
pellets were unable to be separated from the supernatants).
The same peptide binding assay was used in these studies with only slight
modifications. For the NaCl titration studies, concentrations of NaCl (0.15 M (PBST),
0.25 M, 0.5 M, 0.75 M, 1.0 M and 2.0 M) were used in the peptide-homogenate
incubation step to attempt interference with the peptide-amyloid electrostatic interaction.
Even though we observed that all peptides bound impressively to AA liver and spleen
tissues, we hypothesized that it would take a higher concentration of NaCl to inhibit
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binding by 50% in samples containing p5R+14 due to the +12 net charge on the
peptide.

For the ApoA2c tissues, we hypothesized that the concentration of NaCl

needed to interfere with binding would follow a similar pattern but would be less for all
peptides when compared to the concentrations used in AA tissues—a hypothesis
derived from the observation that the peptides interacted much less avidly with ApoA2c
tissue in PBST as compared to AA.
Results
The data indicated that, with p5, binding to AA liver required ~ 0.4 M NaCl to
inhibit 50% (IC50) of the maximum binding observed with PBST. The IC 50 for p5R with
AA liver was ~ 0.9 M NaCl, and was > 2.0 M NaCl for p5R+14 (Figure 4.5). The same
pattern was observed with AA spleen with IC50 values for each peptide: IC50 ~ 0.5 M
NaCl for p5, IC50 ~ 1.7 M for p5R and IC50 > 2.0 M NaCl for p5R+14 (Figure 4.5). The
NaCl titration on AA tissues indicated that there was an ionic interaction between the
peptides and amyloid since binding decreased with increasing salt concentration.
Additionally, the strength of the ionic binding for the tested peptides followed the
expected pattern for AA tissues: p5 < p5R < p5R+14. Interestingly, these data suggest
that, for peptide p5R+14, binding other than electrostatic interactions may be occurring.
Titration of peptides on ApoA2c tissues demonstrated lower IC50 values for most
samples, which was consistent with the decreased binding seen earlier. For both p5
and p5R, the IC50 for each of the 4 tissues tested was < 0.35 M NaCl. However, for
p5R+14, there was a much wider range of NaCl concentrations needed to interfere with
tissue amyloid binding. For the heart and liver, the IC50 of p5R+14 was < 0.4 M NaCl,
whereas the spleen IC50 was 0.47 M, and the lung required a concentration >0.8 M
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Figure 4.5: Peptide binding to AA tissues in the presence of NaCl. The NaCl
titration indicated that the peptides bind to AA liver and spleen with differing affinities.
For this type of amyloid, peptide binding followed the hypothesized pattern: p5 < p5R <
p5R+14.
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NaCl. These data, summarized in Figure 4.6, suggested that the peptides had a lower
binding affinity for ApoA2c amyloid than AA amyloid, but of the 3 peptides, p5R+14
exhibited the strongest binding to most tissues, consistent with our hypothesis.
The differences observed in the NaCl titration reiterate that AA and ApoA2c
amyloids, while comprised of similar components, are obviously “different”. The varying
degrees of peptide binding may be the result of differing amounts of HSPG or fibrils in
the tissues and the different affinity that each peptide has for these components. If
peptides exhibit a greater affinity for HSPG but the composition of the deposit contains
more fibrils than HSPG, the peptides would not be expected to bind as well to these
samples. Since p5 and p5R bind with much lower affinity than p5R+14, perhaps the
former 2 peptides have a greater propensity for a target that is underrepresented in
ApoA2c amyloid. A report in 2013 by Wall et al. indicates that p5 and p5R both bind
immobilized heparin, but p5R (~ 1.3 M NaCl) has a greater affinity than p5 (~ 0.9 M
NaCl) [371].
Affinity for immobilized heparin may suggest that p5 and p5R preferentially bind
to HSPG in amyloid deposits. All 3 peptides were subjected to a NaCl titration binding
study with rVλ6Wil fibrils to directly compare their affinity for fibril-binding in the absence
of HSPG. The titration revealed that p5R+14 expressed a much higher affinity for
synthetic fibrils than the other two peptides (Figure 4.7); an IC 50 of between 0.75 M and
1.5 M NaCl was seen previously with p5 and p5R. On the contrary, p5R+14 appeared
to plateau at 2.0 M NaCl as evidenced by > 50% bound even in the presence of 4.0 M
NaCl. Thus, there was a very high affinity of p5R+14 for this synthetic fibril.
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Figure 4.6: Peptide binding to ApoA2c tissues in the presence of NaCl. (A) 125I-p5
reactivity. (B) 125I-p5R reactivity. (C) 125I-p5R+14 reactivity. The peptide reactivity with
ApoA2c amyloid required a much lower concentration of NaCl than was seen with the
AA tissues, but the same pattern was observed: p5 < p5R < p5R+14. (Many thanks to
Brianna Rader and Angela Lee for their assistance in obtaining the NaCl titrations).
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Figure 4.7: Peptide affinity for recombinant synthetic Vλ6Wil fibrils measured by
NaCl titration. The peptides showed variable affinity for fibrils. Notice that p5R+14
would require > 4.0 M NaCl for 50% binding inhibition. (Thank you to Mrs. Angela
Williams for the historic p5 and p5R NaCl titration data).
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Since the binding inhibition of p5R+14 plateaued, it was worth speculating that
the binding may be more than simply ionic in nature. To test this, we examined the
binding of p5R+14 to rVλ6Wil in the presence of 4.0 M urea which should disrupt
peptide-fibril hydrophobic interactions. As shown in Figure 4.8, urea treatment resulted
in a decrease in p5R+14 binding to rVλ6Wil fibrils by ~ 20% compared to fibril binding in
PBST.

To ensure that the 4.0 M urea treatment reduced peptide-fibril interactions

without diminishing fibril structure, four different concentrations of urea were added to
plated fibrils alone; after 1 hour at room temperature, ThT fluorescence was measured
at 490 nm. The data indicated that there was no significant difference between the
fluorescence emissions in any of the fibril samples, treated or untreated with urea
(Figure 4.9); therefore, the fibrils were intact. The data suggested that p5R+14 binding
to fibrils may consist of both ionic and hydrophobic interactions; the two tested
treatments were unable to completely inhibit binding, however.

These experiments

could assist in explaining the various peptide-ApoA2c amyloid interactions. In short, the
molecular composition of ApoA2c amyloid may contain more fibrils with respect to
HSPG, resulting in greater p5R+14 binding and decreased affinity of peptides p5 and
p5R.

4.5. Conclusions
The studies presented in this chapter were designed to characterize the
interactions of peptides p5, p5R and p5R+14 with synthetic and “native” amyloid and to
assess the nature of those interactions. The data support the thesis that peptides can
be used to specifically target amyloid in various forms—patient extracts, tissue
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Figure 4.8: 125I-p5R+14 binding to rVλ6Wil fibrils in the presence of both NaCl and
urea treatments. Peptide binding in PBS alone represented maximum binding. After
4.0 M urea treatment, ~ 20% of the maximum peptide reactivity with fibrils was lost. As
was previously determined, 4.0 M NaCl interfered with ~ 50% of the maximum binding.
These treatments and the resultant peptide reactivity indicated that p5R+14 may use
both hydrophobic and ionic interactions to bind to synthetic fibrils. Neither treatment
resulted in full interference of peptide binding, however.

Figure 4.9: Urea treatment of rVλ6Wil fibrils. The one-way ANOVA test revealed
that up to 4.0 M urea treatment resulted in no significant difference in fibril structure as
measured by ThT fluorescence (p = 0.9649).
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homogenates and synthetic fibrils.

The model systems used proved that the

modifications made to p5 resulted in stronger amyloid binding (in most cases). The
data also indicated that AA and ApoA2c amyloids are structurally different regardless of
the ubiquitous presence of fibrils and HSPG in both types of deposits. The peptides did
not behave identically in each of the model systems, which suggested that they may
each prefer binding to HSPG or fibrils differentially. These ex vivo studies were used to
characterize how p5 and its variants interact with multiple amyloid types; this
information was the foundation on which the following experiments were designed and
conducted to examine amyloid-targeting with various peptides.
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Chapter 5
Dual isotope SPECT/CT imaging of peptides in ApoA2c mice

5.1. Overview
In our laboratory, we have found that many peptides interact with amyloid
materials in ex vivo assays. The previous chapter indicated that peptides p5, p5R and
p5R+14 bound with varied affinities to AA and ApoA2c amyloid extracts likely due to
preferential interactions with GAGs and fibrils, but these data could not guarantee that
similar peptide behavior would be observed in vivo since possible hindrances to
peptide-amyloid reactivity (i.e. weak vascularization of amyloid-laden tissues and serum
half-life of the peptide tracer) are factors that must be considered.

The literature

provides data pertaining to the in vivo reactivity of the parent peptide, p5, in the
transgenic H2/IL-6 model of AA amyloidosis [293, 409]. With this peptide, SPECT/CT
imaging studies have been conducted and revealed positive and specific uptake in
amyloid-laden organs; the murine model deposited ample AA amyloid in several
tissues, and autoradiographs (ARG) showed preferential binding and co-localization of
125I-p5

with amyloid deposits (see Figure 1.24; [409]). To ascertain amyloid-reactivity in

a different model of the disease, this chapter focuses on the in vivo analyses of peptides
p5 and p5R+14 in transgenic ApoA2c mice. To induce amyloidosis, the mice were
injected with 50 μg of ApoA2c intestine-derived AEF at 14 weeks of age, and they were
used at 12 weeks post AEF induction when sufficient amyloid was present. Prior to this
study, no in vivo small animal imaging of ApoA2c mice had been conducted or reported.
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With that, we were uncertain which, if any, peptides would target amyloid in these mice
such that the pathology could be visualized. Given that p5 is the parent peptide to
these studies and that it provided positive amyloid imaging in AA mice, we opted to
investigate it first in this model of amyloidosis; additionally, we investigated p5R+14
since it bound most effectively of all the tested peptides to ApoA2c tissue homogenates
in the ex vivo binding assay (Figure 4.4C). The method by which these 2 peptides were
comparatively evaluated was dual-isotope SPECT/CT imaging; by radiolabeling the two
peptides with different radioisotopes, in this case

99mTc

and

125I,

a direct comparison

within a single mouse was possible. This type of study was previously conducted in
which peptide p5 and SAP were compared [293]. In addition to imaging, tissues were
harvested in order to obtain biodistribution measurements for both radiotracers, and for
the 125I-labeled p5R+14, ARG was performed to confirm peptide-amyloid co-localization.

5.2. Dual-isotope SPECT/CT imaging of peptides in ApoA2c mice
As previously stated, radioiodinated p5 successfully imaged AA amyloidosis with
significantly higher tissue biodistribution measurements compared to WT controls [423].
Experimental conditions from those studies involved injection of the radiotracer and
imaging using mice at approximately 3 – 6 weeks post induction of amyloidosis with AA
spleen-derived AEF.

The transgenic model of AA amyloidosis yielded abundant

amyloid deposition within this time frame. For ApoA2c transgenic mice, however, 9 –
11 weeks post AEF induction were required to yield a comparable amount of amyloid.
For the peptide comparison study, p5R+14 was radiolabeled with

125I

(Section 3.5), and

peptide p5 was radiolabeled with 99mTc (Section 3.7). For each radiotracer,
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Figure 5.1: Quality assurance of radiolabeled p5 and p5R+14. (A) Results of the
SDS-PAGE radiopurity analysis for 99mTc-p5 and 125I-p5R+14. Both the non-reduced
and reduced samples of peptides are included. The gel indicates that there was a small
quantity of free 125I in the p5R+14 product and no detectable 99Tc in the radiolabeled p5
product.
(B) Peptide binding assays demonstrating amyloid reactivity.
Both
radiolabeled peptides show positive reactivity with AA liver homogenate and minimal
reactivity with WT liver.
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1 μL of 1:100 diluted product in 0.1% purified gelatin was tested for radiopurity with
SDS-PAGE (Section 3.8).

Little free isotope was detected for either peptide (Figure

5.1A). To ensure that both radiolabeled peptides were amyloid-reactive, they were
tested by binding to AA liver homogenate in the ex vivo (pull down) assay (Section
3.10.1; Figure 5.1B), and both peptides were shown to be amyloid-reactive.

An

approximately equal amount of radioactivity of each tracer (~ 200 μCi) was injected into
the lateral tail vein of WT and ApoA2c mice (total volume ~ 200 μL per mouse). Mice
were euthanized at 2 h pi, and biodistribution of each radiotracer was established with
SPECT/CT imaging.

The imaging protocol consisted of 2 consecutive SPECT

acquisitions—the first to acquire only high energy (~ 140 keV)
second for low energy (~ 30 keV)

125I

photons.

99mTc

photons and the

A single CT acquisition provided

anatomical reference for both SPECT datasets.
Since the peptide tracers were radiolabeled with different isotopes, both their
catabolism and their distribution in mice were not expected to be equivalent (e.g.
dehalogenation of only the radioiodinated peptide). To determine the “background” in
vivo distribution of radioactivity associated with these tracers, approximately the same
activity equivalent was injected into healthy mice.
Results
SPECT/CT imaging of WT mice at 2 h pi revealed that

125I-p5R+14

underwent

dehalogenation when it encountered deiodinase enzymes in both the liver and kidneys
[416, 426]; this resulted in the release of radioiodide and its uptake in the stomach and
thyroid. In contrast, the

99mTc-p5

radiotracer accumulated in the kidneys and intestines

as a result of peptide clearance (N.B.

99mTc

is not prone to dehalogenation activity). A
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representative WT mouse demonstrating these two different radiotracer distributions is
shown (Figure 5.2). The bladder was emptied naturally when mice were euthanized
prior to image acquisition and was not visible with either radiotracer in the image.
Although peptide p5 has previously been shown to interact with AA amyloid in all
affected organs such that whole-body amyloid burden could be visualized with
SPECT/CT imaging [293], the visual biodistribution of p5 in ApoA2c mice provided
much less information about the amyloid burden due to decreased reactivity with
ApoA2c amyloid.

99mTc-p5

in the ApoA2c mouse revealed minimal uptake in amyloid-

laden tissues; the image was dominated by radiotracer accumulation in the kidneys in
addition to hepatobiliary clearance evidenced by radiotracer in the intestines (Figure
5.3). For ApoA2c mice, renal amyloid pathology is typically less extensive than that
seen in AA mice, and the kidneys are not considered a major organ for amyloid
deposition [382]; thus, the enhanced renal uptake in ApoA2c mice is presumably
associated with radiotracer clearance rather than amyloid-reactivity.

Since amyloid

deposition within the intestines of ApoA2c is a common manifestation, the radioactivity
displayed in the intestines of the ApoA2c mice could be considered amyloid-specific, but
the biodistribution measurements suggested otherwise (Figure 5.4). After the removal
of feces from the upper and lower intestines, there was little
these organs in ApoA2c or WT mice.

99mTc-p5

SPECT images of

associated with

99mTc-p5

distribution

demonstrated similar patterns between diseased and healthy mice—this further
suggested that presence of

99mTc-p5

in these tissues was associated with radiotracer

clearance and not amyloid uptake. Biodistribution measurements (reported as % ID/g)
were made for the liver, spleen, upper/lower intestines, heart, kidneys, lungs and
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Figure 5.2: Dual energy SPECT/CT image representing the distribution of 125Ip5R+14 and 99mTc-p5 at 2 h pi. The standard distribution of 125I-p5R+14 is shown in
blue and is present in the thyroid and stomach due to peptide dehalogenation. The
distribution of 99mTc-p5 is shown in orange and is seen in the renal cortices due to
peptide clearance and, potentially, retention of the 99mTc nuclide in the proximal tubules.
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Figure 5.3: Dual energy SPECT/CT image demonstrating the distribution of both
99mTc-p5 and 125I-p5R+14 in a representative ApoA2c mouse. The image shows
uptake of 99mTc-p5 (yellow-orange) in the kidneys and intestines which are both likely
associated with peptide clearance. Distribution with 125I-p5R+14 (blue) was more
extensive and can be seen in the liver and heart. Intestinal uptake may be associated
with clearance or amyloid reactivity. Accumulations in both the thyroid and stomach,
however, are a clear result of radiotracer dehalogenation and free iodide sequestration.
The image demonstrates that 125I-p5R+14 provided a more informative picture of
amyloid deposition.
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Figure 5.4: Biodistribution measurements of 99mTc-p5 in ApoA2c and WT mice at
2 h pi. These measurements revealed that the uptake of radiotracer in each tissue did
not differ between diseased and healthy mice. Since the tracer was not dehalogenated,
the route of clearance, the kidneys, displayed a much higher % ID/g than other tissues.
The kidneys were plotted against the right axis due to their high level of uptake.
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stomach of both ApoA2c and WT mice (Figure 5.4). These quantitative measurements
of tracer tissue distribution indicated that the difference in uptake of

99mTc-p5

between

diseased and healthy mice was not significant in all tissues, with the exception of the
observed renal activity. Although not shown, SPECT/CT imaging of WT mice with free
99mTc

shows uptake in the renal cortices; therefore, it is likely that the radionuclide itself

gets retained in the proximal tubules. This suggests that the uptake observed with
99mTc-p5

in ApoA2c mice was not amyloid-specific but was associated with peptide

clearance and radionuclide retention.
Images and biodistribution measurements of
quite disparate to those seen with
uptake of

125I-p5R+14

99mTc-p5.

125I-p5R+14

in ApoA2c mice were

The SPECT/CT imaging data revealed

in amyloid-laden organs including the liver and heart (see Figure

5.3). There was also evidence of radiotracer dehalogenation with stomach and thyroid
uptake of radioiodide. As was stated before, the intestinal accumulation seen with

125I-

p5R+14 could have been associated with amyloid, or it might be associated with
hepatobiliary clearance of the peptide. It was more likely in this case, however, that the
intestinal uptake was amyloid-specific because: 1) the biodistribution measurements
obtained after imaging showed enhanced lower intestinal

125I-p5R+14

uptake compared

to that seen in WT mice, and 2) the peptide would be dehalogenated in the liver and,
therefore, not visible in the intestines.

A greater accumulation of

125I-p5R+14

was

observed in most ApoA2c tissues (% ID/g) when compared to the WT tissues, but this
finding was particularly noticeable in the spleen, lower intestines and lung, sites of
significant ApoA2c amyloid accumulation (Figure 5.5). To directly compare the uptake
of both tracers in each of the tissues and accounting for any possible off-target binding,
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Figure 5.5: Biodistribution measurements of 125I-p5R+14 in ApoA2c and WT mice
at 2 h pi. A higher % ID/g of 125I-p5R+14 accumulated in most ApoA2c tissues (green)
when compared to WT tissue (red) accumulation. This was especially noticeable in the
spleen, lower intestines and the heart.
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the % ID/g of the tracers in each tissue was scaled by the average uptake obtained in
the respective tissue within WT mice (i.e. ApoA2c mouse/mean WT).
comparisons for each mouse independently revealed that

125I-p5R+14

These

dominated the

accumulation profiles in most organs as compared to p5, due to its increased reactivity
with ApoA2c amyloid (Figure 5.6).
To further evaluate the accumulation of these two peptide radiotracers in ApoA2c
mice, image analysis of the dual isotope acquisition was performed by drawing regions
of interest over known ApoA2c amyloid-laden tissues such as the liver, heart and lungs.
Although the uptake in these tissues was not clearly visible in each mouse, image
analysis revealed a higher mean voxel intensity (reported as arbitrary units [au]) of
p5R+14 radiotracer in each of these organs when compared to

99mTc-p5

125I-

distribution

(Figure 5.7). Since the intestinal uptake visible in the images could not discern whether
the radioactivity was associated with clearance or with specific amyloid-binding, the
intestines were not included in the image analysis.

Image analyses confirmed the

findings in the tissue biodistribution data—p5R+14 accumulated in ApoA2c amyloidladen tissues more effectively than p5.
To ensure that the

125I-p5R+14

tissue uptake was amyloid-specific, portions of

the harvested tissues were analyzed with microautoradiography (ARG). Tissues were
fixed in 10% buffered formalin for 24 h and developed after an emulsion exposure of 4
days (Section 3.16). Examination of the ARG revealed that

125I-p5R+14

co-localized

with amyloid deposits (seen as CR birefringent material in consecutive slides; data not
shown). Although peptide p5R+14 clearly bound amyloid, there was evidence in the
ARG that not all of the amyloid within certain tissues—namely the spleen and lung—
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Figure 5.6: Scaled comparisons of 99mTc-p5 and 125I-p5R+14 uptake in ApoA2c
mice. These graphs display the ratio of radiotracer uptake in ApoA2c tissues to the
average uptake in respective WT tissues. This accounts for any non-specific binding
that biased radiotracer accumulation. There was greater 125I-p5R+14 (red) than 99mTcp5 (blue) accumulation in most tissues but most notably in the lower intestines and
spleen. In ApoA2c # 3, both the liver and heart also showed enhanced accumulation of
125I-p5R+14. Error bars are not shown because these data are ratios.
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Figure 5.7: Image analyses revealed greater 125I-p5R+14 uptake in amyloid-laden
organs. These data were acquired by drawing ROI over the liver, heart and lung. In
each mouse, it was evident that a more 125I-p5R+14 (red) bound as compared to 99mTcp5 (blue). Since intestinal activity could have been amyloid-specific or a result of
clearance, this organ was removed from the analysis. Error bars are not shown
because these data represent individual animals.
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was covered by silver black grains. This meant that the amyloid deposits were not
entirely targeted with the peptide. Additionally, there was no reactivity with healthy
tissue in the evaluated organ specimens (Figure 5.8).

5.3. Conclusions
Perhaps the most remarkable finding in these studies was positive cardiac
imaging which was made possible with

125I-p5R+14

in ApoA2c mice.

We have

observed that, unlike the AA model of amyloidosis which inconsistently develops small
amounts of cardiac amyloid, the ApoA2c transgenic mice unfailingly generate a large
amount of cardiac amyloid.

The biodistribution measurements associated with

125I-

p5R+14 in ApoA2c tissues yielded a diseased heart tissue:healthy tissue ratio of ~ 3 in
one mouse. This value was high enough to clearly visualize the radiotracer within the
heart (see Figure 5.3). Since cardiac amyloid is a particularly ominous manifestation in
patients with amyloidosis, the ability of this radiotracer to visualize amyloid burden in
this critical organ may be clinically relevant.
In summary, dual isotope imaging provided a facile method for assessing two
different peptide radiotracers in individual mouse, thus subjecting them to the same in
vivo conditions. This direct comparison generated data suggesting that peptide p5 was
not suitable for ApoA2c amyloid detection; peptide p5R+14, however, was able to detect
ApoA2c amyloid effectively.

Both tissue biodistribution measurements and image

analyses revealed that p5R+14 was superior to p5 in ApoA2c amyloid reactivity and that
it could positively detect cardiac amyloidosis. The previous chapter discussed ex vivo
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Figure 5.8: Autoradiographs of 125I-p5R+14 in ApoA2c tissues at 2 h pi. These
ARG indicate that peptide, seen as black silver grains, avoids reactivity with healthy
tissue in these samples and preferentially binds to amyloid deposits.
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findings which indicated that p5R+14 bound to ApoA2c tissue homogenates better than
both p5 and p5R peptides; the translation of these findings in vivo was made credible
through the dual isotope study. Additionally, p5R+14 ARG and CR tissue examination
confirmed that the peptide co-localized with amyloid in all tissues, but it also revealed
that amyloid coverage did not reach entirety with the radiotracer which is the focus of
the next few chapters.
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Chapter 6
Comparison of in vivo and ex vivo ApoA2c amyloid binding with p5R+14

6.1. Overview
The in vivo reactivity of p5R+14 with ApoA2c amyloid was clearly established by
using dual isotope imaging, tissue biodistribution and microautoradiography (Chapter 5).
Autoradiographs of various tissues revealed that the peptide co-localized specifically
with the amyloid deposits, leaving healthy tissue unaffected. The amyloid reactivity in
tissues with extensive, “waxy deposition”, however, was incomplete with p5R+14 (i.e.
not all of the amyloid was decorated with peptide). This effect was observed most
commonly in the spleen. There are a number of possible explanations for the lack of full
amyloid coverage by

125I-p5R+14

in vivo: 1) There was a lower concentration of peptide

binding sites in splenic amyloid compared to other tissues; 2) dense amyloid deposition
rendered the peptide incapable of fully penetrating the pathological material; or 3) the
binding site became buried in the thick amyloid depots which commonly form in the
spleen. Peptide reactivity with ApoA2c tissues in the ex vivo binding assays (Chapter 4)
demonstrated that p5R+14 bound to amyloid-laden spleen with a greater percentage
relative to its reactivity with most other tissues and the reactivity of other peptides with
ApoA2c spleen.

Thus, the peptide binding site must be present in splenic tissue

amyloid and is likely no less pronounced than in other tissues. Since the much larger
SAP radiotracer (MW 250,000 Da) could fully penetrate ApoA2c splenic amyloid in vivo
(Figure 6.1), it seemed unlikely that the peptide would be incapable of doing the same.
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Figure 6.1: Autoradiograph of 125I-SAP in ApoA2c amyloid-laden spleen. The
black silver grains deposited perifollicularly in the splenic tissue sample demonstrated
full ApoA2c amyloid coverage with 125I-SAP. The healthy red pulp and white pulp were
unaffected by the radiotracer which suggested that SAP preferentially bound amyloid in
this tissue. (Image provided by Dr. Jonathan Wall).

154

Therefore, it appeared most likely that the binding site for the peptide became buried or
more inaccessible within in vivo conditions as the deposits grew denser over time. If
this were the case, p5R+14 reactivity with tissue amyloid in vivo may underrepresent
the full burden of amyloid, especially if these tissues had developed extensive
deposition. This hypothesis was tested by performing a study that compared the in vivo
reactivity of p5R+14 in ApoA2c mice using tissue biodistribution measurements with the
ex vivo reactivity of the peptide in the pull down binding assay utilizing tissues harvested
from the same mice. To achieve this, the peptide was radiolabeled with I-123 for the in
vivo biodistribution study because it has a half-life of only 13 hours which would allow
for a full radioactive decay of the harvested tissues (10 half-lives as recommended by
UT Radiation Safety) within 5 days.

These tissues could then be prepared as

homogenates for the ex vivo assay. In order to have enough material to homogenize, a
sample of each tissue was not collected for ARG in this study. Thus, the p5R+14
peptide was tested under both conditions using the same tissues to determine if the
under-representation of amyloid burden, when analyzed in vivo, was due to
inaccessibility of the peptide binding site.

6.2. Biodistribution measurements of 123I-p5R+14 in ApoA2c and WT mice
To obtain in vivo measurements of peptide binding, p5R+14 was radiolabeled
with I-123 as described in the methods chapter (Section 3.5) with the help of Dr.
Stephen Kennel. Radiopurity was assessed, and the peptide was evaluated in the ex
vivo binding assay with AA liver (Figure 6.2). Mice were injected with approximately 20
μCi of radiolabeled peptide with an uptake time of 4 hours. Mice were then euthanized
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Figure 6.2: Assessment of radiopurity and amyloid-reactivity of 123I-p5R+14. (A)
SDS-PAGE analysis of radiolabeled peptide. The reduced and non-reduced samples
migrated identically on the gel and revealed no oligomeric species within the product.
Additionally, no free isotope was detected. (B) Results of the ex vivo peptide binding
assay. The radiolabeled p5R+14 binds amyloid-laden tissue and yields low reactivity
with healthy tissue.
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by inhalation overdose of isoflurane, and tissues of interest (liver, spleen, kidneys,
intestines, lungs and heart) were harvested for biodistribution measurements.

As

indicated in Figure 6.3, there was a higher percent injected dose per gram in most
ApoA2c tissues relative to the amount detected in an average of 2 WT mice for each
tissue; however, the uptake (% ID/g) was, with the exception of the heart, not more than
2 or 3-fold higher than the non-specific reactivity of p5R+14 with healthy tissue, and no
measurement was higher than 7 %ID/g for any tested tissue. With biodistribution values
less than 7% in all examined tissues, it was unclear whether or not these ApoA2c mice
had actually developed significant amyloid or if the pathological deposits were
incompletely targeted. Since samples were not harvested for Congo red histological
examination, an additional study was performed to test for the presence of amyloid.

6.3. 125I-p5R+14 binding assay on ApoA2c tissue homogenates
As a means of confirming amyloid deposition and comparing in vivo peptide
reactivity with ex vivo binding data, the harvested tissues were frozen for 5 days for
radioactive decay (10 half-lives) and homogenates prepared for the ex vivo peptide
binding assay (Section 3.10.1). Each of 6 individual tissues from 3 ApoA2c mice and 2
WT mice were homogenized as previously described (Section 3.9) and a pull down
assay performed. Peptide p5R+14 was radiolabeled with

125I

for the ex vivo binding

assays due to cost efficiency and radioisotope half-life (T1/2 = 59 days; the assays took 3
weeks to complete). Our data indicated that p5R+14 bound to all ApoA2c tissues (>
20%) to a much greater degree than the non-specific binding associated with WT
tissues (< 10%; Figure 6.4). Given that the peptide can bind the amyloid-laden tissue
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Figure 6.3: Biodistribution measurements of 123I-p5R+14 in ApoA2c and WT mice
at 4 h pi. The radiotracer accumulation in various tissues harvested from 3 individual
ApoA2c amyloid-laden mice is shown. In addition, the mean plus SD of peptide
accumulation obtained from 2 WT mice is included to represent any non-specific binding
within the tissues. Notice that the % ID/g for the liver, spleen, lung and heart of each
ApoA2c mouse exceeded the average WT value. The kidneys, a tissue less affected by
ApoA2c amyloid, revealed similar values for diseased and healthy mice. After removal
of the feces, the ApoA2c intestines did not appear to accumulate much more peptide
than that seen with WT mice.
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Figure 6.4: Ex vivo assessment of 125I-p5R+14 binding to ApoA2c and WT
homogenized tissues. The tissues analyzed in this assay were harvested from the 3
ApoA2c mice and 2 WT mice used in section 6.2. The data indicate that there was
greater peptide reactivity with all diseased tissues as compared to that seen in an
average measurement of non-specific peptide binding to amyloid-free tissue
homogenates.
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from the healthy tissue for each organ as suggested by the percentage of radiolabeled
peptide bound to the pellet in this assay, it seemed logical to assume that p5R+14,
when exposed to the multitude of binding sites presented after tissue homogenization,
can effectively target ApoA2c amyloid.

6.4. Comparison of in vivo and ex vivo peptide binding data
In order to directly compare the in vivo and ex vivo data, the amount of
radioactivity (counts per minute; cpm) in each tissue was reported relative to the weight
of the tissue. In the ex vivo binding assay, approximately 5 mg of tissue and 100,000
cpm were used in each sample. Thus, if complete binding was achieved, 1 mg of tissue
would bind 20,000 cpm. For the biodistribution study, each tissue was weighed, and a
percentage of the injected dose (measured in cpm) in the tissue was recorded. With
these data, the in vivo analyses could be directly compared to the data generated from
the binding assay. An example of the analysis can be seen in Figure 6.5, and the
results from each individual mouse are presented in Figure 6.6.
The direct comparison of p5R+14 binding to amyloid in vivo and ex vivo showed
that the peptide underrepresented the amount of amyloid in half of the tested tissues—
notably the spleen, lungs and heart. Since the tissues harvested at necropsy were to
be homogenized and used as substrate for the ex vivo pull down assay, there was not
enough of each sample to develop ARG. Thus, we were unable to visually locate
regions of amyloid in these specific tissues that were not completely targeted by the
peptide radiotracer. Previous studies utilizing p5R+14 in ApoA2c mice produced ARG

160

Figure 6.5: Method for analyzing ex vivo and in vivo data with comparable
peptide binding values. Since there was a different amount of tissue used in the ex
vivo binding assay (5 mg as compared to the whole organ used in the in vivo
biodistribution measurements) and a different amount of radioactivity, the two methods
were scaled by a theoretical maximum of counts bound to a certain weight of tissue.
The example shown revealed a theoretical maximum of 2.7% binding in vivo for the
amount of peptide that could bind to an equivalent piece of tissue ex vivo. Additionally,
non-specific binding to each tissue was accounted for by the subtraction of peptide
reactivity observed with respective WT tissues. All data were scaled according to the
provided example in order to compare the datasets.
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Figure 6.6: Comparative analysis of ex vivo peptide-binding data and in vivo
biodistribution data in 3 ApoA2c mice. The ex vivo data (solid bars) are plotted
against the left axis and in vivo data (striped bars) are plotted against the theoretical
maximum axis on the right. In all 3 mice, there was a good representation of the liver
and intestines with both the ex vivo and in vivo data. Since there is not typically a large
amount of renal ApoA2c amyloid, the low kidney binding with both techniques was also
expected. In the spleen, lungs and heart, however, there was a consistent underrepresentation of amyloid in the in vivo biodistribution analysis. This suggested that, in
these tissues, radiotracer accessibility to the amyloid may be hindered in vivo.
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which demonstrated the lack of complete amyloid coverage in the spleen, lung and
heart (Figure 6.7).

These observations further confirmed that peptide p5R+14

quantitatively underestimated the ApoA2c amyloid burden in vivo.

6.5. Conclusions
The data presented here indicate that even though p5R+14 was the optimal
agent for imaging ApoA2c amyloid, it bound to ApoA2c tissues more effectively in the ex
vivo assay for many of the tested tissues—particularly the spleen, lungs and heart.
These findings indicate that the peptide binding site within amyloid that is associated
with these organs was more readily available in the homogenized tissue samples than
in the pathological tissue deposits in situ.

Therefore, to enhance the reactivity of

peptide with ApoA2c amyloid in vivo, a different peptide might be necessary. According
to the literature [371], comparison of peptides p5 and p5R (the variant of p5 with
arginine residues substituted for all lysine residues) in a murine model of AA
amyloidosis revealed that the arginine variant had a higher affinity for amyloid resulting
in a “binding site barrier effect” which limited amyloid coverage by the peptide in tissues
with extensive amyloid deposition [371].

Given that p5R+14 has twelve arginine

residues, it may also suffer from a similar effect in the extensive ApoA2c amyloid
deposits. Additionally, it is worth considering that the biological half-life of a peptide is
generally relatively short [410-412], due to its small size, which may have hindered the
peptide’s ability to access the entirety of amyloid deposition due to its rapid catabolism
and removal from the blood pool. To address this specific issue, we tested modified
peptides which are discussed in the next chapter.
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Figure 6.7: ApoA2c amyloid deposits which were unidentified by the 125I-p5R+14
radiotracer in various tissues. Autoradiographs (ARG) of ApoA2c spleen, lung and
heart demonstrated that the peptide, visualized as black silver grains, was incapable of
fully targeting the entirety of amyloid deposition in these tissues. The regions of amyloid
are shown as bright red in the Congo red (CR) fluorescent images of splenic and
cardiac tissue, and the amyloid within the lung tissue appears as birefringent greenishgold material in the center CR image. The black arrows indicate regions of amyloid that
are not fully covered with 125I-p5R+14 in these tissues. The white arrows indicate
regions of amyloid which lack radiotracer co-localization. (Heart image was supplied by
Dr. Jonathan Wall).
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Chapter 7
Assessment of modified peptides designed to enhance
quantitative ApoA2c amyloid detection

7.1. Overview
It has been shown that peptide p5R+14 effectively binds to ApoA2c amyloid such
that many amyloid-laden organs can be non-invasively visualized with SPECT/CT
imaging. Observations obtained from the in vivo vs. ex vivo amyloid binding experiment
suggested that the peptide could not bind ApoA2c amyloid deposition in its entirety,
however. In mice with advanced deposition, tissues accumulated dense pathological
deposits of amyloid that the peptide was unable to bind to or fully penetrate. Thus, the
representation of ApoA2c amyloid in vivo was underestimated with

125I-p5R+14,

notably

in the spleen, lung and heart. While the peptide imaging agent may be effective at
detecting amyloidosis, the lack of full amyloid coverage could be detrimental to the
clinical use of this peptide in monitoring quantitative response to therapy aimed at
clearing dense tissue amyloid deposits. We hypothesized that this phenomenon may
be likely due to: 1) the high affinity of p5R+14 for the amyloid resulting in a binding site
barrier effect, or 2) the short half-life of the peptide in the circulation did not allow for
complete uptake of the peptide by poorly “vascularized”, dense amyloid lesions. To
address these potential concerns, modified peptides were designed and tested in
ApoA2c mice. These peptides addressed issues pertaining to amyloid binding affinity
and serum half-life in an attempt to enhance uptake by dense amyloid.
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7.2. Studies using

125I-p5+14:

A peptide addressing amyloid affinity and binding

site barrier effects
A recent study using amyloid-reactive peptides suggested that enhanced affinity
to the target resulted in a binding site barrier effect which hindered full amyloid coverage
in extensive deposits [371].

This study utilized heparin-binding peptide, p5, and a

variant of this peptide, p5R.

The latter peptide was modified to contain arginine

residues in place of all lysine residues, resulting in a greater propensity of the peptide to
adopt an α-helical secondary structure [371, 425]. Since the helical structure of peptide
p5 has been postulated as an important property required for amyloid-binding [371,
409], the potential for a more helical peptide, which could result in higher-affinity
amyloid-targeting, was appealing. The arginine variant, indeed, had a higher affinity for
heparin and AA amyloid as evidenced by HPLC and ex vivo NaCl titration, respectively
[371]. Additionally, p5R was shown to co-localize with congophilic material in a murine
model of AA amyloidosis indicating preferential in vivo binding to amyloid.
Autoradiographs with

125I-p5

or

125I-p5R

in tissues harvested from AA mice, with “1+”

and “4+” splenic amyloid burden, were compared (Figure 7.1). Results of ARG studies
indicated that, in mice with less amyloid, the peptides were equally efficient at
quantitatively targeting all deposits, i.e. full coverage of the amyloid by peptide was
achieved. In mice with greater amyloid burden, however, the high affinity of peptide
p5R hindered its ability to penetrate dense deposits, resulting in a “binding site barrier
effect”; thus, the lower affinity peptide p5 was more effective at quantitative amyloid
coverage in mice with extensive deposition [371]. These findings introduced the notion
that enhanced affinity of a peptide may lead to a binding site barrier effect causing less
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Figure 7.1: Autoradiographs (ARG) indicating disparate AA amyloid targeting
with two radiotracers. These ARG demonstrate that amyloid coverage with peptides
p5 and p5R decrease as the amount of amyloid within tissues increases. The coverage
in mouse tissue with little amyloid (AA +1) looks similar with both peptides. Coverage of
amyloid in tissue with more pathological deposition (AA 4+) revealed a pattern of p5
distribution which appeared less dense than that seen with p5R, but the coverage
seemed to be more complete. The last row in the figure shows full amyloid coverage on
the left (p5; black arrow) and incomplete coverage on the right (p5R; black arrow). The
black arrowhead points to a region near a blood vessel that contains dense peptide
deposition—thought to be the presence of a “binding site barrier effect”. (Image taken
from [371]).
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than complete target coverage. Given that incomplete ApoA2c amyloid coverage was
observed with p5R+14, a peptide with 12 arginine residues, we posited that substitution
of these 12 residues with lysines, thus slightly reducing the amyloid affinity, may visibly
increase in vivo amyloid coverage observed with ARG and increase radiotracer
accumulation seen in biodistribution measurements and SPECT/CT image analyses.
Results
For this study, peptides p5+14 and p5R+14 were both radiolabeled with

125I

(Section 3.5) and tested for radiochemical purity and amyloid-reactivity (Sections 3.8
and 3.10.1) prior to in vivo analyses. Additionally, affinity of both peptides for rVλ6Wil
fibrils was assessed by performing a pull down assay with NaCl titration.

It was

determined that: there was no free isotope in the radiolabeled products; both peptides
showed positive reactivity with AA amyloid liver; and a higher concentration of NaCl was
required to interfere with rVλ6Wil fibril reactivity for peptide p5R+14 as compared to the
lysine variant, which was expected (Figure 7.2).

The radiolabeled peptides were

intravenously injected into the lateral tail vein of ApoA2c mice that had been induced
with ApoA2c AEF ~ 12 weeks prior to the imaging study (n = 5 with p5+14 and n = 4
with p5R+14). Necropsies were performed on all mice at 2 h pi, and harvested tissues
were analyzed by using tissue biodistribution measurements and microautoradiography
(Sections 3.14 – 3.16).
The accumulation of the radiotracers in harvested tissues was reported as a
percent of the injected dose per gram of tissue (Figure 7.3). Results indicated that, on
average, mice that received p5R+14 had greater accumulation of radioactivity in all
tissues as compared to mice that received p5+14. The hypothesis that a peptide with
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Figure 7.2: Assessment of radiopurity and amyloid-laden tissue and synthetic
rVλ6Wil fibril reactivity. (A) Electrophoresis of radiolabeled peptides. The SDSPAGE revealed that reduced and non-reduced samples migrated similarly. Additionally,
no free isotope was detected in the products. (B) Ex vivo peptide binding assay.
Amyloid-reactivity as evidenced by enhanced binding to amyloid-laden liver compared
to binding to WT liver. (C) NaCl titration with peptides on rVλ6Wil fibrils. The titration
indicated fibril reactivity with both peptides but higher affinity with p5R+14 compared to
the lysine variant, p5+14.

169

Figure 7.3: Biodistribution measurements 2 h pi of either 125I-p5+14 or 125I-p5R+14
in ApoA2c mice. The in vivo amyloid reactivity of both peptides showed that, in most
tissues, there was greater 125I-p5R+14 accumulation than 125I-p5+14. One mouse,
however, appeared to have very little 125I-p5R+14 accumulation in any tissue. This
mouse (red bar in bottom graph) likely had less amyloid than the other mice since only
the stomach had comparable uptake which was due to free iodide sequestration after
peptide dehalogenation. Each bar on the graphs represents individual mice; thus, no
error bars are included.
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less affinity may provide enhanced amyloid coverage did not hold true based on the
biodistribution measurements alone—peptide p5+14 would likely have had greater
accumulation if its lower affinity for amyloid improved coverage. To confirm that the
peptides were specifically associated with amyloid deposits in the tissues, ARG was
performed.

The appearance of black silver grains seen in representative tissues

confirmed that both peptides co-localized specifically with amyloid material, but p5R+14
achieved enhanced amyloid coverage as compared to peptide p5+14 (Figure 7.4). The
binding site barrier effect was again present with p5R+14, but this peptide remained the
most effective peptide for ApoA2c detection due to its high affinity for this type of
amyloid.
These data suggested that the low affinity, lysine-rich peptide was less efficient
than p5R+14 at detecting ApoA2c amyloid in vivo. In these experiments, contrary to the
hypothesis, the peptide with a lower amyloid affinity did not enhance target (amyloid)
coverage. Instead, the p5R+14 peptide that exhibited the binding site barrier effect in
the lung and spleen was surprisingly the most effective at ApoA2c amyloid detection in
vivo as evidenced by tissue biodistribution measurements and ARG. Given these data,
we turned our attention to the second hypothesis and attempted increasing the serum
half-life of the peptide without altering the arginine amino acids responsible for the
strong interaction with amyloid. We posited that this peptide may achieve improved
target coverage if it remained in circulation longer and was, therefore, “exposed” to the
amyloid for longer periods.
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Figure 7.4: Autoradiographs demonstrating radiotracer accumulation in amyloidladen tissues. ARG revealed that both peptides bound to amyloid within the tissues,
but 125I-p5R+14 exhibited greater accumulation when compared to 125I-p5+14 as
evidenced by the density of black silver grains within the amyloid deposits.
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7.3. Studies using PEGylated

125I-p5R+14:

A peptide to study the effects of longer

serum half-life
As stated in Chapter 1 (Section 4.4), there are several advantages to using
peptides as imaging agents: they can be chemically synthesized; they are generally
non-immunogenic; they clear rapidly when not bound to target; they can penetrate
vessels due to small size [409-413]. Given that peptides are relatively small biological
agents, in comparison to other potential radiotracers (i.e. antibodies, scFv’s and
proteins), their biological half-life is shorter compared to larger agents. For example,
when the ~ 3100 Da peptide, p5, was radioiodinated and injected into WT mice, it was
determined that the effective half-life of the peptide was ~ 2 – 3 min [416]. In contrast,
when healthy mice were injected with the 250 kDa SAP, the half-life was determined to
be ~ 7.5 h [427]. While rapid clearance of unbound radiotracer can be considered
advantageous in molecular imaging studies because it can improve the signal-to-noise
ratio of images, the short half-life of peptides could potentially limit the extent of ApoA2c
amyloid-binding.

The affinity of p5R+14 for ApoA2c amyloid in vivo and ex vivo

surpasses all other tested peptides, but although it successfully detects deposits, it has
not been shown to fully penetrate dense amyloid material.

Therefore, a true,

quantitative representation of the amyloid load in a mouse (or a patient) injected with
p5R+14 might not be achievable.
In an attempt to extend the serum half-life of p5R+14—which may enhance the
peptide’s

ability

to

penetrate

ApoA2c

amyloid—we

incorporated

a

20

kDa

polyethyleneglycol (PEG) moiety to the N-terminus of the peptide (synthesized by RS
Synthesis, Lexington, KY). This approach, also termed PEGylation, has been well173

documented in the literature for its utility, safety and success in extending the half-life of
various molecules including those already approved by the FDA and in clinical use [428431]. Since PEG is a “neutral, hydrophilic polyether”, it usually “exhibits little [immuno]
reactivity” [432]. The incorporation of a PEG structure to an imaging agent, thus, yields
a non-immunogenic, non-antigenic conjugate with an increased molecular weight which
may alter its physicochemical properties and rate of catabolism within the organism; this
may result in extended serum half-life [428, 432]. Without modification, peptide p5R+14
had a molecular weight of ~ 4,500 Da; after N-terminal addition of PEG, the conjugate
had a molecular weight of ~ 24,500 Da. We tested both p5R+14 and the PEGylated
p5R+14 (PEG-p5R+14) in vivo with expectation of detecting both enhanced serum halflife and amyloid coverage with the latter peptide.
Results
For in vivo studies, predetermined concentrations of the peptides to be studied
(equal to 50 μg per peptide) were radiolabeled for comparable results. To determine
the appropriate concentration of PEG-p5R+14, a BCA peptide concentration analysis
was conducted with the assistance of Mrs. Angela Williams. Since the PEG portion of
the conjugate contains no amino acids, it is not detected with this assay. Thus, unless
the PEG interfered with the analysis, the resulting concentration was likely a direct
indication of the p5R+14 content. The peptide portion of the conjugate is ~ 1/5 of the
molecular weight; therefore, the calculated peptide concentration obtained from the
analysis was multiplied by 5 which yielded a concentration of ~ 1 mg / mL. For the
following in vivo studies, ~ 50 μL (~ 50 μg) of PEG-p5R+14 was radiolabeled with I-125.
The non-PEGylated p5R+14 (~ 50 μg) was also radioiodinated, and both peptides were
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tested for radiochemical purity (Section 3.8) and amyloid fibril reactivity (Section 3.10.2)
prior to their utilization in the following studies. The SDS-PAGE analysis indicated that
both peptides were similar in size—a finding that was initially puzzling since the
PEGylated peptide should be 20,000 Da larger than the other. It was concluded that
the SDS buffer used in the gel electrophoresis did not interact with the neutral, PEG
portion of the conjugated peptide; thus, the analysis only represented the polybasic,
p5R+14.

No free iodide was detected, and the binding assay confirmed positive

reactivity with synthetic fibrils (Figure 7.5). There was evidence of non-specific binding
to WT liver tissue homogenate with the PEGylated peptide—a finding not entirely
unexpected due to the size of the peptide but one that must be taken into consideration
when evaluating in vivo data. Autoradiography was used to determine if there was nonspecific binding to tissue in vivo.
Prior to the injection of PEG-p5R+14 in ApoA2c amyloid-laden mice, the
PEGylated peptide and p5R+14 were administered to cohorts of WT mice in a pilot
study to assess potential off-target binding and to investigate the extended serum halflife of PEG-p5R+14. Mice were injected with ~ 100 μCi of either
125I-p5R+14,

125I-PEG-p5R+14

or

and uptake times were 15 min (n = 2 for PEG-p5R+14 and n = 1 for

p5R+14) or 1 h (n = 2 per peptide). SPECT/CT imaging was performed on mice that
were allotted an uptake time of 1 h (n = 1 mouse per peptide).

All seven mice

underwent necropsies to obtain tissues for biodistribution measurements and ARG.
Due to the size of PEGylated conjugates, clearance through tissues such as the
kidneys, lungs, spleen and lymph nodes is typically lower than that observed with nonPEGylated peptides [428]. Thus, renal clearance was expected to be lower with
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Figure 7.5: Radiopurity and fibril reactivity assays. (A) SDS-PAGE analysis of
radioiodinated PEG-p5R+14 and p5R+14 after 40 min exposure. No free isotope was
detected in the samples. Since PEG was neutral, the SDS buffer did not interact with it
making the peptides migrate as the same size in both reduced and non-reduced
samples. (B) Peptide binding assays. Both peptides exhibited binding to rVλ6Wil fibrils.
The PEGylated peptide had higher background binding than 125I-p5R+14 which was
made evident with WT liver reactivity.
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125I-PEG-p5R+14

in comparison to

125I-p5R+14

in healthy mice.

Results from the

biodistribution measurements indicated that, at 15 min pi, the presence of radiotracer in
the kidneys was greater than 4-fold higher in the mouse that received

125I-p5R+14;

although less pronounced, the same trend was observed at 1 h pi with mice that
received the

125I-p5R+14

having a 2-fold higher % ID/g than mice injected with the

PEGylated peptide. Additionally, the radioiodide accumulation in the stomach—a direct
indication of the dehalogenation of injected radiotracers and uptake by halide
symporters present in the stomach [416]—was 2-fold higher at both 15 min and 1 h pi
for the non-PEGylated peptide (Figure 7.6). These data suggest that the peptides were
processed differently within WT mice and that the dehalogenation, and likely the
clearance, of

125I-p5R+14

was accelerated versus the larger

125I-PEG-p5R+14.

Images

comparing the distribution of these radiotracers at 1 h pi are shown (Figure 7.7).
The in vivo detection of ApoA2c amyloid with these peptides was next analyzed.
Given that we had observed a distinct difference in biological processing of the two
peptides in WT mice, the analysis in diseased mice was extended to 1 h and 4 h pi with
the hypothesis that, after 4 h, the PEGylated peptide would have accumulated to a
greater extent in the amyloid (determined with biodistribution measurements after
confirmation of peptide:amyloid co-localization by CR and ARG observation) as
compared to observations made at 1 h. For the in vivo study, ApoA2c mice (11 weeks
post 100 μg AEF injection) were administered ~ 100 μCi of either radiotracer and were
euthanized at 1 h or 4 h pi (n = 3/peptide/time point). The necropsies of all mice
included harvesting portions of muscle, liver, pancreas, spleen, both kidneys, stomach,
upper intestine, lower intestine, heart and lung for biodistribution measurements and
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Figure 7.6: Biodistribution of 125I-PEG-p5R+14 and 125I-p5R+14 in WT mice at 15
min and 1 h pi. These biodistribution measurements revealed that the two peptides
were processed differently in healthy mice. At 15 min pi, there was a higher % ID/g of
125I-p5R+14 (red) in the kidneys and stomach indicating a higher level of clearance and
dehalogenation in comparison to the larger peptide (blue). At 1 h pi, the same trend
was present. These data support the notion that PEGylated p5R+14 is processed more
slowly than p5R+14 in healthy mice.
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Figure 7.7: SPECT/CT images displaying the distribution of 125I-PEG-p5R+14 and
125I-p5R+14 in WT mice at 1 h pi. Both sets of images were scaled to the same
threshold for comparable visualization. The images on the left show a coronal view of
the distribution of these two radiotracers. At 1 h pi, there was uptake in the thyroid (T)
and stomach (S) with both peptides. Sagittal views on the right also show uptake in the
stomach of these mice. These regions of uptake are likely a result of dehalogenation of
the peptide and accumulation of free iodide. There is evidence, however, that the
PEGylated peptide may have remained in circulation for longer than the non-PEGylated
peptide due to a visibly greater amount of disperse radioactivity seen with this peptide in
both sets of images.

179

histological examination.

Additionally, the tongue and the cecum—sites possibly

affected by ApoA2c amyloid—were taken to be analyzed by ARG to better determine
the severity of amyloid burden.
Results comparing the biodistribution of both peptides at 1 h and 4 h pi are
displayed (Figure 7.8). These graphs display the average of 3 mice. There was no
significant difference between the peptides at 1 h pi. However, there was slightly higher
PEG-p5R+14 in the liver and lower intestines, this finding was also observed in ApoA2c
tissues at 4 h pi. The increased accumulation of PEGylated peptide in the liver and
intestines may have been due to the preferential route of clearance of the larger peptide
(hepatobiliary) versus the renal clearance associated with the non-PEGylated p5R+14.
These results suggest that the two peptides behave more similarly in the presence of
amyloid in vivo than they do in healthy mice with no amyloid. Upon examination of
tissue autoradiographs, amyloid coverage with

125I-p5R+14

(see Figure 5.8) and

125I-

PEG-p5R+14 (Figure 7.9) confirmed similar amyloid-binding behavior between the two
peptides.

7.4. Conclusions
A lack of full ApoA2c amyloid coverage had been observed in autoradiographs of
tissue sections with

125I-p5R+14;

this led to the investigation of strategically modified

peptides to potentially enhance ApoA2c amyloid-targeting based on two reasonable
hypotheses. Data suggests that the arginine-rich, high affinity peptide may suffer from a
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Figure 7.8: Biodistribution of peptides 125I-PEG-p5R+14 and 125I-p5R+14 in
ApoA2c mice. At 1 h and 4 h pi, the peptides behaved similarly in vivo. These data
suggest that PEGylation of p5R+14 may alter the metabolism of the peptide, but it did
not improve amyloid targeting.
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Figure 7.9:
Autoradiographs of 125I-PEG-p5R+14 in ApoA2c amyloid-laden
tissues. The distribution of black silver grains confirmed peptide co-localization with
amyloid in various tissues. Comparison of these images with those seen in Figure 5.8
suggest that 125I-p5R+14 and 125I-PEG-p5R+14 bind similarly to amyloid in vivo.
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“binding-site barrier” effect which can hinder the extent of amyloid coverage in vivo
[371]. This prompted the use of a lysine-rich variant of p5R+14, designated p5+14, with
the hypothesis that a peptide with less affinity for amyloid would penetrate deeper into
the mass and provide a better representation of the pathology.

This study yielded

results that were incongruent with the hypothesis—125I-p5+14 did not improve amyloid
coverage.

Experiments were then conducted with a larger, N-terminal-PEGylated

version of p5R+14 which was thought to enhance the serum half-life of the peptide
without sacrificing the arginine residues believed to facilitate the observed peptideamyloid interaction.

A larger targeting agent was hypothesized to undergo altered

catabolism (i.e. slower rate), thus increasing its serum half-life and allowing for
enhanced amyloid contact and improved accessibility and coverage.

Evaluation of

PEG-p5R+14 in WT mice suggested that it was, indeed, catabolized differently as
compared to the non-PEGylated peptide, but in ApoA2c amyloid-laden mice, the
peptides were nearly indistinguishable which also did not support the hypothesis.
Although full coverage was never reached, p5R+14 remained the most effective peptide
for ApoA2c amyloid targeting in vivo.
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Chapter 8
A non-dehalogenable, novel peptide for amyloid targeting

8.1. Overview
In the previous chapter, modified peptide variants of p5R+14 were examined as
amyloid-targeting agents in the murine model of ApoA2c amyloidosis. Experiments with
the lysine-rich and PEGylated variants revealed that altering the affinity or size of the
peptide, respectively, was incapable of improving ApoA2c amyloid coverage as
evidenced in ARGs. Given that peptides are typically cleared rapidly from circulation,
an alternative technique addressing half-life extension as a way to counteract this and
improve amyloid uptake—one which did not alter the size of the peptide—was
employed.
There are two enantiomers of amino acids: the L-type conformation and, its
“mirror image”, the D-type conformation (Figure 8.1). In nature, most amino acids are Ltype; except for those found within some bacteria, the D-types of amino acids are
commonly considered to be “non-natural” structures and are resistant to degradation—a
characteristic of D-amino acids which has been exploited in the development of certain
peptide-based drugs [433]. Data suggests that substitution of L-amino acids with the Dform can lead to stabilization through the increased resistance to protease degradation
and prolonged half-life of peptides [433, 434]. Some clinically available peptides, which
are analogues of luteinizing hormone releasing hormone (LHRH), have been developed
as drugs (e.g., Triphorelin, leuprolide, buserelin, goserelin and nafarelin). These
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Figure 8.1: Illustration of both the L-type and D-type conformations of valine.
With the exception of glycine, all amino acids can exist in one of two forms. This figure
demonstrates both the L and D forms of the amino acid, valine. The two enantiomers
are mirror images of each other. In nature, most amino acids exist in the L-type
conformation. (Image taken from [433]).

185

reagents contain D-amino acids in certain positions, and as a result, they have
prolonged reactivity in vivo [434, 435].

One clinically available, peptide-based

antagonist of LHRH, Cetrorelix, incorporates D-amino acids at 5 different positions
rendering the peptide resistant to degradation for up to 50 hours [436]. Other LHRH
antagonists without non-natural amino acids are reported to circulate in the serum for
only a maximum of a few hours before complete degradation [434, 437]. A more recent
study evaluating the oostatic potential of a peptide containing D-amino acids indicates
that the modified peptide had decreased catabolism and degraded at a significantly
lower rate when compared to L-form of the peptide; this observation was likely due to
decreased enzymatic degradation of the peptide bonds neighboring the non-natural Damino acids [438].
Given that the incorporation of D-amino acids can enhance the serum half-life of
peptides in vivo without increasing the size of the targeting agent, we hypothesized that
this approach might result in improved ApoA2c amyloid uptake and detection.
Therefore, we evaluated the amyloid-binding potential of a modified peptide p5 variant.
This peptide, designated p43, was altered at the N-terminus by substitution of GGG at
the N-terminal with D-amino acid forms of AQA (the GGG had to be substituted
because there is no enantiomer for glycine).

The p43 binding and catabolism

characteristics were compared to historic p5 data to determine if D-amino acid
incorporation could enhance half-life and amyloid uptake. Another peptide, designated
p50, was synthesized as an additional control peptide for p43 to better determine
whether any differences in reactivity were simply due to the amino acid substitution or
the incorporation of D-enantiomers—p50 contained L-type AQA at the N-terminus.
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These peptides were radiolabeled with I-125 and initially tested in the ex vivo binding
assay to ensure that the modifications did not hinder reactivity of the peptide with
amyloid-laden tissue. Observations in this assay prompted in vivo evaluations of the
peptides in both AA amyloid and WT mice.

The in vivo studies revealed that

incorporation of D-amino acids altered more than was expected.

8.2. Ex vivo tissue binding assays with 125I-p43 and 125I-p50
To determine if D-amino acid incorporation these modifications of peptide p5
hindered the peptide-amyloid interaction, binding of radioiodinated p43 and p50 AA to
amyloid-laden mouse tissue homogenates (Section 3.10.1) was tested. The reactivity
of p43 with AA amyloid-laden liver and spleen confirmed that the modifications made to
this p5 variant did not interfere with its binding to AA amyloid. In fact, the data showed
that p43 had enhanced binding to these tissue homogenates as compared to the parent
peptide (> 70% and > 60%, respectively) while maintaining the low, non-specific
reactivity that p5 established with healthy tissues (~ 5%, Figure 8.2A). Interestingly, the
reactivity of

125I-p43

with AA tissues was not reproduced when ApoA2c tissues (liver,

spleen, heart and lung) were tested.

With all ApoA2c tissues, decreased peptide

binding (even less than p5 binding), with the exception of the liver, was observed
(Figure 8.2B). This was a counterintuitive finding since p43 bound well to AA amyloid,
and a similar outcome was expected with ApoA2c amyloid. This finding was seen in
two independent preparations of ApoA2c amyloid-containing tissue homogenates. Of
all the peptides that have been evaluated, the most effective in vivo ApoA2c amyloidtargeting was p5R+14 (Chapter 4). The increased helicity achieved by incorporation of
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Figure 8.2: Ex vivo peptide-binding assays with 125I-p43 and 125I-p5. (A) Peptide
binding assays on AA and WT tissues. The data showed that 125I-p43 (red) exhibited
greater binding to both AA liver and spleen compared to the parent peptide, 125I-p5
(green). The enhanced binding with 125I-p43 did not cause higher non-specific binding
compared to 125I-p5 as evidenced by similar percentages of the peptides bound to WT
liver tissue. (B) Peptide binding assays on ApoA2c tissues. Binding with peptide 125Ip43 to ApoA2c tissues was much less impressive than the binding established with AA
tissues. There was minimal binding in each tissue with both peptides, but 125I-p43 was,
unexpectedly, even less effective than 125I-p5 with this type of amyloid.
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arginine residues as well as an additional 4 positively charged residues (total of 12
arginine residues) likely resulted in the optimal ApoA2c binding in vivo. Peptides p43
and p5, both containing 8 positively charged Lys residues, clearly did not possess the
necessary characteristics for efficient ApoA2c amyloid-binding.
Peptide p50, the all-L-amino acid peptide control for p43, was not tested in the
ApoA2c amyloid system due to p43’s unimpressive binding.

Instead, p50 was

evaluated for positive AA binding with both liver and spleen homogenates. Reactivity
with these tissues was similar to that seen with p5 and lower than the binding observed
with p43 (Figure 8.3). Given that peptide p50 exhibited reduced AA amyloid interaction
as compared to p43, the data indicated that an N-terminal composed of non-natural, Dtype AQA residues enhanced binding compared to that observed with a peptide
containing N-terminal L-type AQA residues or N-terminal GGG residues.
To assess the “affinity” of the binding with amyloid, the peptides were subjected
to sodium chloride (NaCl) titrations on AA liver and AA spleen.

It was hypothesized

that p43 would bind with greater affinity to AA amyloid than p50 based on its increased
retention in PBS. This hypothesis was tested using the following NaCl concentrations:
0.15 M (equivalent to PBS), 0.25 M, 0.5 M, 0.75 M and 1.0 M. The data revealed that
p43, in the presence of both the liver and spleen homogenates, required a higher
concentration of NaCl (~ 0.1 – 0.25 M greater) to interrupt the electrostatic peptideamyloid interaction and reduce binding by 50% (IC50) as compared to p50 (Figure 8.4).
These data supported the hypothesis that p43 binds AA amyloid with slightly higher
affinity as compared to p50. Also, because we observed greater binding to the amyloid
of p43 at each salt concentration, it suggests that there are more “binding sites” for the
189

Figure 8.3: Ex vivo peptide-binding assay demonstrating 125I-p50 reactivity with
AA tissues and WT liver. Amyloid reactivity with the L-type N-terminal AQA peptide
p5 variant was established, and data revealed that 125I-p50 positively binds to AA
amyloid in both the liver and spleen. The reactivity was less than that previously
established with p43 in this assay, however. Non-specific binding to WT liver was low,
and similar to that seen previously with both p43 and p5.
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Figure 8.4: NaCl titrations assessing 125I-p43 and 125I-p50 affinity for AA liver and
spleen homogenates. Concentrations up to 1.0 M of NaCl were used in the peptide
binding assay to demonstrate the affinity of both 125I-p43 (red) and 125I-p50 (blue) to AA
liver and spleen. As shown in the graphs on the left, there was a higher percentage of
125I-p43 bound to both tissues in all concentrations of NaCl than was observed with 125Ip50. When the data were plotted against the percentage of maximum peptide bound to
pellet (value obtained in PBS alone), the IC50 for 125I-p43 (yellow stars) was determined
to be slightly higher than the IC50 for 125I-p50 (black stars) with both tissues.
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p43 peptide. It may be that p43 binds HS and fibrils in the amyloid, whereas p50 (and
p5) may only bind HS. Since positive reactivity with AA amyloid had been established,
we then assessed peptides p43 and p50 in the H2/IL-6 murine model of amyloidosis to
elucidate whether they could effectively detect amyloid in vivo.

8.3. Time course biodistribution and SPECT/CT studies with 125I-p43 and 125I-p50
Peptide 125I-p43
It was previously shown that both p43 and p50 bind to AA amyloid in the pull
down peptide binding assay. Since p43 did not effectively bind to ApoA2c amyloid,
further comparisons of p43 and p50 focused on the AA mouse.

Given that p43

contained D-amino acids, we were uncertain of how the peptide would “behave” in vivo.
The AA homogenate binding assay suggested that binding to AA amyloid was
enhanced, which would facilitate uptake by amyloid in diseased mice. To determine if
preferential AA amyloid binding of p43 could be reproduced in vivo, cohorts of AA mice
(n = 3 per time point), at ~ 6 – 8 weeks post injection of AEF, were administered
radioiodinated p43 or p50 iv in the lateral tail vein and euthanized at either 1 h, 4 h or 24
h

pi

for

SPECT/CT

imaging,

tissue

biodistribution

measurements

and

microautoradiography. The radiopurity of the peptide samples was established by SDSPAGE and amyloid reactivity confirmed by AA liver homogenate binding (Figure 8.5).
To characterize potential non-specific, off-target binding associated with these peptides,
WT mice were also administered the radiotracers and examined at the same time points
post injection.
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Figure 8.5: Radiopurity and amyloid-reactivity of the radiolabeled peptides. (A)
SDS-PAGE analysis of radioiodinated p43 and p50. The gel shows there was no
detectable free iodide in the peptide samples. (B) Ex vivo assessment of peptide
reactivity with AA liver and WT liver. The data indicate that both peptides behaved as
expected in the peptide-binding assay with positive reactivity to AA liver (~ 60 – 70%)
and < 5% reactivity with WT liver.
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The tissue biodistribution data generated by using gamma counting of

125I-p43

in

AA mice revealed uptake of the radiotracer (~ > 10 %ID/g) in the liver, pancreas, spleen
and intestines—all common sites of AA amyloid deposition (Figure 8.6). This uptake
was observed at each time point, which indicated that the peptide-amyloid interaction
occurred within 1 hour of radiotracer injection, and the interaction was stable for at least
24 h (Figure 8.6). The post mortem SPECT/CT imaging confirmed the biodistribution
data, revealing uptake in tissues that exhibited the highest % ID/g and showing stability
of

125I-p43

binding to amyloid-laden tissues up to at least 24 h pi, i.e. liver, spleen and

pancreas (Figure 8.7). This prolonged amyloid reactivity was previously observed with
125I-p5

in the tissues of AA mice (see Figure 1.27) [416].
In WT mice, however, there was an interesting discrepancy in the biodistribution

of

125I-p43

when compared to the historical

125I-p5

data. Accumulation of radioiodide—

liberated when radioiodinated peptide tracers encounter deiodinase enzymes in the liver
and kidneys [416]—in both the stomach and thyroid of mice injected with

125I-p5

was

observed due to the presence of sodium-iodide symporters in the stomach and thyroid.
SPECT/CT imaging of 125I-p5 in WT mice revealed expected uptake in both the stomach
and thyroid within 1 h pi (Figure 8.8). In WT mice injected with
dehalogenation was not present.

125I-p43,

however,

This was evidenced by a lack of free iodide

accumulation in the stomach and thyroid in images and tissue biodistribution (Figure
125I-p5

and ~ 1

in the stomach. Instead, only the kidneys in WT mice with

125I-p43

8.9) values that were lower than that seen for
%ID/g with

125I-p43)

125I-p5

(~ 20 %ID/g with

achieved a % ID/g high enough (~ 40%) to be visualized with SPECT/CT imaging
(Figure 8.10A). The whole body 125I-p43 activity was most prominent in the SPECT/CT
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Figure 8.6: Biodistribution measurements of 125I-p43 in a time course study with
AA mice. These graphs demonstrated the uptake of 125I-p43 in ApoA2c mice at various
time points pi. There was evidence of accumulation of radiotracer in the liver, pancreas,
spleen and intestines at each time point. The kidney binding gradually decreased over
time as unbound radiotracer was catabolized. Each dataset on the graph represents an
individual mouse.
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Figure 8.7: Representative SPECT/CT images of 125I-p43 in AA mice at 1 h, 4 h
and 24 h pi. The distribution of radiotracer 125I-p43 at 1 h pi demonstrated that there
was uptake in the liver (L), spleen (Sp), pancreas (P) and intestines (I). The stomach
(St; green arrow) remained empty for the time course duration. There was evidence of
125I-p43 accumulation in amyloid-laden tissues up to 24 h pi.
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Figure 8.8: 3D SPECT/CT representation of 125I-p5 in a WT mouse. This image
displays uptake of liberated free iodide in the stomach and thyroid of a WT mouse at 1 h
pi. (Image adapted from [409].

Figure 8.9: Biodistribution of 125I-p43 in WT mice. The graph shows mean
distribution (n = 3) in WT mice at each time point pi. At 1 h pi (blue), the radiotracer was
present in the liver and kidneys. All tissues were “clear” by 4 h pi (red), and by 24 h pi
(green), the biodistribution of 125I-p43 was nearly completely diminished. Notice the lack
of accumulation of free iodide in the stomach at any time point. This suggested that the
peptide radiotracer was, unexpectedly, not dehalogenated in vivo.
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Figure 8.10: Representative SPECT/CT images of 125I-p43 in WT mice at 1 h, 4 h
and 24 h pi. (A) Axial images demonstrating renal accumulation at various times pi.
The renal uptake of 125I-p43 is most prominent at 1 h pi and is no longer evident by 4 or
24 h pi. (B) Whole body images demonstrating the distribution of 125I-p43. These
images display uptake of the radiotracer in the kidneys (K) and liver (L) at 1 h pi. The
kidneys are cleared by the 4 h pi time point leaving only trace amounts of peptide
clearing through the intestines. By 24 h pi, there was no evidence of any radiotracer in
the image.
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images at 1 h pi and progressively diminished in the 4 and 24 h pi images (Figure
8.10B). The lack of

125I

sequestration by the stomach and thyroid suggested that p43

had been catabolized without undergoing dehalogenation—an unexpected outcome.
When compared to the parent peptide, p5, the incorporation of AQA D-amino acids at
the N-terminal in p43 resulted in alternative catabolic processing of the radiotracer.
However, instead of exhibiting a longer serum half-life prior to its dehalogenation and
clearance (which was the expected biological behavior), the peptide avoided renal and
hepatic deiodinases altogether.

Since radiolabeling of peptides with

125I

results in

incorporation into the L-tyrosine residue, we anticipated that the dehalogenation
enzymes would “recognize” and act upon the iodinated amino acid; instead, the Nterminal D-amino acids appeared to have a “protective” effect over the radiolabeled
tyrosine residue, resulting in no dehalogenation. Although this characteristic of p43 was
unforeseen, we speculated that it could offer an advantageous property for AA amyloid
imaging.

With other peptides, dehalogenation in the kidneys makes renal amyloid

imaging improbable at early time points pi because the tracer is slowly catabolized and
125I

is liberated; with p43, however, a lack of dehalogenation and rapid renal clearance

could theoretically be exploited for imaging amyloid-laden regions in the kidneys by
SPECT/CT imaging at very early time points.
The microautoradiographs (ARG) of

125I-p43

in harvested AA tissues revealed

that the radiotracer specifically co-localized with amyloid at all time points examined as
demonstrated by the accumulation of black silver grains in regions of tissues that were
also Congophilic (i.e. amyloid) in consecutive tissue sections. Representative ARG of
various tissues at different time points are shown (Figure 8.11). In healthy tissues, ARG
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Figure 8.11: Co-localization of 125I-p43 to AA amyloid at various time points pi.
Microautoradiography (ARG; 20 X) shows distribution of the peptide (black silver
grains), and Congo red (CR; 20 X) birefringence displays amyloid distribution in the
tissues. Peptide is shown to co-localize with amyloid in all tissues. The distributions
seen in the spleen and heart were at 1 h pi, the pancreas was at 4 h pi and the kidney
and stomach were at 24 h pi.
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indicated that there was dense accumulation of

125I-p43

in the glomeruli, Bowman’s

capsules and proximal tubules (likely luminal) of the kidney, in addition to binding to,
presumably, hyaline cartilage associated with tracheal tissue at 1 h pi. No other tissues
revealed

125I-p43

binding. Both the renal radioactivity and cartilage binding were much

diminished at 4 h pi. The radiotracer distribution in the kidneys at this time point was
detected in the distal tubules—indicative of natural radiotracer clearance. “Off-target”
binding

to

cartilage

was

likely

the

result

of

peptide

interaction

glycosaminoglycan, chondroitin sulfate, in the tracheal cartilage.

with

the

With a sulfation

pattern similar to heparin (see Figure 1.5), the interaction of a heparin-binding peptide
derivative, such as p43, with chondroitin sulfate would not be implausible. Indeed, we
have seen this with most of our amyloid-reactive peptides. By 24 h pi, the black silver
grains that were previously present in the kidneys and associated with cartilage tissue
had diminished, indicating that the radiotracer had cleared and that the non-specific
binding that 125I-p43 demonstrated was seemingly weak and temporary (Figure 8.12).
Although the incorporation of D-amino acids in peptide p43 had not dramatically
altered the blood half-life as was initially hypothesized, discovery of its new
characteristic (i.e. non-dehalogenation) adds value to its potential clinical use. If, by 24
h pi, the peptide was fully cleared through the kidneys in a manner which did not result
in dehalogenation of the radiotracer, then injection of radiolabeled p43 into a patient
with a heavy renal amyloid burden could be used to specifically image amyloid rather
than be attributed to radiotracer clearance. Since renal involvement is common in all
AL, AA and ALect2 patients and yields a poor prognosis, the use of a radiotracer which
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Figure 8.12: Autoradiograph visualization of 125I-p43 binding to healthy kidney
and cartilage tissue at various time points pi. The accumulation in the kidney seen
at 1 h pi is primarily within the Bowman’s capsules and renal tubules. At 4 h and 24 h
pi, the density of radiotracer uptake in the kidney diminished which indicated clearance.
The off-target binding observed in the tracheal cartilage was likely due to peptide
reactivity with chondroitin sulfate. This interaction was transient, however, which was
evidenced by decreased peptide binding observed at 4 h pi and a lack of peptide
binding to cartilage at 24 h pi. No other tissues within WT mice demonstrated 125I-p43
accumulation at any time point.
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could determine the amyloid load in this particular organ may have clinical merit as a
diagnostic agent or as a tool to monitor the response to therapies.

Studies with 125I-p50
The previous studies determined that p43 exhibited different biological behavior
in vivo when compared to historical p5 data. The incorporation of N-terminal D-amino
acids was likely the factor which resulted in a non-dehalogenable product, but this
hypothesis could not be confirmed without similarly testing p50 in AA and WT mice.
Peptide p50 has the same amino acid sequence as p43, but there are no D-amino
acids. Examining p50 in AA and WT mice would determine if the different biological
behavior observed with p43 was a result of substituting N-terminal GGG residues with
AQA or a result of incorporating D-amino acids. Therefore, p50 was analyzed in AA
and WT mice to examine amyloid reactivity and dehalogenation.
experimental conditions were used to examine the

125I-p50

The same

radiotracer in AA (~ 6 – 8

weeks post AEF induction) and WT mice. SPECT/CT imaging was performed after
mice were euthanized at 1 h, 4 h or 24 h pi.
The images and mean tissue biodistribution measurements (at 1 h pi) of
in WT mice indicated that this peptide behaved similarly to
vivo as was suggested by the uptake of liberated

125I

125I-p5

rather than

125I-p50

125I-p43

in

in the stomach (31 %ID/g) and

thyroid and a lack of radiotracer accumulation in the kidneys (9 %ID/g) (Figure 8.13A).
Additionally, the images and mean tissue biodistribution measurements (at 1 h pi) of
125I-p50

in AA mice revealed positive uptake in amyloid-laden tissues such as the liver
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Figure 8.13: SPECT/CT images of 125I-p50 in WT and AA mice at 1 h, 4 h and 24 h
pi. (A) Distribution of radiotracer in WT mice. There was evidence of 125I-p50
dehalogenation at all each time point due to free iodide uptake in the stomach (St) and
thyroid (T). By 24 h pi, the stomach had cleared. Notice that at 1 h pi, there was no
accumulation of radiotracer in the kidneys (K) which was in stark contrast to that seen
with 125I-p43. (B) Distribution of radiotracer in AA mice. 125I-p50 accumulated in AA
amyloid-laden tissues such as the liver (L), spleen (Sp), pancreas (P) and intestines (I).
The radiotracer uptake was stable and was still visible at 24 h pi.
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(17 %ID/g), spleen (19 %ID/g), pancreas (35 %ID/g) and upper/lower intestines (28 and
10 %ID/g, respectively) (Figure 8.13B).

The uptake of

125I-p50

was stable enough to

provide positive amyloid imaging up to at least 24 h pi. The whole-body distribution in
AA mice was similar to that observed with both peptides p5 and p43 indicating that all of
the radiotracers, regardless of biological processing, were capable of targeting AA
amyloid in multiple tissues.

Confirmation of the preferential binding of

125I-p50

to

amyloid deposition over healthy tissue was similarly evidenced by ARG analysis of
representative AA and WT tissue sections (Figures 8.14 and 8.15). Based on these
findings, we speculate that, since

125I-p50

behaved more similarly to

125I-p5

than

125I-

p43 in AA and WT mice, it confirmed that it was the incorporation of AQA D-amino
acids, not simply the N-terminal sequence, which resulted in a non-dehalogenable
peptide capable of detecting AA amyloid.

8.4. Dynamic PET/CT analysis of 125I-p43 in WT mice
Recently, we published a study in which dynamic PET/CT imaging was
performed to better characterize the in vivo biokinetic profile of radioiodinated p5 in live
WT and AA mice [416].

Analysis of dynamic PET/CT data, i.e. generation of time

activity curves (TAC) for various organs of interest, was performed. These curves of the
dynamic distribution of

124I-p5

from the time it was injected, made possible the analysis

of the uptake and clearance of the radiotracer in each organ. To gain insight into the
non-dehalogenable nature of p43, dynamic PET/CT scans were conducted on WT mice,
and data were compared to the published TAC for p5. Since it was thought that the
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Figure 8.14: Microautoradiographs displaying 125I-p50 in amyloid-laden tissues
representative of various time points pi. These tissues demonstrate the ability of
peptide p50 (black silver grains) to preferentially target amyloid within several tissues at
1 h, 4 h and 24 h pi. The radiotracer does not bind healthy tissue within these sections.

Figure 8.15: Microautoradiographs demonstrating a lack of 125I-p50 accumulation
in various WT tissues. These images confirm that 125I-p50 does not bind healthy
tissue in vivo.
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dehalogenation of these peptides primarily takes place in the kidneys, the TAC for this
organ was expected to differ between

124I-p43

and 124I-p5.

Dynamic PET/CT imaging requires the use of a positron emitting radioisotope.
With a half-life of 4.2 days, radioiodination with iodine-124 (124I) was performed for this
study. Radiolabeling of peptide p43 with

124I

was achieved as described in Section 3.6.

The product was diluted with sterile PBS such that each administered dose was ~ 200
µCi.

Since this type of imaging was conducted with live animals, the mice were

administered isoflurane anesthesia (2 % in air) prior to, and throughout the duration of
the procedure (see Section 3.12.2). The PET data were analyzed using the Inveon
Research Workplace software (Siemens). Time activity curves were created by drawing
regions of interest over the heart, kidneys, thyroid and bladder of a co-registered
PET/CT image since these organs represent blood pool and sites of catabolism and
iodide uptake.
distribution of

Given that we expected dissimilarities between the dynamic renal

124I-p43

and

124I-p5,

the generated TAC of the kidneys was compared to

the historical p5 kidney TAC data [416].
The data indicated that the profiles of the radiotracers in WT mice did, indeed,
differ in the kidneys (Figure 8.16). With

124I-p5,

the peak renal accumulation value

occurred between 7 and 8 min pi followed by rapid clearance of the radiotracer from the
organ; with

124I-p43,

however, the peak renal value occurred approximately 10 min later

(~ 17 min pi), and the radioactivity was cleared at a much slower rate from the kidney
than was observed with

124I-p5.

The delay in peak uptake that was observed with

124I-

p43 may suggest that this radiotracer had a slightly extended serum half-life prior to
renal catabolism. Since p43 was designed as a p5 variant containing D-amino acids to
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Figure 8.16: Time activity curves depicting renal accumulation and clearance of
124I-p43 and 124I-p5.
The peak renal uptake values were measured. The curves
124
demonstrate that I-p43 (green) took ~ 10 min longer to reach maximum accumulation
in the kidneys as compared to 124I-p5 (red). The black stars pinpoint the respective
peak renal activity time points. The two peptides differed in clearance of the tracers as
well which was shown by the different shapes of the curves; 124I-p43 had a broad peak
in the kidneys, and 124I-p5 had a sharp peak indicating much more rapid clearance of
radioactivity of the latter. The y-axes are not scaled equally due to the differing
amounts of radioactivity injected in the two studies. (Historical 124I-p5 data was taken
from [416] to create the image.)
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possibly extend the half-life of the peptide, this was a gratifying finding that was not
obvious in the previous SPECT/CT study.
In regard to the observed difference in renal clearance,

124I-p5

was

dehalogenated within the kidneys which resulted in a TAC that partially depicted the
loss of free iodide to the blood instead of radiolabeled peptide to the bladder. This
would further explain why the curve for
124I-p43.

124I-p5

revealed a sharper peak as compared to

With the latter peptide, the TAC was broad, indicating that the radiotracer was

retained within the kidney for a longer time period. Instead of monitoring the loss of
liberated iodide from the kidney, the p43 TAC was indicative of the movement of
radiolabeled p43, presumably intact, into the bladder.
SPECT/CT time course also indicated the presence of

The previously described

124I-p43

in the renal tubules of

WT mice at 1 h pi (see Figure 8.12), which further confirmed the extended presence of
the radiotracer in the kidneys.
Since the

125I-p43

radiotracer was resistant to dehalogenation, the stomach was

devoid of radioactivity, and the thyroid only contained minimal amounts of radioiodide
(Figure 8.10). Analysis of the dynamic PET/CT TAC for the heart, kidney, liver, thyroid
and bladder was then performed. These curves indicated uptake and rapid clearance
from the heart (blood pool), a delayed accumulation and prolonged clearance from the
kidneys, slight uptake and steady level of radiotracer in the liver and minimal amounts of
radiotracer in the thyroid as evidenced by very little accumulation toward the end of the
120 min acquisition (Figure 8:17A).

The TAC for the bladder revealed steady

accumulation that eventually plateaued; due to the high amount of radioactivity in this
organ, it dominated the plot of TAC and was, thus, only shown in one of the graphs
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Figure 8.17: Time activity curves for 124I-p43 in WT mice. (A) Curves depicting the
accumulation and clearance of the heart, thyroid, liver and kidneys. The TAC showed
rapid clearance from the heart (red), slight uptake in the thyroid (black), little
accumulation in the liver (purple) that remained steady for the 120 min acquisition and
delayed uptake in the kidney with slow clearance that was achieved by ~ 80 min pi. (B)
TAC including bladder accumulation. The bladder (blue) began a steady accumulation
of radiotracer at the beginning of the acquisition and eventually plateaued at ~ 60 min.

210

(Figure 8.17B). These curves support our hypothesis that

124I-p43,

in a WT mouse,

exhibited slow renal clearance (relative to p5) and bladder accumulation which
suggested that the peptide could be followed throughout the duration of the acquisition.
It is noteworthy that little or no bladder radioactivity was observed when

124I-p5

was

injected into WT mice [416]. This is an especially interesting finding that could be
clinically beneficial in certain circumstances. If, for instance, a patient were to receive a
dose of

124I-p43

peptide and be imaged at an appropriate time pi, the lack of

dehalogenation of the radiotracer would, theoretically, allow for accumulation and
visualization of peptide bound to scant amyloid deposits in the kidneys, stomach,
pancreas and spleen of patients with amyloidosis.

If the radiotracer is prone to

dehalogenation, accumulation of free iodide in the stomach could make visualization of
amyloid deposits in nearby regions nearly impossible.

8.5. Conclusions
Development of a peptide with non-natural, D-amino acid incorporation was an
attempt to address issues with the relatively short half-life associated with peptide
radiotracers.

Incorporation of amino acids that are not naturally recognized by

biological enzymes was the strategy to extend peptide half-life in order to enhance the
time-frame in which the radiotracer could be taken up by amyloid in vivo.

It was

hypothesized that this type of modification would improve peptide bioavailability without
altering the size, which may hinder its targeting capabilities.
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Studies conducted ex vivo revealed that the D-amino acid peptide variant, p43,
(like the p5 reagent) was incapable of binding to ApoA2c amyloid. In contrast, peptide
p43 effectively targeted AA pathology by using both ex vivo and in vivo measures. The
peptide was shown to bind more efficiently to amyloid-laden tissue homogenates ex
vivo as compared to the parent peptide, p5. The alternative control peptide for these
studies, p50 (no D-amino acids), was shown to bind in a similar fashion to p5. Thus,
incorporation of D-amino acids modestly enhanced uptake and affinity for AA in the ex
vivo binding assays.
The in vivo analyses with p43 revealed its effectiveness at targeting whole body
amyloid burden in H2/IL-6 AA amyloid-laden mice. It was in WT mice, however, where
the most interesting findings were made with p43.

Instead of undergoing

dehalogenation of the Tyr residue, which has been shown in multiple studies with

125I-p5

[293, 416], the peptide avoided dehalogenase enzymes within the kidneys, and the
radioiodination remained intact. This was shown by using SPECT/CT, biodistribution
studies and analyses of TAC from dynamic PET/CT imaging. The control peptide made
with only L-type amino acids, p50, did not display these properties.
dynamic PET/CT revealed that the peak renal uptake time of
approximately 10 min longer than the uptake time published for

124I-p5

Additionally,
124I-p43

was

in healthy mice.

Serum half-life extension may account for this delay. Thus, the incorporation of Nterminal D-type AQA immediately in front of the L-Tyr in p5 resulted in a nondehalogenable peptide capable of effectively and specifically targeting AA amyloid in
vivo with slightly extended serum bioavailability. This peptide could meet clinical needs
that other amyloid-reactive peptides have not been able to achieve.
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Chapter 9
Summary and future directions

Summary of data presented:
In the US, there are approximately 3500 new diagnoses of amyloidosis every
year, and this number is expected to rise with greater clinical awareness and improved
detection systems. The prognoses for these patients varies, but those with cardiac
involvement have a considerably less favorable prognosis. In an attempt to facilitate a
more complete and accurate diagnosis, we have begun a program developing
molecular imaging techniques using amyloid-reactive tracers such that a non-invasive
“picture” of amyloid burden in patients may be established. There is an unmet clinical
need for a facile method of quantitatively detecting whole body amyloid burden in
patients.
To this end, we have developed synthetic, amyloid-reactive peptides for use as
radiotracers with SPECT/CT or PET/CT molecular imaging to detect amyloid deposition,
using as a preclinical test-bed transgenic murine models of amyloidosis. In this thesis
we tested a series of hypotheses and characterized a panel of peptides that could, one
day, provide clinical benefit for the early detection of multiple types of amyloidosis.
Here I summarize the findings of this thesis describing our ongoing developmental
and translational research:

213

 Polybasic, synthetic, heparin-binding peptides have been shown to bind both AA
amyloid-laden tissue homogenates and synthetic AL fibrils in ex vivo pull down
assays.

 Peptide affinity for ApoA2c amyloid-laden tissue homogenates ex vivo, however,
increased according to the series p5, p5R and p5R+14, which exhibited the
highest affinity for this substrate.

 Dual-isotope SPECT/CT imaging in association with tissue radioactivity
biodistribution measurements, and SPECT image analyses revealed that peptide
125I-p5R+14

provided more complete information on the whole body amyloid

burden in ApoA2c mice as compared to 99mTc-p5 in the same animal.

 Autoradiographic analyses of

125I-p5R+14

in ApoA2c amyloid-laden mouse

tissues confirmed specific peptide co-localization with amyloid; however, amyloid
deposits in certain tissues, notably the spleen, lung and heart, exhibited variable
and incomplete uptake of the peptide radiotracer. Instead, a “binding site barrier”
effect was observed in these tissues, likely due to the high affinity binding of the
peptide to the dense ApoA2c amyloid deposits in these organs. This observation
suggested that

125I-p5R+14

imaging of amyloid may underestimate the extent of

true amount of amyloid deposition in vivo.
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 A comparative study of peptide p5R+14 binding to ApoA2c amyloid-laden tissues
in vivo and ex vivo was performed to study the incomplete uptake of peptide by
amyloid in vivo. These analyses showed that the peptide “underestimated” the
amount of amyloid in vivo in the spleen, lungs and heart, as compared to ex vivo
uptake of the peptide. These experiments showed that the peptide binding sites
in these tissues may be “inaccessible” in vivo since ex vivo homogenization
increased peptide reactivity.

 A modified peptide was developed to potentially improve in vivo ApoA2c amyloidtargeting and uptake.

Since Wall et al. demonstrated that an arginine-rich

peptide resulted in higher affinity for amyloid and a binding site barrier effect in
AA amyloid-laden tissues [371], we hypothesized that a lysine variant of p5R+14,
designated p5+14, would penetrate regions of dense ApoA2c amyloid deposits
that were untouched by p5R+14 due to its lower affinity for the deposits.
SPECT/CT imaging, tissue radioactivity biodistribution measurements and
autoradiographic analyses of

125I-p5+14

in ApoA2c amyloid mice yielded data

that did not support this hypothesis, however, and revealed that

125I-p5R+14

was

a more effective at ApoA2c amyloid-targeting.

 While

125I-p5R+14

specifically and effectively bound ApoA2c amyloid in vivo, the

radiotracer was unable to completely decorate (cover) dense amyloid deposits.
Lowering peptide affinity by substituting lysine for arginine residues in the peptide
did not enhance amyloid coverage; thus, we developed another peptide
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radiotracer which addressed a different physical property— the serum half-life.
Peptides have short bioavailability in vivo due to their small size [410-412], which
led to our hypothesis that extending the serum half-life of the peptide radiotracer
may enhance amyloid-targeting due to its longer exposure to amyloid.
Therefore, a PEGylated p5R+14 peptide (20 kDa PEG) was synthesized and
evaluated in both WT and ApoA2c mice. Data from these studies indicated that
catabolism of

125I-PEG-p5R+14

differed from that seen with unmodified

125I-

p5R+14 as evidenced by hepatobiliary clearance of the larger peptide compared
to renal clearance with the non-PEGylated peptide. SPECT imaging indicated
that, at 1 h pi, there was a higher concentration of
as compared to

125I-p5R+14

125I-PEG-p5R+14

in WT mice

suggesting that the serum half-life was modestly

extended. The serum bioavailability did not, however, enhance amyloid-targeting
efficacy. Autoradiographic analyses suggested the two peptides exhibited similar
amyloid-binding throughout all tissues.

 Peptide p5R+14 was the most effective at binding ApoA2c amyloid, but despite
modifications its amyloid targeting abilities remained sub-optimal.

To further

investigate this limitation, an alternative method for serum half-life extension—the
use of peptides containing non-natural, D- amino acids—led to the development
and investigation of peptide p43, a variant of p5 with D-type AQA residues
replacing GGG at the N-terminal. Ex vivo “pull down” binding assays using
p43 showed its AA amyloid-binding potential exceeded that of

125I-p5,

125I-

but much

like p5, it was incapable of binding ApoA2c amyloid; thus, p5R+14 remained the
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most effective ApoA2c amyloid-targeting agent. Based on our studies using AA
and ApoA2c amyloid-peptide interactions we speculated that the composition of
ApoA2c amyloid differs in nature relative to AA amyloid, e.g. the HSPG/fibril
content may vary, which could influence successful peptide-amyloid interactions.

 Because p43 did not effectively bind ApoA2c amyloid ex vivo, we determined its
in vivo characteristics instead in both AA amyloid-laden H2/IL-6 and WT mice.
SPECT/CT imaging, tissue radioactivity biodistribution measurements and ARG
at 1 h, 4 h and 24 h pi revealed that

125I-p43,

like

125I-p5,

amyloid in numerous tissues. In WT mice, however,
unlike that previously observed with

125I-p5

specifically bound AA

125I-p43

exhibited behavior

[293]. At 1 h pi, there was evidence

of 125I-p43 in the renal cortices, but at later time points pi, the renal activity rapidly
diminished. Remarkably, no radioiodide was detected in the stomach or thyroid
at any time point, which indicated that the radiotracer was not dehalogenated—
an unexpected finding based on peptide p5 data.

 The lack of dehalogenation of p43 was directly related to the presence of the Damino acids at the N-terminal rather than simply substitution of AQA amino acids.
This was confirmed in studies with p50, a peptide with the same amino acid
sequence as p43 but with all L-entantiomers. The in vivo reactivity of p50 in AA
and WT mice showed behavior similar to peptide p5, which proved that the Denantiomers were responsible for protecting p43 from dehalogenase activity.

217

 To further characterize p43 in vivo, dynamic PET/CT imaging was performed
using live WT mice. Analysis of PET images revealed the peak uptake time in
the kidneys was

124I-p43

was 10 min longer than that seen for

124I-p5

[416], likely

indicating serum half-life extension. These studies also confirmed that

124I-p43

was not dehalogenated as evidenced by accumulation of radioactivity in the
bladder. Thus, p43 was characterized as a non-dehalogenable, amyloid-binding
peptide with slightly enhanced serum bioavailability—it offered properties of
amyloid-imaging that no other examined peptide could achieve.

Future Directions:
The use of biological agents as imaging radiotracers is not a novel approach to
disease detection. The data presented in this thesis and recent publications, validate
the use of peptides for the detection of amyloidosis—a devastating disease which would
benefit from early detection to improve patient survival. Our data indicated that there
were unique characteristics associated with each of the peptides evaluated, which may
make them more suitable for the clinical detection of certain types of amyloid disease.
For instance, the enhanced binding of peptides with an additional 4 positively charged
amino acids (e.g., p5R+14 or p5+14) may allow detection of scant amyloid deposits in
vivo where high-affinity targeting is required; such would be the case in early disease
detection where amyloid deposits are relatively small and the likelihood of detection
would increase with a high-affinity, amyloid-binding reagent.

In addition, diseases

where small amyloid deposits form such as in cases of type 2 diabetes or cerebral
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amyloid angiopathy in the brains of the elderly may benefit from a high affinity peptide
imaging agent that would not suffer from the binding site barrier effect. Furthermore,
the lack of dehalogenation of peptides with N-terminal, D- amino acids neighboring the
iodinated tyrosine, may enhance the likelihood of detecting pancreatic or gastric amyloid
deposits in patients with type 2 diabetes or AL/AA amyloidosis, respectively. Without
dehalogenation, there would not be uptake of free iodide in the stomach, which could
hinder the visualization of amyloid deposits in in organs in close proximity to the
stomach. Although we did not identify a single peptide to address all unmet clinical
needs for amyloid detection, the many characteristics identified during these studies can
be exploited for the detection of certain amyloid-associated conditions.
Defining the utility of peptides with unique characteristics and optimizing them for
appropriate amyloid detection strategies would be clinically invaluable. Since cardiac
and renal amyloidosis are associated with the most critical conditions in patients, earlier
detection of such deposits should be the focus of peptide optimization for imaging.
Combining and exploiting certain properties that were identified in this thesis may yield
a superior peptide for targeting these types of deposition; the serum plasma half-life and
avoidance of dehalogenation associated with D-amino acid incorporation

of the

extended, high-affinity peptide p5R+14 could provide the characteristics needed for
successful detection of amyloid in the heart and kidneys of patients with AL. This
combination of biochemical properties may also be advantageous in pancreatic amyloid
detection. Therefore, future experiments that focus on optimizing and combining certain
peptide characteristics should be conducted to assess hypothetically improved amyloidtargeting agents.
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In the long term, before peptides are translated into the clinic, additional preclinical studies would need to be performed to ensure there are no adverse issues
associated with toxicology or immunogenicity in mice. Additionally, it may be valuable
to evaluate certain of the newly developed peptides in another species. This could be
possible working in conjunction with the UT College of Veterinary Medicine, i.e. type 2
diabetic cats could receive a non-dehalogenable peptide radiolabeled with
h) to assess radiotracer efficacy in detecting pancreatic AIAPP.

123I

(T½ = 13

Once sufficient

preliminary data has been generated to justify a human clinical trial, GMP grade
material would be developed and tested prior to applying to the FDA for approval to
translate the reagent into human clinical trials.
A dire need for disease detection and monitoring exists for patients with
amyloidosis around the world since approved strategies are not universally available, do
not provide information for all critical organs, or do not target both AL and ATTR amyloid
deposition—the two types most commonly seen in patients. The use of peptides as
imaging agents for these diseases has yielded promising results, and transitioning these
reagents into clinical trials could provide more information about the amyloid burden in
patients than has been generated with other clinically available reagents. As has been
stated by many researchers and physicians in the field, earlier detection is the key to
fighting this devastating disease.
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